
<html lang="en"     class="pb-page"  data-request-id="b761854b-9d6b-4f09-bf0e-9feae59df8fe"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01961;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure" /></meta><meta name="dc.Creator" content="Lun  Wang" /></meta><meta name="dc.Creator" content="Yunhua  Zheng" /></meta><meta name="dc.Creator" content="Dan  Li" /></meta><meta name="dc.Creator" content="Jianhong  Yang" /></meta><meta name="dc.Creator" content="Lei  Lei" /></meta><meta name="dc.Creator" content="Wei  Yan" /></meta><meta name="dc.Creator" content="Wei  Zheng" /></meta><meta name="dc.Creator" content="Minghai  Tang" /></meta><meta name="dc.Creator" content="Mingsong  Shi" /></meta><meta name="dc.Creator" content="Ruijia  Zhang" /></meta><meta name="dc.Creator" content="Xiaoying  Cai" /></meta><meta name="dc.Creator" content="Hengfan  Ni" /></meta><meta name="dc.Creator" content="Xu  Ma" /></meta><meta name="dc.Creator" content="Na  Li" /></meta><meta name="dc.Creator" content="Feng  Hong" /></meta><meta name="dc.Creator" content="Haoyu  Ye" /></meta><meta name="dc.Creator" content="Lijuan  Chen" /></meta><meta name="dc.Description" content="Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic cast..." /></meta><meta name="Description" content="Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic cast..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 3, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01961" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01961" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01961" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01961" /></link>
        
    
    

<title>Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01961" /></meta><meta property="og:title" content="Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0017.jpeg" /></meta><meta property="og:description" content="Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin’s surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, 8a exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved in vivo antitumor effects. The X-ray crystal structure suggested that 8a both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01961"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01961&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01961&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01961&amp;href=/doi/10.1021/acs.jmedchem.0c01961" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 8127-8141</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00040" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02144" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Lun Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lun Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lun++Wang">Lun Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yunhua Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunhua Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunhua++Zheng">Yunhua Zheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dan Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dan Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Li">Dan Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianhong Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianhong Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianhong++Yang">Jianhong Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Lei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Lei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Lei">Lei Lei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Yan">Wei Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Zheng">Wei Zheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minghai Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minghai Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minghai++Tang">Minghai Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingsong Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingsong Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingsong++Shi">Mingsong Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ruijia Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ruijia Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ruijia++Zhang">Ruijia Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoying Cai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoying Cai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoying++Cai">Xiaoying Cai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hengfan Ni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hengfan Ni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Ministry of Education Key Laboratory of Standardization of Chinese Herbal Medicine, State Key Laboratory, Breeding Base of Systematic Research Development and Utilization of Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hengfan++Ni">Hengfan Ni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xu Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xu Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xu++Ma">Xu Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Na Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Na Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Na++Li">Na Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feng Hong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Hong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Hong">Feng Hong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haoyu Ye</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haoyu Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#dbb3bab4a2aefba2be9ba8b8aef5bebfaef5b8b5">haoyu <span class="__cf_email__" data-cfemail="700915300313055e1514055e131e">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haoyu++Ye">Haoyu Ye</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9185-1040" title="Orcid link">https://orcid.org/0000-0002-9185-1040</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lijuan Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lijuan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#ed8e858883818487988c83dcdfd8addcdbdec38e8280"><span class="__cf_email__" data-cfemail="0b68636e656762617e6a653a393e4b3a3d3825686466">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lijuan++Chen">Lijuan Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8076-163X" title="Orcid link">https://orcid.org/0000-0002-8076-163X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01961&amp;href=/doi/10.1021%2Facs.jmedchem.0c01961" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 8127–8141</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 November 2020</li><li><span class="item_label"><b>Published</b> online</span>3 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01961" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01961</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8127%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLun%2BWang%252C%2BYunhua%2BZheng%252C%2BDan%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.0c01961%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBioactivity%2BEvaluation%2Bof%2BDual-Target%2BInhibitors%2Bof%2BTubulin%2Band%2BSrc%2BKinase%2BGuided%2Bby%2BCrystal%2BStructure%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8141%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01961"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1099</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01961" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Lun&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yunhua&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jianhong&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Lei&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Minghai&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Mingsong&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Ruijia&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Xiaoying&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Hengfan&quot;,&quot;last_name&quot;:&quot;Ni&quot;},{&quot;first_name&quot;:&quot;Xu&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Na&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Haoyu&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Lijuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8127-8141&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01961&quot;},&quot;abstract&quot;:&quot;Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin’s surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, 8a exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved in vivo antitumor effects. The X-ray crystal structure suggested that 8a both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01961&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01961" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01961&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01961" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01961&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01961" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01961&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01961&amp;href=/doi/10.1021/acs.jmedchem.0c01961" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01961" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01961" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01961%26sid%3Dliteratum%253Aachs%26pmid%3D34081857%26genre%3Darticle%26aulast%3DWang%26date%3D2021%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBioactivity%2BEvaluation%2Bof%2BDual-Target%2BInhibitors%2Bof%2BTubulin%2Band%2BSrc%2BKinase%2BGuided%2Bby%2BCrystal%2BStructure%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D8127%26epage%3D8141%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (5)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291880" title="Crystal structure">Crystal structure</a>,</li><li><a href="/action/doSearch?ConceptID=292232" title="Polymerization">Polymerization</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin’s surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, <b>8a</b> exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved <i>in vivo</i> antitumor effects. The X-ray crystal structure suggested that <b>8a</b> both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubules composed of α,β-tubulin heterodimers are ubiquitous cytoskeletal filaments that play a critical role in multiple cellular processes,<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> making interfering with microtubule dynamics a well-verified means of cancer drug design.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Six agent binding sites on tubulin dimers have been found to date, with five sites on β-tubulin (paclitaxel, vinblastine, colchicine, laulimalide, and maytansine sites) and one site on α-tubulin (a pironetin site).<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Over the past several decades, numerous antitubulin agents targeting paclitaxel or vinblastine sites have been approved by the FDA and exhibited excellent clinical success in cancer chemotherapy.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a></div><div class="NLM_p">Klisyri (KX01, KX2-391, or tirbanibulin) is a potent tubulin polymerization inhibitor that was first discovered as a non-ATP-competitive Src protein inhibitor.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> On December 15, 2020, the FDA approved the use of Klisyri ointment for the topical treatment of actinic keratosis of the face or scalp, a type of preskin cancer caused by skin exposure to ultraviolet light. Note that KX01 is not a Pgp substrate and therefore retains a potent inhibitory effect against high Pgp-expressing paclitaxel-resistant cell lines (MES-SA/Dx5 and NCI/ADR-RES cell lines), indicating a potential therapeutic effect on tumors.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, a phase II clinical study of oral KX01 in humans with bone-metastatic castration-resistant prostate cancer was prematurely terminated because of low antitumor efficacy.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> A drug dosage of 40 mg twice daily did not produce the required level of tubulin polymerization inhibition,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> which we previously explained in terms of the crystal structure of the tubulin–KX01 complex at a 2.5 Å resolution.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The morpholine group of KX01 in this complex extends out of the colchicine pocket to approach the GTP molecule of α-tubulin, and only amide and pyridine moieties form hydrogen bonds with β-tubulin via a water molecule (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>). Thus, we hypothesized that enhancing the interaction between KX01 and tubulin could increase inhibition of tubulin polymerization.</div><div class="NLM_p">The colchicine site is located on the intradimer interfaces of the α,β-tubulin dimer.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Some colchicine site inhibitors have been previously reported, such as colchicine<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and 4β-(1,2,4-triazol-3-ylthio)-4-deoxypodophyllotoxin,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> whose crystal structure reveals that these inhibitors are located on the α-tubulin surface and hydrogen-bond with Ser178. Inspired by these results, we decided to synthesize KX01 derivatives to extend into the interior of α-tubulin and increase inhibitory activity against tubulin. Here, guided by the KX01–tubulin crystal complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>) and the docking mode, we rationally designed and synthesized a series of derivatives of KX01 by extending the chains linking the morpholine group to the aryl group and modifying the morpholine group (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>); the bioactivities of the KX01 derivatives were subsequently evaluated both <i>in vitro</i> and <i>in vivo</i>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of KX01 derivatives with extended chains. (A) Chain length extended to <i>n</i> = 2 or 3. Predicted binding mode of (B) <b>6a</b> and (C) <b>6d</b> with tubulin (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>). Blue sticks show the structure of <b>6a</b> and <b>6d</b>; yellow dashed lines show the hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Based on a patent and a previous study,<a onclick="showRef(event, 'ref9 ref14'); return false;" href="javascript:void(0);" class="ref ref9 ref14">(9,14)</a> we designed a novel and convenient synthesis route (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) for the target compounds <b>6a</b>–<b>u</b> to explore structural diversity. 2-(5-Bromopyridin-2-yl)acetic acid (<b>1</b>) and benzylamine (<b>2</b>) were used as starting materials to form intermediate <b>3</b> followed by a Suzuki coupling reaction to obtain <b>4</b>. To obtain intermediate <b>5</b>, the base, solvent, and reaction temperature were screened, and the final reaction conditions were set using CsCO<sub>3</sub> as the base and CH<sub>3</sub>CN as the solvent. The mixture was reacted at 50 °C for 6 h in an almost 98% yield. Finally, the bromine in intermediate <b>5</b> was substituted with different amines to form the target compounds <b>6a</b>–<b>6u</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of KX01 Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, DMF, r.t., overnight, and 71.5%; (b) 4-hydroxybenzeneboronic acid pinacol ester, PdCl<sub>2</sub>(dppf)CH<sub>2</sub>Cl<sub>2</sub>, KF, 1,4-dioxane/H<sub>2</sub>O, 80 °C, 8 h, and 75.2%; (c) 1,2-dibromoethane or 1,3-dibromopropane or 1,4-dibromobutane, CsCO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, and 98%; (d) KI, Et<sub>3</sub>N, DMF, 50 °C, 8 h, and 25.4–80.2%.</p></p></figure><div class="NLM_p">The synthesis of <b>8a</b>–<b>g</b> is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The <i>t</i>-butyloxy carbonyl protective compound <b>6u</b> was deprotected with trifluoroacetic acid (TFA) to obtain <b>7</b> followed by amide condensation to afford <b>8a</b>–<b>f</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of KX01 Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TFA, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 2 h, and 84.5%; (b) HATU, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 4 h, and 52.5–97.3%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> <i>In Vitro</i> Structure–Activity Analysis</h3><div class="NLM_p">The inadequate efficiency of KX01 in clinical trials motivated the rational design and synthesis of derivatives with higher tubulin inhibitory effects, where the binding mode of KX01 with tubulin was exploited to increase <i>in vitro</i> and <i>in vivo</i> antitumor activity.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> KX01 occupied two hydrophobic centers (I and II) and the hydrogen bond centers IV based on a structure-based colchicine-binding site inhibitor (CBSI) pharmacophore model that we previously proposed (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref11 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref13">(11,13)</a> The morpholine moiety extended out of the colchicine binding site and approached GTP bound with α-tubulin.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> We hypothesized that increasing the length of the chain between the phenyl and morpholine moieties could enable KX01 derivatives to interact with α-tubulin. Then, compounds <b>6a</b> (<i>n</i> = 2) and <b>6d</b> (<i>n</i> = 3) were docked with the α,β-tubulin crystal structure (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B,C) (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>). The results indicated that the ether linkage turned over, while the ether oxygen and nitrogen atoms of morpholine simultaneously formed hydrogen bonds with Ser178. Additionally, the oxygen atom of the morpholine moiety of <b>6d</b> bound potently with Arg221. We then synthesized <b>6a</b>–<b>f</b> with longer chains (<i>n</i> = 2 or 3), <b>6g</b>, and <b>6h</b> (<i>n</i> = 1). However, almost all the compounds with longer chains showed lower antiproliferation activity than KX01 against the K562, SKOV3, and Ramos cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These results revealed that simply increasing the chain length did not significantly improve the antiproliferation activity. However, the IC<sub>50</sub> of the bridge ring compound <b>6g</b> (<i>n</i> = 1) demonstrated significantly higher antiproliferation activity than KX01, especially in Ramos cell lines (IC<sub>50</sub> = 3.1 nM, more than 5-fold), indicating that the morpholine moiety could tolerate further modification.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. An Investigation of the Effects of Increasing the Chain Length</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0011.gif" alt="" id="gr10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0012.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values, which are the compound concentration required to inhibit half of the tumor cell proliferation detected by an MTT assay. Data are expressed as the mean ± SD of the results of at least three independent experiments.</p></div></div><div></div></div><div class="NLM_p">Then, morpholine was substituted with three-, five- or six-membered saturated heterocyclyl, bridging, or spiral heterocyclyl to enhance the binding affinity with α-tubulin (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In these compounds, <b>6i</b> and <b>6j</b> retained their antiproliferation activity, whereas <b>6k</b>–<b>p</b> exhibited decreased activity, suggesting the important role of the oxygen atoms, in accordance with our docking result that the morpholine oxygen of <b>6d</b> formed a high-affinity hydrogen bond with Arg221 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C). We then replaced oxygen with nitrogen atoms to synthesize <b>6q</b>–<b>u</b>. Surprisingly, among these compounds, the 1-(cyclopropylcarbonyl)piperazine-replaced compound <b>6r</b> demonstrated significantly increased antiproliferation activity against the three assayed cell lines. The docking study showed that <b>6r</b> had a similar binding mode to <b>6d</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicting the binding mode of <b>6r</b> with tubulin (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>). Blue sticks show the structure of <b>6r</b>; yellow dashed lines show the hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Replacement of the Morpholine Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0013.gif" alt="" id="gr12" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values, which are the compound concentration required to inhibit half of the tumor cell proliferation detected by an MTT assay. Data are expressed as the mean ± SD of the results of at least three independent experiments.</p></div></div><div></div></div><div class="NLM_p">More acylpiperazine-substituted compounds were subsequently synthesized (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The introduction of cyclopropylacetyl (<b>8a</b>) and cyclobutyryl (<b>8b</b>) resulted in more than 10-fold higher activities. Fluorine-substituted cyclopropionyl was also applied. Interestingly, compound <b>8c</b> with (1<i>S</i>,2<i>S</i>)-fluorocyclopropyl demonstrated approximately dozens-fold higher antiproliferation activity than <b>8d</b> with (1<i>R</i>,2<i>S</i>)-fluorocyclopropyl, which has resulted from the higher tubulin-binding affinity of the former conformation. The dual fluorine-substituted compound <b>8e</b> also showed decreased activity. We then replaced the acyl with a sulfonyl group to obtain compound <b>8f</b>. <b>8f</b> still exhibited good activity with IC<sub>50</sub> values of 5.8, 2.4, and 4.1 nM against the K562, SKOV3, and Ramos cell lines, respectively. <b>6r</b>, <b>8a</b>, <b>8b</b>, and <b>8c</b> also showed a several-fold increase in antiproliferation activity against the Jurkat, MDA-MB-231, and MDA-MB-468 cell lines compared with KX01 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf" class="ext-link">Table S1</a>). In addition, <b>6r</b>, <b>8a</b>, and <b>8c</b> exhibited acceptable <i>in vitro</i> liver microsomal stability. The potency of the compounds toward tubulin was directly determined using a tryptophan-based binding assay (TFD), which is commonly used to detect the dissociation constant (Kd) of drugs binding to tubulin. <b>6r</b>, <b>8a</b>, <b>8b</b>, and <b>8c</b> showed a significant increase in binding affinity with dissociation constants (Kd) of 0.29, 0.61, 0.63, and 0.30 μM, respectively, which were better than that of KX01 (Kd = 1.11 μM). These results indicated that the increased activities may have resulted from the oxygen atom within the acyl or sulfonyl group forming high-affinity hydrogen bonds with Arg221, causing the ether bond to turn over, as predicted by the docking study.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Investigation of the Acylpiperazine Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0015.gif" alt="" id="gr14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0016.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values, which are the compound concentration required to inhibit half of the tumor cell proliferation detected by an MTT assay. Data are expressed as the mean ± SD of the results of at least three independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><i>T</i><sub>1/2</sub> (min), <i>in vitro</i> half-life of human liver microsomes.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Cl<sub>int</sub>, <i>in vitro</i> clearance rate of human liver microsomes.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Kd, the dissociation constant of tubulin compounds, as measured by a tryptophan-based binding assay. ND, not detected.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> <i>In Vivo</i> Pharmacokinetic and Pharmacodynamic Study</h3><div class="NLM_p">Before conducting a pharmacodynamic study, we first evaluated the pharmacokinetic profiles in rats with KX01, <b>6r</b>, <b>8a</b>, <b>8b</b>, and <b>8c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). <b>6r</b>, <b>8a</b>, and <b>8c</b> showed higher AUCs at 5 mg/kg and lower cleavage rates but decreased <i>T</i><sub>1/2</sub> values. In initial toxicity experiments on the selected compounds, <b>8c</b> exhibited clear toxicity at a dosage of 10 mg/kg in C57 mice, whereas <b>6r</b>, <b>8a</b>, and <b>8b</b> showed no significant toxicity, even at dosages of 40 mg/kg twice daily (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf" class="ext-link">Table S1</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Profiles of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char=".">KX01 (<i>p.o.</i>)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><b>6r</b> (<i>p.o.</i>)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><b>8a</b> (<i>p.o.</i>)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><b>8b</b> (<i>p.o.</i>)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><b>8c</b> (<i>p.o.</i>)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC(0–<i>t</i>) (μg/L × h)</td><td class="colsep0 rowsep0" align="char" char=".">839.57</td><td class="colsep0 rowsep0" align="char" char=".">1618.74</td><td class="colsep0 rowsep0" align="char" char=".">1054.00</td><td class="colsep0 rowsep0" align="char" char=".">382.53</td><td class="colsep0 rowsep0" align="char" char=".">4177.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">12.33</td><td class="colsep0 rowsep0" align="char" char=".">2.63</td><td class="colsep0 rowsep0" align="char" char=".">3.85</td><td class="colsep0 rowsep0" align="char" char=".">2.31</td><td class="colsep0 rowsep0" align="char" char=".">5.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">0.83</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/(h·kg))</td><td class="colsep0 rowsep0" align="char" char=".">5.31</td><td class="colsep0 rowsep0" align="char" char=".">3.34</td><td class="colsep0 rowsep0" align="char" char=".">4.81</td><td class="colsep0 rowsep0" align="char" char=".">12.56</td><td class="colsep0 rowsep0" align="char" char=".">1.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/L)</td><td class="colsep0 rowsep0" align="char" char=".">431.44</td><td class="colsep0 rowsep0" align="char" char=".">592.54</td><td class="colsep0 rowsep0" align="char" char=".">398.33</td><td class="colsep0 rowsep0" align="char" char=".">483.62</td><td class="colsep0 rowsep0" align="char" char=".">741.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">34.92</td><td class="colsep0 rowsep0" align="char" char=".">52.23</td><td class="colsep0 rowsep0" align="char" char=".">24.32</td><td class="colsep0 rowsep0" align="char" char=".">13.27</td><td class="colsep0 rowsep0" align="char" char=".">79.92</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">5 mg/kg for <i>p.o.</i> administration of rats (<i>n</i> = 6, mean ± SD).</p></div></div></div><div class="NLM_p">We compared the <i>in vivo</i> efficacy of <b>6r</b>, <b>8a</b>, and <b>8b</b> in a C26 xenograft mouse model. <b>6r</b> and <b>8a</b> at 10 mg/kg exhibited tumor growth inhibition (TGI) values of 73 and 71%, respectively, indicating higher <i>in vivo</i> activity than KX01, which exhibited a TGI of only 51% (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The TGI of <b>8b</b> of only 32% was in accordance with a high <i>in vitro</i> liver microsomal clearance rate and low oral bioavailability. Two mice died on the eighth day in the <b>6r</b> treatment group. After a comprehensive consideration of the pharmacokinetic profile, <i>in vivo</i> activity, and safety issues, <b>8a</b> was selected for additional <i>in vivo</i> pharmacodynamic evaluation and further investigation. Oral administration of <b>8a</b> (5 and 10 mg/kg) for 1 month remarkably inhibited tumor growth in a SKOV3 xenograft mouse model, where the TGIs of 52 and 70%, respectively, were higher than the TGI of KX01 (10 mg/kg) of 42% (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). No significant body weight loss was observed in any group.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antitumor effects of selected compounds on C26 and SKOV3 xenograft mouse models. C26 xenograft mice were administered <b>6r</b>, <b>8a</b>, or <b>8b</b> at a dose of 10 mg/kg (<i>p.o.)</i>, with KX01 (10 mg/kg, <i>p.o.</i>) as a control (<i>n</i> = 6, means ± SD). (A) Tumor volume (mm<sup>3</sup>) evaluated once every 2 days for 10 days. (B) Body weight (g) changes of each group. (C) Tumor weight (g) of each group on day 10. All the data are expressed as the mean ± SD (<i>n</i> = 6 per group). SKOV3 xenograft mice were administered <b>8a</b> at doses of 5 and 10 mg/kg (<i>p.o.)</i>, with KX01 (10 mg/kg, <i>p.o.</i>) as a control (<i>n</i> = 5, mean ± SD). (D) Tumor volume (mm<sup>3</sup>) evaluated once every 3 days for 1 month. (E) Body weight (g) of each group. (F) Tumor weight (g) of each group on day 30.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <b>8a</b> Inhibited Tubulin Polymerization and Arrested the Cell Cycle in the G2/M Phase</h3><div class="NLM_p">We previously reported<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> that KX01 inhibited tubulin polymerization and induced cell cycle arrest in the G2/M phase in the HepG2, HeLa, and H460 tumor cell lines. To verify whether <b>8a</b> could demonstrate an antitumor effect by inhibiting tubulin polymerization, an immunofluorescence assay was performed using colchicine, a tubulin depolymerization agent,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> as the positive control. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A shows that <b>8a</b> inhibited tubulin polymerization in SKOV3 cells. We determined that <b>8a</b> had a higher inhibitory effect on tubulin polymerization than KX01 at a concentration of 5.0 μM in an <i>in vitro</i> tubulin polymerization assay (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). All tubulin inhibitors can arrest the cell cycle in the G2/M phase.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> A cell cycle analysis was subsequently performed. The results showed that <b>8a</b> induced G2/M-phase cell cycle arrest in SKOV3 cell lines more effectively than KX01, even at lower concentrations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). These results also revealed that <b>8a</b> demonstrated higher antitumor activity than KX01, at least partially because of enhanced tubulin polymerization inhibitory activity.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>8a</b> inhibited tubulin polymerization and induced G2/M-phase cell cycle arrest in SKOV3 cells. (A) SKOV3 cells were treated with 100 nM colchicine (Col), paclitaxel (PTX) or 10 or 100 nM <b>8a</b> for 16 h, and the microtubule morphology was monitored by immunofluorescence. (B) KX01, Col, and <b>8a</b> at 5.0 μM were coincubated with tubulin (3 mg/mL) at 37 °C, and the absorbance was collected every second for 30 min at 340 nm. (C) SKOV3 cells were treated with 0, 1, 5, or 10 nM <b>8a</b> or 10, 20, or 100 nM KX01 for 16 h, and the cell cycle was analyzed by PI staining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <b>8a</b> Reversibly Arrested the Cell Cycle in the G2/M Phase</h3><div class="NLM_p">Microtubules participate in several cellular processes and have become a successful target of cancer therapy.<a onclick="showRef(event, 'ref3 ref18'); return false;" href="javascript:void(0);" class="ref ref3 ref18">(3,18)</a> Microtubule-targeting agents, such as vinca alkaloids and taxanes, have been clinically used as chemotherapy agents for over 50 years.<a onclick="showRef(event, 'ref7 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref7 ref19 ref20">(7,19,20)</a> Microtubules are ubiquitous cytoskeletal filaments that play a critical role in multiple cellular processes and are present in both malignant and normal cells. The characteristics of <b>8a</b> were elucidated at this stage by conducting a mitotic block reversibility assay based on a time schedule.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> A proportion of cells in the G2/M phase above 50% was considered to indicate a significant mitotic block (SMB).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> show that <b>8a</b> and colchicine presented an SMB at 0 h at concentrations of 10 and 30 nM, respectively. However, the SMB was almost eliminated at the same concentration after washout of colchicine (reversibility ratio of 30 nM/30 nM = 1), whereas a high concentration (300 nM) of <b>8a</b> was required to sustain the SMB at 10 h (reversibility ratio of 300 nM/10 nM = 30), which was lower than the required KX01 concentration (reversibility ratio of 10000 nM/30 nM = 333),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> indicating an additional interaction between <b>8a</b> and α-tubulin.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>8a</b> reversibly inhibited tubulin polymerization. (A) Time schedule of the mitotic block reversibility assay. (B) SKOV3 cell cycle histograms for colchicine (Col) and <b>8a</b> in the mitotic block reversibility assay. Blue rectangles show the minimum drug concentrations required to induce the SMB at 0 h or maintain the SMB at 10 h. Data represent the results of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> X-ray Crystal Structure of <b>8a</b> with Tubulin</h3><div class="NLM_p">The predicted binding mode of <b>6r</b> with tubulin led us to speculate that <b>8a</b> could potentially form more interactions with α-tubulin and enhance the inhibitory effect on tubulin polymerization. To elucidate the binding mode of <b>8a</b> with tubulin, we soaked <b>8a</b> into complex crystals composed of two α,β-tubulin heterodimers, one stathmin-like protein RB3, and one tubulin tyrosine ligase (T2R-TTL) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Then, we successfully resolved the crystal structure of the <b>8a</b>–tubulin complex at a 2.61 Å resolution (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBZ">7CBZ</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf" class="ext-link">Table S2</a>). The a, b, and c ring and the amide moiety of <b>8a</b> occupied similar positions to those in KX01, whereas the cyclopropylacetyl piperazine and the chain moiety rotated and extended into a novel region (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). The nitrogen of piperazine and the oxygen of the carbonyl group formed hydrogen bonds with Ser178 and Arg221 within α-tubulin, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D). The cyclopropyl moiety was buried in a hydrophobic cavity formed by the α-H7 strand and the α-T5 loop in α-tubulin. Known tubulin colchicine site inhibitors have only been found to hydrogen-bond with the surface of α-tubulin,<a onclick="showRef(event, 'ref4 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref4 ref22 ref23">(4,22,23)</a> whereas <b>8a</b> can extend into an inner binding pocket in α-tubulin to form stronger interactions.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structure of tubulin complexed with <b>8a</b>. (A) Chemical structure of <b>8a</b>. (B) Overall structure of the tubulin–<b>8a</b> complex (PDB code: 7CBZ). RB3-SLD is colored blue, TTL is yellow, α-tubulin is black, β-tubulin is gray, and <b>8a</b> is shown as cyan spheres. (C) Comparison of the binding modes between KX01 and <b>8a</b>. The crystal structures of tubulin–KX01 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>; green) and tubulin–<b>8a</b> (gray) were superimposed. (D) Interactions between tubulin and <b>8a</b>. <b>8a</b> is shown as sticks. Residues that formed interactions with <b>8a</b> are shown as sticks and labeled. Hydrogen bonds are shown as red dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Inhibition of the Src/FAK Signal Pathway</h3><div class="NLM_p">KX01 was initially regarded as a potent non-ATP-competitive Src protein inhibitor. Src is normally maintained in an inactive conformation.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> However, after binding with focal adhesion kinases (FAKs) through SH2, the Src protein turns on an activation condition and undergoes autophosphorylation of the Tyr<sup>416/419</sup> residue within the protein kinase domain; thus, the FAKs are further phosphorylated followed by a downstream signal transition.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> The inhibition of Src kinase activation was investigated by a Western blot assay to confirm that these compounds could inhibit the phosphorylation of Src kinase and the Src/FAK signal pathway in SKOV3 cells. <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf" class="ext-link">Figure S1</a> show that <b>8a</b>, <b>6r</b>, <b>8b</b>, and <b>8c</b> significantly inhibited the phosphorylation of Src and FAK protein in a dose-dependent manner, indicating that <b>8a</b> maintained Src kinase suppression activity. Src is a nonreceptor protein tyrosine kinase, for which mutants in human cancers/tumors rarely occur, and is not a primary driver of carcinogenesis.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> No Src kinase monotherapeutic drug has been successfully applied in clinical trials. However, several Src kinase inhibitors, such as saracatinib, an Src/Abl dual kinase inhibitor, in combination with chemotherapeutic drugs have progressed through clinical stages and shown significant synergistic effects.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> Thus, <b>8a</b> is a single chemical entity that simultaneously inhibits tubulin and Src kinase and may be applied as a promising strategy for maintaining the advantages of drug combinations without any significant concerns, such as compliance problems amplified by complex regimens and drug–drug interaction issues.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>8a</b> inhibited the Src/FAK signaling pathway in the SKOV3 cell line. Data represent the results of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81346" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81346" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">KX01 is a tubulin and non-ATP-competitive Src kinase dual-target inhibitor.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Phase I/II clinical trials of KX01 for the treatment of hematologic and solid malignancies (NCT01074138, NCT00658970, NCT00646139, and NCT01397799) uncovered that low efficacy resulted from not meeting the required plasma concentration for tubulin inhibition.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> In the present study, we modified the chain moiety and morpholine group of KX01 considering the crystal structure of the KX01–tubulin complex to increase the tubulin inhibitory activity. As expected, KX01 was highly tolerant to morpholine moiety replacement by the acylpiperazine method, resulting in significantly increased antitumor activity against the K562, SKOV3, and Ramos cell lines. Successful resolution of the crystal structure of the <b>8a</b>–tubulin complex indicated that <b>8a</b> bound to both the colchicine site in β-tubulin and a cavity in α-tubulin. The cyclopropylacetyl piperazine and the chain moiety of <b>8a</b> rotated and extended into a cavity formed by the α-H7 strand and the α-T5 loop in α-tubulin. Colchicine sites are targeted by some tubulin inhibitors, such as colchicine and 4β-(1,2,4-triazol-3-ylthio)-4-deoxypodophyllotoxin, which also extend out of β-tubulin to hydrogen-bond with Ser178; however, these compounds only approach the α-tubulin surface.<a onclick="showRef(event, 'ref4 ref23'); return false;" href="javascript:void(0);" class="ref ref4 ref23">(4,23)</a> The cyclopropylacetyl piperazine of <b>8a</b> occupies a novel cavity in α-tubulin. Subsequent mechanistic studies revealed that <b>8a</b> exhibited higher inhibitory effects in the tubulin polymerization assay than KX01 while continuing to inhibit the Src signaling pathway; the reversibility ratio of tubulin polymerization was lower than that of KX01, which was consistent with the crystal complex result that <b>8a</b> formed additional potent hydrogen bonds with α-tubulin compared with KX01. In an <i>in vivo</i> study, <b>8a</b> demonstrated proper pharmacokinetic profiles, toxicity, and higher efficacy compared with KX01 in both C26 and SKOV3 mouse models. In conclusion, <b>8a</b> is a promising tubulin/Src dual-target antitumor candidate, and the novel <b>8a</b>–tubulin binding mode presents a novel design strategy for enhancing tubulin inhibition.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67736" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67736" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Chemistry</h3><div class="NLM_p last">All commercially available reagents were used without further purification. All solvents were dried and redistilled prior to use in the usual manner. Reaction progress was monitored using analytical thin layer chromatography (TLC) on precoated silica gel GF254 (Yantai, China) plates, and the corresponding spots were detected under UV light (254 and 360 nm). Column chromatography was performed on silica gel (200–300 mesh, Yantai, China). <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained on a Bruker Avance 400 spectrometer (Bruker Company, Germany) using TMS as an internal standard. Chemical shifts are reported in ppm (d) using the residual solvent line as an internal standard. The splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; and m, multiplet. Mass spectra were recorded on a Q-TOF Premier mass spectrometer (Micromass, Manchester, UK). The purity of all the compounds (>95%) was determined on a Waters e2695 series LC system (column, Agilent C<sub>18</sub>, 4.6 mm × 150 mm, 5 μm; flow rate, 1.0 mL/min; UV wavelength, 254–400 nm; temperature, 25 °C; injection volume, 10 μL).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-Benzyl-2-(5-bromopyridin-2-yl)acetamide (<b>3</b>)</h3><div class="NLM_p last"><i>O</i>-(7-Aza-1<i>H</i>-benzotriazole-1-yl)-<i>N</i>,<i>N</i>,<i>N′</i>,<i>N′</i>-tetramethyluronium hexafluorophosphate (HATU) (26.4 g, 69.5 mmol, and 1.5 equiv) was added to a solution of 2-(5-bromopyridin-2-yl)acetic acid (10.0 g, 46.3 mmol, and 1.0 equiv) and benzylamine (7.6 mL, 69.5 mmol, and 1.5 equiv) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) (40 mL). The mixture was reacted overnight and monitored by TLC. The reaction was quenched with 300 mL of water and filtered. The filter was washed with water and dried to obtain the desired product <b>3</b>. Yield: 71.5%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.59 (dd, <i>J</i> = 10.6, 3.9 Hz, 2H), 7.99 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 7.33 (dd, <i>J</i> = 17.0, 7.9 Hz, 3H), 7.24 (dd, <i>J</i> = 11.9, 7.1 Hz, 3H), 4.28 (d, <i>J</i> = 5.9 Hz, 2H), 3.68 (s, 2H). Exact mass calcd for C<sub>14</sub>H<sub>13</sub>BrN<sub>2</sub>O [M + Na]<sup>+</sup>, 327.0109; found, 327.0104.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure A</h3><div class="NLM_p last">4-Hydroxybenzeneboronic acid pinacol ester (1.0 equiv), the corresponding substituted bromobenzene (1.2 equiv), PdCl<sub>2</sub>(dppf)CH<sub>2</sub>Cl<sub>2</sub> (0.1 equiv), and potassium fluoride (5.0 equiv) were added to a three-neck bottle followed by the solvent dioxane/H<sub>2</sub>O (v/v = 10/1) under a N<sub>2</sub> atmosphere and heating to 80 °C for 8 h. After the reaction was completed, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified using flash chromatography to obtain the desired compounds.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-Benzyl-2-(5-(4-hydroxyphenyl)pyridin-2-yl)acetamide (<b>4</b>)</h3><div class="NLM_p last">Following the <a class="ref internalNav" href="#sec4_3" aria-label="General Procedure A">General Procedure A</a>, the intermediate <b>3</b> was coupled with 4-hydroxybenzeneboronic acid pinacol ester to produce <b>4</b>. Yield: 75.2%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.62 (s, 1H), 8.71 (d, <i>J</i> = 2.0 Hz, 1H), 8.59 (d, <i>J</i> = 2.6 Hz, 1H), 7.92 (dd, <i>J</i> = 8.1, 2.5 Hz, 1H), 7.53 (d, <i>J</i> = 8.6 Hz, 2H), 7.38 (d, <i>J</i> = 8.1 Hz, 1H), 7.28 (ddd, <i>J</i> = 12.1, 11.5, 7.3 Hz, 4H), 6.87 (d, <i>J</i> = 8.6 Hz, 2H), 4.30 (d, <i>J</i> = 5.9 Hz, 2H), 3.70 (s, 2H). Exact mass calcd for C<sub>20</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 319.1447; found, 319.1440.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure B</h3><div class="NLM_p last">1,2-Dibromoethane, 1,3-dibromopropane, or 1,4-dibromobutane (2.0 equiv) was added to a solution of substituted phenol (1.0 equiv) and cesium carbonate (2.0 equiv) in acetonitrile (CH<sub>3</sub>CN) and refluxed for 6 h. The reaction was diluted with water and extracted with ethyl acetate three times. The combined organic phase was washed with saturated sodium chloride solution three times and concentrated under reduced pressure to obtain the desired intermediate.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-Benzyl-2-(5-(4-(2-bromoethoxy)phenyl)pyridin-2-yl)acetamide (<b>5a</b>)</h3><div class="NLM_p last">Following the <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure B">General Procedure B</a>, the intermediate <b>4</b> reacted with 1,2-dibromoethane to give <b>5a</b>. Yield: 98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (d, <i>J</i> = 2.1 Hz, 1H), 8.60 (t, <i>J</i> = 5.8 Hz, 1H), 7.97 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.66 (d, <i>J</i> = 8.7 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.36–7.20 (m, 5H), 7.09 (d, <i>J</i> = 8.7 Hz, 2H), 4.42–4.36 (m, 2H), 4.30 (d, <i>J</i> = 5.8 Hz, 2H), 3.87–3.79 (m, 2H), 3.71 (s, 2H). Exact mass calcd for C<sub>22</sub>H<sub>21</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 425.0865; found, 425.0860.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-Benzyl-2-(5-(4-(3-bromopropoxy)phenyl)pyridin-2-yl)acetamide (<b>5b</b>)</h3><div class="NLM_p last">Following the <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure B">General Procedure B</a>, the intermediate <b>4</b> reacted with 1,3-dibromopropane to give <b>5b</b>. Yield: 98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (d, <i>J</i> = 2.1 Hz, 1H), 8.62 (t, <i>J</i> = 5.7 Hz, 1H), 7.97 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.66 (dd, <i>J</i> = 8.9, 2.8 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.35–7.20 (m, 6H), 7.08 (dd, <i>J</i> = 8.8, 2.3 Hz, 2H), 4.30 (d, <i>J</i> = 5.9 Hz, 2H), 4.14 (t, <i>J</i> = 6.0 Hz, 2H), 3.72 (s, 2H), 3.69 (t, <i>J</i> = 6.6 Hz, 2H), 2.34–2.22 (m, 2H). Exact mass calcd for C<sub>23</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 439.1021; found, 439.1020.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-Benzyl-2-(5-(4-(4-bromobutoxy)phenyl)pyridin-2-yl)acetamide (<b>5c</b>)</h3><div class="NLM_p last">Following the <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure B">General Procedure B</a>, the intermediate <b>4</b> reacted with 1,4-dibromobutane to give <b>5c</b>. Yield: 98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (d, <i>J</i> = 2.1 Hz, 1H), 8.62 (t, <i>J</i> = 5.8 Hz, 1H), 7.97 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.65 (d, <i>J</i> = 8.7 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.35–7.21 (m, 5H), 7.06 (d, <i>J</i> = 8.8 Hz, 2H), 4.31 (d, <i>J</i> = 5.9 Hz, 2H), 4.06 (t, <i>J</i> = 6.3 Hz, 2H), 3.72 (s, 2H), 3.62 (t, <i>J</i> = 6.6 Hz, 2H), 1.99 (dt, <i>J</i> = 14.6, 6.6 Hz, 2H), 1.86 (dt, <i>J</i> = 12.7, 6.2 Hz, 2H). Exact mass calcd for C<sub>24</sub>H<sub>25</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 453.1178; found, 453.1172.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure C</h3><div class="NLM_p last">Potassium iodide (4.0 equiv) and triethylamine (2.0 equiv) were added to a solution of a bromine-substituted intermediate (1.0 equiv) in DMF (2 mL) followed by a secondary or primary amine (1.5 equiv). The mixture was reacted at 50 °C for 8 h. The reaction was diluted with excess water (10 mL) and extracted with ethyl acetate (2 mL × 4). The combined organic phase was washed with saturated sodium chloride solution three times and concentrated under reduced pressure. The residue was purified using flash chromatography (silica gel: CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 97:3 v/v) to obtain the target compounds.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-Benzyl-2-(5-(4-(3-morpholinopropoxy)phenyl)pyridin-2-yl)acetamide (<b>6a</b>)</h3><div class="NLM_p last">Yield: 78.2%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.74 (d, <i>J</i> = 2.1 Hz, 1H), 8.63 (t, <i>J</i> = 5.9 Hz, 1H), 7.96 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.64 (d, <i>J</i> = 8.7 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.35–7.20 (m, 5H), 7.04 (d, <i>J</i> = 8.8 Hz, 2H), 4.30 (d, <i>J</i> = 5.9 Hz, 2H), 4.06 (t, <i>J</i> = 6.4 Hz, 2H), 3.71 (s, 2H), 3.62–3.52 (m, 4H), 2.43 (t, <i>J</i> = 7.2 Hz, 2H), 2.37 (s, 4H), 1.94–1.84 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.21, 158.69, 154.56, 146.41, 139.43, 133.86, 133.25, 129.21, 128.27 (2C), 127.88 (2C), 127.24 (2C), 126.75, 123.77, 115.11 (2C), 66.23 (2C), 65.91, 54.85, 53.40 (2C), 44.49, 42.25, 25.88. Exact mass calcd for C<sub>27</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub> [M + Na]<sup>+</sup>, 468.2263; found, 468.2264.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 2-(5-(4-(3-((1<i>S</i>,4<i>S</i>)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6b</b>)</h3><div class="NLM_p last">Yield: 79.2%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.64 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (dd, <i>J</i> = 12.8, 7.1 Hz, 3H), 7.27–7.20 (m, 3H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.7 Hz, 2H), 4.40 (s, 1H), 4.09 (t, <i>J</i> = 6.2 Hz, 2H), 4.05 (d, <i>J</i> = 7.8 Hz, 1H), 3.81 (s, 2H), 3.63 (dd, <i>J</i> = 7.7, 1.3 Hz, 1H), 3.49 (s, 1H), 2.95 (d, <i>J</i> = 9.9 Hz, 1H), 2.87–2.78 (m, 1H), 2.78–2.68 (m, 1H), 2.55 (d, <i>J</i> = 10.0 Hz, 1H), 1.96 (dt, <i>J</i> = 13.3, 6.7 Hz, 2H), 1.87 (d, <i>J</i> = 9.7 Hz, 1H), 1.74 (d, <i>J</i> = 9.7 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.42, 159.42, 153.71, 147.30, 138.50, 135.14, 134.94, 129.74, 128.73 (2C), 128.22 (2C), 127.66 (2C), 127.41, 124.08, 115.31 (2C), 77.08, 69.20, 66.27, 61.67, 60.84, 50.42, 45.03, 43.66, 35.68, 29.13. Exact mass calcd for C<sub>28</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 458.2444; found, 458.2441.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 2-(5-(4-(3-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)propoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6c</b>)</h3><div class="NLM_p last">Yield: 74.5%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 1.8 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.62 (s, 1H), 7.49 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (dd, <i>J</i> = 12.7, 7.3 Hz, 3H), 7.25 (d, <i>J</i> = 7.2 Hz, 3H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.28 (s, 2H), 4.07 (t, <i>J</i> = 6.4 Hz, 2H), 3.82 (s, 2H), 2.60 (d, <i>J</i> = 10.8 Hz, 2H), 2.48 (t, <i>J</i> = 6.7 Hz, 2H), 2.32 (d, <i>J</i> = 10.6 Hz, 2H), 1.99–1.87 (m, 4H), 1.87–1.78 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.41, 159.53, 153.74, 147.33, 138.51, 135.15, 134.96, 129.74, 128.75 (2C), 128.25 (2C), 127.67 (2C), 127.43, 124.10, 115.32 (2C), 74.91 (2C), 66.35, 58.84 (2C), 54.41, 45.05, 43.68, 28.75 (2C), 26.59. Exact mass calcd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 472.2600; found, 472.2600.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-Benzyl-2-(5-(4-(4-morpholinobutoxy)phenyl)pyridin-2-yl)acetamide (<b>6d</b>)</h3><div class="NLM_p last">Yield: 80.3%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.74 (d, <i>J</i> = 2.1 Hz, 1H), 8.63 (t, <i>J</i> = 5.8 Hz, 1H), 7.96 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.64 (d, <i>J</i> = 8.7 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.35–7.19 (m, 5H), 7.04 (d, <i>J</i> = 8.8 Hz, 2H), 4.31 (d, <i>J</i> = 5.9 Hz, 2H), 4.03 (t, <i>J</i> = 6.5 Hz, 2H), 3.72 (s, 2H), 3.60–3.52 (m, 4H), 2.33 (s, 4H), 1.80–1.69 (m, 2H), 1.64–1.53 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.24, 158.72, 154.55, 146.43, 139.44, 133.88, 133.29, 129.16, 128.29 (2C), 127.87 (2C), 127.26 (2C), 126.77, 123.79, 115.12 (2C), 67.43, 66.26 (2C), 57.81, 53.35 (2C), 44.51, 42.28, 26.56, 22.41. Exact mass calcd for C<sub>28</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub> [M + Na]<sup>+</sup>, 482.2420; found, 482.2422.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 2-(5-(4-(4-((1<i>S</i>,4<i>S</i>)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)butoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6e</b>)</h3><div class="NLM_p last">Yield: 59.6%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.64 (s, 1H), 7.53–7.45 (m, 2H), 7.35–7.28 (m, 3H), 7.27–7.21 (m, 3H), 6.99 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.39 (s, 1H), 4.03 (t, <i>J</i> = 6.5 Hz, 3H), 3.81 (s, 2H), 3.62 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 3.50 (s, 1H), 2.94 (dd, <i>J</i> = 10.0, 1.5 Hz, 1H), 2.69 (dt, <i>J</i> = 11.6, 7.3 Hz, 1H), 2.60 (dt, <i>J</i> = 11.6, 7.6 Hz, 1H), 2.52 (d, <i>J</i> = 10.0 Hz, 1H), 1.91–1.82 (m, 3H), 1.73 (d, <i>J</i> = 9.7 Hz, 1H), 1.66 (dt, <i>J</i> = 14.8, 7.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.41, 159.43, 153.71, 147.31, 138.51, 135.13, 134.95, 129.70, 128.73 (2C), 128.23 (2C), 127.66 (2C), 127.41, 124.07, 115.29 (2C), 77.05, 69.03, 68.00, 61.43, 60.79, 53.35, 45.03, 43.66, 35.68, 27.26, 25.88. Exact mass calcd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 472.2600; found, 472.2599.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 2-(5-(4-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)butoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6f</b>)</h3><div class="NLM_p last">Yield: 79.4%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.63 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.39–7.27 (m, 3H), 7.26–7.21 (m, 3H), 6.99 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.28 (d, <i>J</i> = 2.2 Hz, 2H), 4.03 (t, <i>J</i> = 6.4 Hz, 2H), 3.81 (s, 2H), 2.59 (d, <i>J</i> = 10.8 Hz, 2H), 2.35 (t, <i>J</i> = 7.1 Hz, 2H), 2.28 (d, <i>J</i> = 9.6 Hz, 2H), 1.96–1.89 (m, 2H), 1.84 (td, <i>J</i> = 12.5, 6.8 Hz, 4H), 1.62 (dt, <i>J</i> = 14.4, 7.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.41, 159.47, 153.71, 147.31, 138.51, 135.14, 134.96, 129.68, 128.74 (2C), 128.23 (2C), 127.67 (2C), 127.41, 124.09, 115.30 (2C), 74.92 (2C), 68.09, 58.84 (2C), 57.59, 45.04, 43.67, 28.72 (2C), 27.12, 23.22. Exact mass calcd for C<sub>30</sub>H<sub>35</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 486.2757; found, 486.2756.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-(5-(4-(2-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)ethoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6g</b>)</h3><div class="NLM_p last">Yield: 74.4%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.61 (s, 1H), 7.51–7.46 (m, 2H), 7.36–7.28 (m, 3H), 7.24 (d, <i>J</i> = 2.3 Hz, 2H), 7.00 (d, <i>J</i> = 8.8 Hz, 2H), 4.49 (d, <i>J</i> = 5.8 Hz, 2H), 4.29 (s, 2H), 4.11 (t, <i>J</i> = 5.7 Hz, 2H), 3.82 (s, 2H), 2.77 (t, <i>J</i> = 5.5 Hz, 2H), 2.65 (d, <i>J</i> = 11.0 Hz, 2H), 2.49 (d, <i>J</i> = 10.8 Hz, 2H), 1.95 (d, <i>J</i> = 6.3 Hz, 2H), 1.90–1.81 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.40, 158.94, 153.80, 147.36, 138.52, 135.19, 134.93, 129.97, 128.76 (2C), 128.28 (2C), 127.68 (2C), 127.44, 124.11, 115.46 (2C), 80.15 (2C), 74.89, 59.09 (2C), 56.76, 45.06, 43.69, 42.10, 28.66 (2C). Exact mass calcd for C<sub>28</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 458.2447; found, 458.2444.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-(5-(4-(2-((1<i>S</i>,4<i>S</i>)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)ethoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6h</b>)</h3><div class="NLM_p last">Yield: 80.5%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.63 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (dd, <i>J</i> = 12.4, 7.3 Hz, 3H), 7.27–7.19 (m, 3H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.42 (s, 1H), 4.18–4.05 (m, 3H), 3.81 (s, 2H), 3.67 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 3.60 (s, 1H), 3.13–2.96 (m, 3H), 2.66 (d, <i>J</i> = 10.1 Hz, 1H), 1.84 (dd, <i>J</i> = 52.2, 9.7 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.41, 159.14, 153.77, 147.30, 138.49, 135.16, 134.88, 129.98, 128.73 (2C), 128.26 (2C), 127.66 (2C), 127.41, 124.09, 115.37 (2C), 77.05, 69.21, 67.95, 62.31, 61.63, 52.66, 45.03, 43.66, 35.92. Exact mass calcd for C<sub>27</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 444.2287; found, 444.2289.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-(5-(4-(2-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)ethoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6i</b>)</h3><div class="NLM_p last">Yield: 78.5%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.63 (s, 1H), 7.52–7.45 (m, 2H), 7.36–7.27 (m, 3H), 7.26–7.20 (m, 2H), 7.01 (d, <i>J</i> = 8.8 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.15 (t, <i>J</i> = 5.9 Hz, 2H), 3.96 (s, 4H), 3.81 (s, 2H), 2.88 (t, <i>J</i> = 5.9 Hz, 2H), 2.76–2.63 (m, 4H), 1.81–1.76 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.41, 159.18, 153.76, 147.33, 138.51, 135.17, 134.91, 129.95, 128.75 (2C), 128.25 (2C), 127.67 (2C), 127.42, 124.09, 115.44 (2C), 107.12, 66.40, 64.39 (2C), 56.87, 52.02 (2C), 45.04, 43.67, 34.93 (2C). Exact mass calcd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 488.2549; found, 488.2549.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-methoxypiperidin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6j</b>)</h3><div class="NLM_p last">Yield: 67.9%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.63 (s, 1H), 7.51–7.44 (m, 2H), 7.35–7.27 (m, 3H), 7.26–7.21 (m, 3H), 7.03–6.98 (m, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.15 (t, <i>J</i> = 5.9 Hz, 2H), 3.81 (s, 2H), 3.34 (s, 3H), 3.28–3.20 (m, 1H), 2.85 (m, 4H), 2.38–2.26 (m, 2H), 1.97–1.87 (m, 2H), 1.69–1.59 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>); δ 169.39, 159.21, 153.77, 147.35, 138.52, 135.16, 134.91, 129.93, 128.75 (2C), 128.25 (2C), 127.67 (2C), 127.42, 124.08, 115.43 (2C), 77.36, 66.47, 57.25, 55.69, 51.72, 45.05, 43.67, 30.97 (2C). Exact mass calcd for C<sub>28</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 460.2600; found, 460.2595.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 2-(5-(4-(2-(6-Azaspiro[2.5]octan-6-yl)ethoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6k</b>)</h3><div class="NLM_p last">Yield: 74.7%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 1.7 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.1 Hz, 1H), 7.64 (s, 1H), 7.48 (d, <i>J</i> = 8.6 Hz, 2H), 7.31 (dd, <i>J</i> = 11.5, 7.3 Hz, 3H), 7.25 (d, <i>J</i> = 7.6 Hz, 3H), 7.02 (d, <i>J</i> = 8.6 Hz, 2H), 4.48 (d, <i>J</i> = 5.7 Hz, 2H), 4.19 (t, <i>J</i> = 6.0 Hz, 2H), 3.81 (s, 2H), 2.88 (t, <i>J</i> = 6.0 Hz, 2H), 2.62 (s, 4H), 1.45 (s, 4H), 0.29 (s, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.42, 159.21, 153.74, 147.32, 138.50, 135.16, 134.92, 129.89, 128.74 (2C), 128.24 (2C), 127.66 (2C), 127.41, 124.09, 115.42 (2C), 66.31, 57.61, 53.91 (2C), 45.03, 43.66, 35.10 (2C), 17.42, 11.63 (2C). Exact mass calcd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 456.2651; found, 456.2656.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-Benzyl-2-(5-(4-(2-(3-methylpiperidin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6l</b>)</h3><div class="NLM_p last">Yield: 76.7%. HPLC purity: 97%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.65 (s, 1H), 7.48 (d, <i>J</i> = 8.8 Hz, 2H), 7.35–7.27 (m, 3H), 7.24 (dt, <i>J</i> = 6.6, 4.0 Hz, 3H), 7.01 (d, <i>J</i> = 8.8 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.17 (t, <i>J</i> = 6.0 Hz, 2H), 3.81 (s, 2H), 2.95 (dd, <i>J</i> = 20.9, 9.3 Hz, 2H), 2.82 (t, <i>J</i> = 6.0 Hz, 2H), 2.22 (m, 1H), 2.03 (td, <i>J</i> = 11.1, 3.9 Hz, 1H), 1.78–1.58 (m, 5H), 0.88 (d, <i>J</i> = 5.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.42, 159.18, 153.72, 147.29, 138.49, 135.14, 134.90, 129.87, 128.72 (2C), 128.22 (2C), 127.65 (2C), 127.39, 124.07, 115.41 (2C), 66.14, 62.61, 57.72, 54.59, 45.01, 43.65, 32.90, 31.17, 25.58, 19.87. Exact mass calcd for C<sub>28</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 444.2651; found, 444.2650.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-(5-(4-(2-(3-Azabicyclo[3.1.0]hexan-3-yl)ethoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6m</b>)</h3><div class="NLM_p last">Yield: 67.2%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 2.1 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.63 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.36–7.27 (m, 3H), 7.24 (d, <i>J</i> = 2.4 Hz, 2H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 4.49 (d, <i>J</i> = 5.8 Hz, 2H), 4.08 (t, <i>J</i> = 6.0 Hz, 2H), 3.81 (s, 2H), 3.08 (d, <i>J</i> = 8.6 Hz, 2H), 2.88 (t, <i>J</i> = 6.0 Hz, 2H), 2.47 (d, <i>J</i> = 8.1 Hz, 2H), 1.39–1.32 (m, 2H), 0.70 (dd, <i>J</i> = 7.6, 3.8 Hz, 1H), 0.36 (td, <i>J</i> = 7.7, 4.4 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.20, 158.53, 154.56, 146.42, 139.42, 133.87, 133.24, 129.27, 128.27 (2C), 127.87 (2C), 127.24 (2C), 126.75, 123.76, 115.17 (2C), 66.89, 54.81 (2C), 53.17, 44.49, 42.25, 15.00 (2C), 6.44. Exact mass calcd for C<sub>27</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 428.2338; found, 428.2340.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-Benzyl-2-(5-(4-(2-(6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6n</b>)</h3><div class="NLM_p last">Yield: 72.8%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.63 (s, 1H), 7.51–7.43 (m, 2H), 7.36–7.28 (m, 3H), 7.26–7.21 (m, 3H), 7.02–6.95 (m, 2H), 4.49 (d, <i>J</i> = 5.8 Hz, 2H), 4.04 (t, <i>J</i> = 6.1 Hz, 2H), 3.81 (s, 2H), 2.92–2.79 (m, 6H), 1.25 (d, <i>J</i> = 1.6 Hz, 2H), 1.15 (s, 3H), 0.99 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.40, 159.37, 153.73, 147.35, 138.53, 135.16, 134.98, 129.78, 128.76 (2C), 128.23 (2C), 127.68 (2C), 127.42, 124.08, 115.44 (2C), 67.70, 54.02, 53.93 (2C), 45.05, 43.67, 29.32 (2C), 27.21, 20.56, 14.48. Exact mass calcd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 456.2651; found, 456.2645.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-Benzyl-2-(5-(4-(2-(octahydro-2<i>H</i>-isoindol-2-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6o</b>)</h3><div class="NLM_p last">Yield: 75.4%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.64 (s, 1H), 7.52–7.45 (m, 2H), 7.35–7.28 (m, 3H), 7.26–7.21 (m, 2H), 7.02 (d, <i>J</i> = 8.8 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.13 (t, <i>J</i> = 6.1 Hz, 2H), 3.81 (s, 2H), 3.04 (t, <i>J</i> = 6.1 Hz, 2H), 2.96 (dd, <i>J</i> = 9.2, 6.9 Hz, 2H), 2.64 (dd, <i>J</i> = 9.2, 5.6 Hz, 2H), 2.26–2.12 (m, 2H), 1.64–1.54 (m, 2H), 1.49 (ddd, <i>J</i> = 20.5, 13.9, 8.5 Hz, 4H), 1.39–1.29 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>); δ 169.42, 159.26, 153.73, 147.33, 138.51, 135.17, 134.94, 129.88, 128.74 (2C), 128.24 (2C), 127.66 (2C), 127.42, 124.09, 115.44 (2C), 67.42, 59.06 (2C), 56.36, 45.03, 43.67, 37.38 (2C), 26.90 (2C), 23.00 (2C). Exact mass calcd for C<sub>30</sub>H<sub>35</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 470.2808; found, 470.2800.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-Benzyl-2-(5-(4-(2-(cyclopropylamino)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6p</b>)</h3><div class="NLM_p last">Yield: 25.4%. HPLC purity: 97%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.63 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.37–7.27 (m, 3H), 7.25 (d, <i>J</i> = 7.3 Hz, 3H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.13 (t, <i>J</i> = 5.2 Hz, 2H), 3.82 (s, 2H), 3.13 (t, <i>J</i> = 5.2 Hz, 2H), 2.23 (dt, <i>J</i> = 10.1, 3.4 Hz, 1H), 0.53–0.43 (m, 2H), 0.44–0.34 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.43, 159.28, 153.76, 147.31, 138.49, 135.19, 134.92, 129.98, 128.75 (2C), 128.27 (2C), 127.67 (2C), 127.43, 124.11, 115.34 (2C), 67.38, 48.54, 45.03, 43.68, 30.22, 6.43 (2C). Exact mass calcd for C<sub>25</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 402.2182; found, 402.2178.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-(5-(4-(2-(4-Acetylpiperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)-<i>N</i>-benzylacetamide (<b>6q</b>)</h3><div class="NLM_p last">Yield: 70.7%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 1.8 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.2 Hz, 1H), 7.63 (s, 1H), 7.49 (d, <i>J</i> = 8.6 Hz, 2H), 7.31 (dd, <i>J</i> = 16.4, 7.2 Hz, 3H), 7.25 (dd, <i>J</i> = 8.0, 2.5 Hz, 3H), 7.01 (d, <i>J</i> = 8.6 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.16 (t, <i>J</i> = 5.5 Hz, 2H), 3.82 (s, 2H), 3.69–3.61 (m, 2H), 3.54–3.45 (m, 2H), 2.86 (t, <i>J</i> = 5.5 Hz, 2H), 2.66–2.52 (m, 4H), 2.09 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.41, 169.08, 159.00, 153.82, 147.31, 138.48, 135.18, 134.84, 130.14, 128.74 (2C), 128.30 (2C), 127.66 (2C), 127.42, 124.11, 115.39 (2C), 66.20, 57.20, 53.85, 53.34, 46.40, 45.04, 43.67, 41.52, 29.83, 21.42. Exact mass calcd for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub> [M + Na]<sup>+</sup>, 495.2372; found, 495.2372.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-(cyclopropanecarbonyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6r</b>)</h3><div class="NLM_p last">Yield: 46.4%. HPLC purity: 97%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.61 (s, 1H), 7.49 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (dd, <i>J</i> = 14.8, 7.4 Hz, 3H), 7.26–7.21 (m, 3H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.17 (t, <i>J</i> = 5.6 Hz, 2H), 3.81 (s, 2H), 3.72 (dd, <i>J</i> = 13.9, 7.0 Hz, 4H), 2.87 (t, <i>J</i> = 5.6 Hz, 2H), 2.61 (d, <i>J</i> = 25.9 Hz, 4H), 1.77–1.71 (m, 1H), 1.03–0.94 (m, 2H), 0.81–0.70 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.09, 169.40, 159.04, 153.83, 147.33, 138.50, 135.19, 134.86, 130.14, 128.75 (2C), 128.31 (2C), 127.68 (2C), 127.43, 124.11, 115.41 (2C), 77.36, 66.22, 61.42, 57.25 (2C), 45.05, 43.68 (2C), 11.05, 7.54 (2C). Exact mass calcd for C<sub>30</sub>H<sub>34</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 499.2709; found, 499.2704.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-(<i>tert</i>-butyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6s</b>)</h3><div class="NLM_p last">Yield: 43.8%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.64 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (dd, <i>J</i> = 13.5, 7.4 Hz, 3H), 7.26–7.20 (m, 3H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.15 (t, <i>J</i> = 5.9 Hz, 2H), 3.81 (s, 2H), 2.84 (t, <i>J</i> = 5.9 Hz, 2H), 2.66 (s, 8H), 1.09 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.43, 159.19, 153.74, 147.31, 138.49, 135.18, 134.93, 129.92, 128.74 (2C), 128.24 (2C), 127.66 (2C), 127.42, 124.10, 115.42 (2C), 66.13, 57.24, 54.41 (2C), 45.70 (2C), 45.03, 43.68, 29.83, 25.96 (3C). Exact mass calcd for C<sub>30</sub>H<sub>38</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 487.3073; found, 487.3065.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-ethylpiperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>6t</b>)</h3><div class="NLM_p last">Yield: 37.4%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.64 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (dd, <i>J</i> = 14.0, 7.0 Hz, 3H), 7.25 (dd, <i>J</i> = 8.5, 3.1 Hz, 3H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.16 (t, <i>J</i> = 5.8 Hz, 2H), 3.81 (s, 2H), 2.86 (t, <i>J</i> = 5.8 Hz, 2H), 2.67 (s, 4H), 2.55 (s, 4H), 2.45 (q, <i>J</i> = 7.2 Hz, 2H), 1.10 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.42, 159.16, 153.75, 147.31, 138.49, 135.17, 134.90, 129.95, 128.74 (2C), 128.24 (2C), 127.66 (2C), 127.41, 124.09, 115.41 (2C), 66.19, 57.26, 53.63 (2C), 52.79 (2C), 52.41, 45.03, 43.67, 11.96. Exact mass calcd for C<sub>28</sub>H<sub>34</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 459.2760; found, 459.2754.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>tert</i>-Butyl-4-(2-(4-(6-(2-(benzylamino)-2-oxoethyl)pyridin-3-yl)phenoxy)ethyl)piperazine-1-carboxylate (<b>6u</b>)</h3><div class="NLM_p last">Yield: 56.2%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 2.1 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.62 (s, 1H), 7.49 (d, <i>J</i> = 8.7 Hz, 2H), 7.36–7.27 (m, 3H), 7.25 (dd, <i>J</i> = 7.8, 2.6 Hz, 3H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.16 (t, <i>J</i> = 5.7 Hz, 2H), 3.81 (s, 2H), 3.53–3.41 (m, 4H), 2.85 (t, <i>J</i> = 5.7 Hz, 2H), 2.60–2.48 (m, 4H), 1.46 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.41, 159.07, 154.87, 153.80, 147.32, 138.49, 135.19, 134.88, 130.07, 128.75 (2C), 128.28 (2C), 127.67 (2C), 127.43, 124.11, 115.41 (2C), 79.85, 66.21, 57.36, 53.57, 45.04, 43.68, 28.57 (3C). Exact mass calcd for C<sub>31</sub>H<sub>38</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 531.2971; found, 531.2973.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-Benzyl-2-(5-(4-(2-(piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>7</b>)</h3><div class="NLM_p last">Trifluoroacetic acid (TFA) (5.0 mL) was added to a solution of <b>6u</b> (2.5 g) in CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL) and allowed to react at room temperature for 2 h. The TFA was then evaporated under reduced pressure. The residue was diluted with ethyl acetate (10 mL), washed with saturated sodium bicarbonate solution (10 mL × 2) and saturated sodium chloride solution (10 mL × 2), and then concentrated under reduced pressure. The crude product was purified using flash chromatography (silica gel: CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 97:3 v/v) to obtain compound <b>7</b>. Yield: 84.5%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.65 (s, 1H), 7.52–7.45 (m, 2H), 7.36–7.28 (m, 3H), 7.26–7.22 (m, 3H), 7.00 (d, <i>J</i> = 8.8 Hz, 2H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.16 (t, <i>J</i> = 5.7 Hz, 2H), 3.81 (s, 2H), 3.08–2.92 (m, 4H), 2.84 (t, <i>J</i> = 5.7 Hz, 2H), 2.63 (s, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.45, 159.10, 153.77, 147.29, 138.48, 135.20, 134.90, 130.03, 128.74 (2C), 128.27 (2C), 127.67 (2C), 127.42, 124.12, 115.41 (2C), 66.12, 57.71, 54.15 (2C), 45.65 (2C), 45.02, 43.68, 29.83. Exact mass calcd for C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 431.2447; found, 431.2441.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> General Procedure D</h3><div class="NLM_p last">HATU (1.5 equiv) was added to a solution of <i>N</i>-benzyl-2-(5-(4-(2-(piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>7</b>) (1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> followed by carboxylic acid or sulfonic acid (1.1 equiv). The mixture was reacted at room temperature for 4 h. The reaction mixture was then concentrated under reduced pressure and purified using flash chromatography to obtain target compound <b>8</b>.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-(2-cyclopropylacetyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>8a</b>)</h3><div class="NLM_p last">Yield: 63.5%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (d, <i>J</i> = 2.2 Hz, 1H), 8.62 (t, <i>J</i> = 5.8 Hz, 1H), 7.96 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.64 (d, <i>J</i> = 8.7 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.35–7.20 (m, 5H), 7.06 (d, <i>J</i> = 8.7 Hz, 2H), 4.30 (d, <i>J</i> = 5.9 Hz, 2H), 4.15 (t, <i>J</i> = 5.6 Hz, 2H), 3.71 (s, 2H), 3.50–3.39 (m, 4H), 2.74 (t, <i>J</i> = 5.6 Hz, 2H), 2.45 (m, 4H), 2.24 (d, <i>J</i> = 6.7 Hz, 2H), 0.93 (ddd, <i>J</i> = 12.8, 7.3, 5.5 Hz, 1H), 0.47–0.39 (m, 2H), 0.10 (q, <i>J</i> = 4.9 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.17, 169.20, 158.48, 154.58, 146.42, 139.42, 133.88, 133.22, 129.33, 128.27 (2C), 127.88 (2C), 127.24 (2C), 126.75, 123.77, 115.18 (2C), 65.56, 56.44, 53.40, 52.86, 45.10, 44.48, 42.24, 40.96, 37.34, 7.27, 4.26 (2C). Exact mass calcd for C<sub>31</sub>H<sub>36</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 513.2866; found, 513.2874.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-(cyclobutanecarbonyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>8b</b>)</h3><div class="NLM_p last">Yield: 56.4%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.63 (s, 1H), 7.48 (d, <i>J</i> = 8.8 Hz, 2H), 7.37–7.27 (m, 3H), 7.26–7.20 (m, 3H), 7.00 (d, <i>J</i> = 8.8 Hz, 2H), 4.48 (d, <i>J</i> = 5.7 Hz, 2H), 4.18 (t, <i>J</i> = 5.4 Hz, 2H), 3.82 (s, 2H), 3.67 (s, 2H), 3.46–3.37 (m, 2H), 3.31–3.18 (m, 1H), 2.88 (t, <i>J</i> = 5.2 Hz, 2H), 2.60 (s, 4H), 2.35 (dtd, <i>J</i> = 17.9, 9.2, 2.2 Hz, 2H), 2.19–2.09 (m, 2H), 2.00–1.84 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.19, 169.36, 158.89, 153.81, 147.22, 138.48, 135.21, 134.83, 130.18, 128.72 (2C), 128.30 (2C), 127.66 (2C), 127.40, 124.13, 115.38 (2C), 65.97, 57.18, 53.89, 53.41, 45.00, 44.80, 43.66, 41.48, 37.27, 25.22 (2C), 18.09. Exact mass calcd for C<sub>31</sub>H<sub>36</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 513.2866; found, 513.2866.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-((1<i>S</i>,2<i>S</i>)-2-fluorocyclopropane-1-carbonyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>8c</b>)</h3><div class="NLM_p last">Yield: 85.3%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.62 (s, 1H), 7.49 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (dd, <i>J</i> = 15.3, 7.0 Hz, 3H), 7.24 (s, 3H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 4.88–4.80 (m, 1H), 4.71–4.64 (m, 1H), 4.48 (d, <i>J</i> = 5.8 Hz, 2H), 4.20 (t, <i>J</i> = 5.4 Hz, 2H), 3.93 (d, <i>J</i> = 11.4 Hz, 1H), 3.81 (s, 3H), 3.76–3.64 (m, 1H), 3.63–3.50 (m, 1H), 2.90 (t, <i>J</i> = 5.3 Hz, 2H), 2.73 (d, <i>J</i> = 29.7 Hz, 2H), 2.65–2.48 (m, 2H), 1.94–1.80 (m, 2H), 1.11–0.98 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.35, 165.05 (d, <i>J</i> = 4.1 Hz), 158.88, 153.84, 147.28, 138.49, 135.20, 134.82, 130.23, 128.74 (2C), 128.32 (2C), 127.66 (2C), 127.41, 124.11, 115.41 (2C), 71.33 (d, <i>J</i> = 225.3 Hz), 65.95, 57.14, 53.97, 53.33, 45.39, 45.02, 43.67, 42.21, 20.15 (d, <i>J</i> = 12.3 Hz), 10.39 (d, <i>J</i> = 11.0 Hz). Exact mass calcd for C<sub>30</sub>H<sub>33</sub>FN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 517.2615; found, 517.2617.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-((1<i>R</i>,2<i>S</i>)-2-fluorocyclopropane-1-carbonyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>8d</b>)</h3><div class="NLM_p last">Yield: 74.3%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.66 (s, 1H), 8.54 (s, 1H), 7.89 (d, <i>J</i> = 6.1 Hz, 1H), 7.57 (d, <i>J</i> = 8.5 Hz, 2H), 7.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.28–7.10 (m, 5H), 6.99 (d, <i>J</i> = 8.6 Hz, 2H), 4.78, 4.62 (d, 1H), 4.23 (d, <i>J</i> = 5.7 Hz, 2H), 4.08 (t, <i>J</i> = 5.3 Hz, 2H), 3.62 (m, 4H), 3.10 (s, 1H), 2.69 (t, <i>J</i> = 5.3 Hz, 2H), 2.57–2.28 (m, 4H), 1.40–1.22 (m, 1H), 1.06 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.20, 167.64, 158.49, 154.59, 146.43, 139.42, 133.88, 133.22, 129.34, 128.27 (2C), 127.88 (2C), 127.24 (2C), 126.75, 123.77, 115.18 (2C), 73.92 (d, <i>J</i> = 223.6 Hz), 65.54, 56.38, 53.41, 52.67, 45.05, 44.48, 42.25, 41.51, 17.42 (d, <i>J</i> = 11.9 Hz), 13.36 (d, <i>J</i> = 8.5 Hz). Exact mass calcd for C<sub>30</sub>H<sub>33</sub>FN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 517.2615; found, 517.2615.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-(2,2-difluorocyclopropane-1-carbonyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>8e</b>)</h3><div class="NLM_p last">Yield: 97.3%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.75 (d, <i>J</i> = 1.9 Hz, 1H), 8.66 (t, <i>J</i> = 5.7 Hz, 1H), 7.97 (dd, <i>J</i> = 8.1, 2.3 Hz, 1H), 7.65 (d, <i>J</i> = 8.7 Hz, 2H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.37–7.18 (m, 5H), 7.08 (d, <i>J</i> = 8.7 Hz, 2H), 4.31 (d, <i>J</i> = 5.9 Hz, 2H), 4.16 (t, <i>J</i> = 5.6 Hz, 2H), 3.72 (s, 2H), 3.66–3.48 (m, 4H), 2.77 (t, <i>J</i> = 5.6 Hz, 2H), 2.71–2.58 (m, 1H), 2.52–2.38 (m, 4H), 1.95–1.76 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.23, 162.33, 158.49, 154.59, 146.42, 139.43, 133.89, 133.23, 129.36, 128.27 (2C), 127.88 (2C), 127.24 (2C), 126.75, 123.77, 115.20 (2C), 110.54 (d, <i>J</i> = 286.9 Hz), 65.57, 56.35, 53.34, 52.70, 45.24, 44.49, 24.54 (m), 14.40 (m). Exact mass calcd for C<sub>30</sub>H<sub>32</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 535.2521; found, 535.2520.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-Benzyl-2-(5-(4-(2-(4-(cyclopropylsulfonyl)piperazin-1-yl)ethoxy)phenyl)pyridin-2-yl)acetamide (<b>8f</b>)</h3><div class="NLM_p last">Yield: 52.5%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, DMSO): δ 8.75 (d, <i>J</i> = 2.2 Hz, 1H), 8.62 (t, <i>J</i> = 5.8 Hz, 1H), 7.96 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 7.65 (d, <i>J</i> = 8.7 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.35–7.20 (m, 5H), 7.07 (d, <i>J</i> = 8.7 Hz, 2H), 4.31 (d, <i>J</i> = 5.9 Hz, 2H), 4.14 (t, <i>J</i> = 5.6 Hz, 2H), 3.72 (s, 2H), 3.25–3.13 (m, 4H), 2.78 (t, <i>J</i> = 5.6 Hz, 2H), 2.66–2.54 (m, 5H), 1.02–0.87 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 169.21, 158.49, 154.58, 146.41, 139.41, 133.87, 133.22, 129.35, 128.26 (2C), 127.87 (2C), 127.23 (2C), 126.74, 123.76, 115.20 (2C), 65.60, 56.14, 52.35 (2C), 45.82 (2C), 44.49, 42.26, 24.58, 3.81 (2C). Exact mass calcd for C<sub>29</sub>H<sub>34</sub>N<sub>4</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 535.2379; found, 535.2377.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Cell Culture and MTT Assays</h3><div class="NLM_p last">Cells were cultured in an RPMI 1640 (Gibco, Milano, Italy) medium supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Milano, Italy), penicillin (100 units/mL, Gibco, Milano, Italy), and streptomycin (100 μg/mL, Gibco, Milano, Italy). These cells were incubated at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>. Cells of SKOV3, MDA-MB-231, and MDA-MB-468 were seeded into 96-well culture plates at densities of 1.0 × 10<sup>4</sup> cells per well and cultured for 24 h. These cells were then treated with different concentrations of compounds for 72 h in a final volume of 200 μL, whereas the K562, Ramos, and Jurkat cells were seeded into 96-well culture plates at densities of 1.0 × 10<sup>5</sup> cells after the addition of different concentrations of compounds and cultured for 72 h. MTT (20 μL, 5 mg/mL) was added to each well, and the cells were incubated for an additional 2–4 h. The supernatant was removed, and 150 μL of dimethyl sulfoxide (DMSO, Sigma-Aldrich) was added to dissolve the purple crystals; the absorbance of the solution was then measured using a spectrophotometer (Molecular Devices, Sunnyvale, USA) at 570 nm. The IC<sub>50</sub> values were calculated from the percentage growth against that of the untreated control.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Tryptophan-Based Binding Assay</h3><div class="NLM_p last">KX01, <b>6r</b>, <b>8a</b>, <b>8b</b>, and <b>8c</b> at different concentrations (0, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128 μM) were incubated with purified tubulin (0.5 M) in PEM buffer (80 mM PIPES (pH 6.9), 2 mM MgCl<sub>2</sub>, 0.5 mM EGTA, and 1 mM GTP). The experiment was carried out as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Molecular Docking Study</h3><div class="NLM_p last">The crystal structure of tubulin bound to KX01 from the Protein Data Bank<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>) was selected as the docking model. The structures of α-tubulin (chain A) and β-tubulin (chain B) were pretreated with AutoDockTools (ADT),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> including the addition of hydrogen and Gasteiger charges,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> as well as conversion to a pdbqt file. The structures of the designed compounds were constructed using InDraw software, hydrogen was added at pH = 7.0, and 3D coordinates were generated using OpenBabel software.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The structure was minimized using a PM3 force field<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> by MOPAC2016 (J.J.P. Stewart, Stewart Computational Chemistry, Colorado Springs, CO, USA). A grid map of 40 × 40 × 48 points with a 0.375 Å grid spacing was generated using the AutoGrid 4.2.6 module<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> based on the center of KX01 in the original coordinates. Finally, 100 conformations were generated for each docking experiment with the Lamarckian genetic algorithm<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> using AutoDock4.2.6.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Subsequently, a reasonable conformation for each compound bound to tubulin was selected for analysis.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Pharmacokinetic Study</h3><div class="NLM_p last">Pharmacokinetic studies were performed on six male Sprague–Dawley rats (aged 6–8 weeks, weighing 270 to 325 g) from each group, following approved internal protocols for animal care and use. The rats were orally or intravenously administered with selected compounds or KX01 at a concentration of 5 mg/kg. Blood samples were withdrawn from the superior vena cava of the rats at serial time points (0 to 24 h), mixed with K3EDTA as an anticoagulant, and centrifuged. Plasma was separated and stored at −20 °C until analysis. Finally, the plasma samples were analyzed by LC/MS/MS, and the pharmacokinetic profiles were estimated by noncompartmental methods using WinNonlin software (ver. 5.2, Pharsight, CA).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> X-ray Crystal Structure of the <b>8a</b>–Tubulin Complex</h3><div class="NLM_p last">The crystal complex was used to elucidate the binding mode of <b>8a</b> with tubulin. These experiments were carried out as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Immunofluorescence Assay</h3><div class="NLM_p last">Immunofluorescence assays were used to evaluate the inhibition of tubulin polymerization by <b>8a</b> in the SKOV3 cell line. Cells were cultured in a 24-well plate and treated with <b>8a</b> (1, 3, 10, and 100 nM) or colchicine (10, 100, and 1000 nM) as the positive control for appropriate times. The cells were then treated using a previously described method.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Finally, the cells were imaged using a fluorescence microscope (Zeiss Axiovert 200, Shanghai, China).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>In Vitro</i> Tubulin Polymerization Assay</h3><div class="NLM_p last">An assay was performed to evaluate the <i>in vitro</i> tubulin polymerization ability of <b>8a</b>. These experiments were carried out as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Cell Cycle Analysis</h3><div class="NLM_p last">SKOV3 cells were cultured in 6-well plates and treated with <b>8a</b> (1, 5, and 10 nM) or KX01 (10, 20, and 100 nM) as the positive control for 24 h. The cells were collected and washed with PBS before being fixed with 70% precooled ethanol overnight at 4 °C. The fixed cells were then washed three times with PBS and stained with 50 μg/mL PI for 20 min. The cell cycle was subsequently observed with a flow cytometer (Beckman Coulter, Miami, FL, USA).</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Mitotic Block Reversibility Assay</h3><div class="NLM_p last">The mitotic block reversibility assay was carried out following the protocol of Towle <i>et al</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> SKOV3 cells were treated with increasing concentrations (0, 1, 3, 10, 30, 100, 300, and 1000 nM) of colchicine or KX01 at the −12 h time point and cultured for 12 h. The compounds were completely washed out at 0 h, and the cells were incubated with a fresh medium and further cultured for 10 h. The cell cycle was analyzed by flow cytometry at 0 and 10 h.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Western Blot Assay</h3><div class="NLM_p last">SKOV3 cells were treated with <b>8a</b> and KX01 at concentrations of 1, 10, and 100 nM for 24 h. The total proteins were then extracted with RIPA lysis buffer (P0013B, Beyotime Co.) according to the manufacturer’s instructions. Equal quantities of protein samples were separated by denaturing SDS-PAGE, transferred to PVDF membranes, and probed with antibodies. The primary antibodies were as follows: Src (Cell Signaling Technology), p-Src (Cell Signaling Technology), FAK (Cell Signaling Technology), and p-FAK (Cell Signaling Technology).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>In Vivo</i> Antitumor Study</h3><div class="NLM_p last">All the animal experiments were performed according to the institutional guide for the care and use of laboratory animals, and all the mouse protocols were approved by the Animal Care and Use Committee of Sichuan University Chengdu, Sichuan, China. Six- to eight-week-old female Balb/c mice were subcutaneously implanted with C26 cells (1.0 × 10<sup>7</sup> cells in 100 μL of physiological saline). C26 xenograft mice were treated with 10 mg/kg compounds (<b>8a</b>, <b>8b</b>, <b>8c</b>, or <b>8d</b>) or KX01 by oral administration every day until being sacrificed on day 10. Six- to eight-week-old female nude mice were subcutaneously implanted with SKOV3 cells (1.0 × 10<sup>7</sup> cells in 100 μL of physiological saline). The SKOV3 xenograft mice were treated with <b>8a</b> (5 or 10 mg/kg) or KX01 (10 mg/kg) by oral administration every day until being sacrificed on day 30. The tumors were collected and weighed at the end of the experiment. The body weights and tumor growth were assessed every 2 days. The latter was measured using a Vernier caliper, and the tumor volumes were calculated by the following formula: short diameter<sup>2</sup> × long diameter/2.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Statistical Analysis</h3><div class="NLM_p last">The data are reported as the mean ± SD. The significant difference between multiple treatments and the control was analyzed using one-way ANOVA with Dunnett’s post-test.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01961" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01961?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Characterization of key compounds, antiproliferation activity data, MTD, table of protein crystal data collection and refinement statistics, and HPLC purity traces for key final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Structural data for compounds <b>6a</b>, <b>6d</b>, and <b>6r</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb" class="ext-link">PDB</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb" class="ext-link">PDB</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">jm0c01961_si_001.pdf (3.72 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">jm0c01961_si_002.csv (28.0 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">jm0c01961_si_003.pdb (1.05 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">jm0c01961_si_004.pdb (1.05 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">jm0c01961_si_005.pdb (1.04 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The structural data of <b>8a</b> have been entered into the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>) and can be accessed with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBZ">7CBZ</a>. The authors will release the atomic coordinates upon publication of the study.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01961" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haoyu Ye</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9185-1040" title="Orcid link">https://orcid.org/0000-0002-9185-1040</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a2cac3cddbd782dbc7e2d1c1d78cc7c6d78cc1cc">haoyu <span class="__cf_email__" data-cfemail="a3dac6e3d0c0d68dc6c7d68dc0cd">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lijuan Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8076-163X" title="Orcid link">https://orcid.org/0000-0002-8076-163X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5c6cdc0cbc9cccfd0c4cb949790e59493968bc6cac8"><span class="__cf_email__" data-cfemail="87e4efe2e9ebeeedf2e6e9b6b5b2c7b6b1b4a9e4e8ea">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lun Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunhua Zheng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianhong Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Lei</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Yan</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Zheng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minghai Tang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingsong Shi</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruijia Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoying Cai</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengfan Ni</span> - <span class="hlFld-Affiliation affiliation">The
Ministry of Education Key Laboratory of Standardization of Chinese
Herbal Medicine, State Key Laboratory, Breeding Base of Systematic
Research Development and Utilization of Chinese Medicine Resources,
School of Pharmacy, Chengdu University of
Traditional Chinese Medicine, Chengdu 611137, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xu Ma</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Na Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Hong</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy
and Cancer Center, West China Hospital of
Sichuan University, Chengdu 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.W., Y.Z., D.L., and J.Y. contributed equally and should be considered as the first coauthors. All the authors have approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was funded by the National Natural Science Foundation of China (grant nos. 81872900 and 81874297), the National Key Programs of China during the 13th Five-Year Plan Period (grant no. 2018ZX09721002-001-004), and the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (grant no. ZY2017202).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">PTK</td><td class="NLM_def"><p class="first last">nonreceptor protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-aza-1<i>H</i>-benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N′</i>,<i>N′</i>-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">CBSI</td><td class="NLM_def"><p class="first last">colchicine-binding site inhibitor</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">Col</td><td class="NLM_def"><p class="first last">colchicine</p></td></tr><tr><td class="NLM_term">PTX</td><td class="NLM_def"><p class="first last">paclitaxel</p></td></tr><tr><td class="NLM_term">SMB</td><td class="NLM_def"><p class="first last">significant mitotic block</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinases</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">Src homology 2 domain</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">TFD</td><td class="NLM_def"><p class="first last">tryptophan-based binding assay</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lj4PCGvsY6Siw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyams, J. S.</span>; <span class="NLM_string-name">Lloyd, C. W.</span></span> <i>Microtubules</i>; <span class="NLM_publisher-name">Wiley-Liss</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1993</span>, pp.  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">412</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=393-412&author=J.+S.+Hyams&author=C.+W.+Lloyd&title=Microtubules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHyams%26aufirst%3DJ.%2BS.%26btitle%3DMicrotubules%26pub%3DWiley-Liss%26date%3D1993%26spage%3D393%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurwerra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of action of microtubule-stabilizing anticancer agents</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1126/science.1230582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1126%2Fscience.1230582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=23287720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=587-590&author=A.+E.+Protaauthor=K.+Bargstenauthor=D.+Zurwerraauthor=J.+J.+Fieldauthor=J.+F.+D%C3%ADazauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=Molecular+mechanism+of+action+of+microtubule-stabilizing+anticancer+agents&doi=10.1126%2Fscience.1230582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Zurwerra, Didier; Field, Jessica J.; Diaz, Jose Fernando; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6119</span>),
    <span class="NLM_cas:pages">587-590</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Microtubule-stabilizing agents (MSAs) are efficacious chemotherapeutic drugs widely used for the treatment of cancer.  Despite the importance of MSAs for medical applications and basic research, their mol. mechanisms of action on tubulin and microtubules remain elusive.  We detd. high-resoln. crystal structures of αβ-tubulin in complex with two unrelated MSAs, zampanolide and epothilone A.  Both compds. were bound to the taxane pocket of β-tubulin and used their resp. side chains to induce structuring of the M-loop into a short helix.  Because the M-loop establishes lateral tubulin contacts in microtubules, these findings explain how taxane-site MSAs promote microtubule assembly and stability.  Further, our results offer fundamental structural insights into the control mechanisms of microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_p8NfCWTU-rVg90H21EOLACvtfcHk0lglAxEWxR2Tjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D&md5=b253c015f75f5eac4857d01e34d65f54</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1230582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1230582%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DZurwerra%26aufirst%3DD.%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DMolecular%2520mechanism%2520of%2520action%2520of%2520microtubule-stabilizing%2520anticancer%2520agents%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D587%26epage%3D590%26doi%3D10.1126%2Fscience.1230582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihydroindeno [1, 2-c] pyrazole analogues as potential anticancer agents targeting tubulin colchicine binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5341</span>– <span class="NLM_lpage">5355</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5341-5355&author=Y.-N.+Liuauthor=J.-J.+Wangauthor=Y.-T.+Jiauthor=G.-D.+Zhaoauthor=L.-Q.+Tangauthor=C.-M.+Zhangauthor=X.-L.+Guoauthor=Z.-P.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1-methyl-1%2C+4-dihydroindeno+%5B1%2C+2-c%5D+pyrazole+analogues+as+potential+anticancer+agents+targeting+tubulin+colchicine+binding+site&doi=10.1021%2Facs.jmedchem.6b00071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site</span></div><div class="casAuthors">Liu, Yan-Na; Wang, Jing-Jing; Ji, Ya-Ting; Zhao, Guo-Dong; Tang, Long-Qian; Zhang, Cheng-Mei; Guo, Xiu-Li; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5341-5355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By targeting a new binding region at the interface between αβ-tubulin heterodimers at the colchicine binding site, the authors designed a series of 7-substituted 1-methyl-1,4-dihydroindeno[1,2-c]pyrazoles as potential tubulin polymn. inhibitors.  Among the compds. synthesized, 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)acetamide (I), and 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)-N-hydroxyacetamide, (II), showed noteworthy low nanomolar potency against HepG2, Hela, PC3, and MCF-7 cancer cell lines.  In mechanism studies, I inhibited tubulin polymn. and disorganized microtubule in A549 cells by binding to the tubulin colchicine binding site.  I arrested A549 cells in G2/M phase that was related to the alterations in the expression of cyclin B1 and p-cdc2.  I induced A549 cells apoptosis through the activation of caspase-3 and PARP.  In addn., I inhibited capillary tube formation in a concn.-dependent manner.  In a nonsmall cell lung cancer xenograft mouse model, I suppressed tumor growth by 59.1% at a dose of 50 mg/kg (i.p.) without obvious toxicity, indicating its in vivo potential as anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ-hoobIDuqrVg90H21EOLACvtfcHk0lglAxEWxR2Tjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D&md5=ba4652575e64aa805d859734ea5b3903</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00071%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-N.%26aulast%3DWang%26aufirst%3DJ.-J.%26aulast%3DJi%26aufirst%3DY.-T.%26aulast%3DZhao%26aufirst%3DG.-D.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DGuo%26aufirst%3DX.-L.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201-methyl-1%252C%25204-dihydroindeno%2520%255B1%252C%25202-c%255D%2520pyrazole%2520analogues%2520as%2520potential%2520anticancer%2520agents%2520targeting%2520tubulin%2520colchicine%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5341%26epage%3D5355%26doi%3D10.1021%2Facs.jmedchem.6b00071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naismith, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1038/ncomms12103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1038%2Fncomms12103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1-9&author=J.+Yangauthor=Y.+Wangauthor=T.+Wangauthor=J.+Jiangauthor=C.+H.+Bottingauthor=H.+Liuauthor=Q.+Chenauthor=J.+Yangauthor=J.+H.+Naismithauthor=X.+Zhuauthor=L.+Chen&title=Pironetin+reacts+covalently+with+cysteine-316+of+%CE%B1-tubulin+to+destabilize+microtubule&doi=10.1038%2Fncomms12103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fncomms12103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12103%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DBotting%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNaismith%26aufirst%3DJ.%2BH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DPironetin%2520reacts%2520covalently%2520with%2520cysteine-316%2520of%2520%25CE%25B1-tubulin%2520to%2520destabilize%2520microtubule%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D1%26epage%3D9%26doi%3D10.1038%2Fncomms12103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devi
Tangutur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamsi Krishna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantevari, S.</span></span> <span> </span><span class="NLM_article-title">Microtubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilizing and destabilizing agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2523</span>– <span class="NLM_lpage">2537</span>, <span class="refDoi"> DOI: 10.2174/1568026617666170104145640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568026617666170104145640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=28056738" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=2523-2537&author=A.+Devi%0ATanguturauthor=D.+Kumarauthor=K.+Vamsi+Krishnaauthor=S.+Kantevari&title=Microtubule+targeting+agents+as+cancer+chemotherapeutics%3A+an+overview+of+molecular+hybrids+as+stabilizing+and+destabilizing+agents&doi=10.2174%2F1568026617666170104145640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F1568026617666170104145640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026617666170104145640%26sid%3Dliteratum%253Aachs%26aulast%3DDevi%2BTangutur%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DVamsi%2BKrishna%26aufirst%3DK.%26aulast%3DKantevari%26aufirst%3DS.%26atitle%3DMicrotubule%2520targeting%2520agents%2520as%2520cancer%2520chemotherapeutics%253A%2520an%2520overview%2520of%2520molecular%2520hybrids%2520as%2520stabilizing%2520and%2520destabilizing%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D2523%26epage%3D2537%26doi%3D10.2174%2F1568026617666170104145640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bariwal, J.</span></span> <span> </span><span class="NLM_article-title">Recent developments in tubulin polymerization inhibitors: an overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2Fj.ejmech.2014.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=25240869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=89-124&author=R.+Kaurauthor=G.+Kaurauthor=R.+K.+Gillauthor=R.+Soniauthor=J.+Bariwal&title=Recent+developments+in+tubulin+polymerization+inhibitors%3A+an+overview&doi=10.1016%2Fj.ejmech.2014.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in tubulin polymerization inhibitors: An overview</span></div><div class="casAuthors">Kaur, Ramandeep; Kaur, Gurneet; Gill, Rupinder Kaur; Soni, Richard; Bariwal, Jitender</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-124</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Microtubules are protein biopolymers formed through polymn. of heterodimers of α- and β-tubulins.  Disruption of microtubules can induce cell cycle arrest in G2-M phase and formation of abnormal mitotic spindles.  Their importance in mitosis and cell division makes microtubules an attractive target for anticancer drug discovery.  A no. of naturally occurring compds. such as paclitaxel, epothilones, vinblastine, combretastatin, and colchicines exert their effect by changing dynamics of tubulin such as polymn. and depolymn.  During past few years, rapid development of the novel tubulin polymn. inhibitors has been witnessed.  Diverse classes of chem. compds. from the natural as well as from the synthetic origin have been extensively studied.  This review highlights the various classes of synthetically derived chem. compds. those have been reported in last few years as potential tubulin polymn. inhibitors.  A brief synthetic methodol. to access these compds. has been highlighted along with the brief SAR studies.  We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compds. to inhibit the tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV6nQysY8nvbVg90H21EOLACvtfcHk0li7DWYRBqRpow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE&md5=2ffd2f9bb073a7830f4aae7c29f070d9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DBariwal%26aufirst%3DJ.%26atitle%3DRecent%2520developments%2520in%2520tubulin%2520polymerization%2520inhibitors%253A%2520an%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D89%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2014.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span> <span> </span><span class="NLM_article-title">Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1648433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1080%2F13543776.2019.1648433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=31353978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSrur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=623-641&author=K.+Haiderauthor=S.+Rahamanauthor=M.+S.+Yarauthor=A.+Kamal&title=Tubulin+inhibitors+as+novel+anticancer+agents%3A+an+overview+on+patents+%282013-2018%29&doi=10.1080%2F13543776.2019.1648433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018)</span></div><div class="casAuthors">Haider, Kashif; Rahaman, Shaik; Yar, M. Shahar; Kamal, Ahmed</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">623-641</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  About 20 patents have been published from 2013 to 2018 for developing advanced cancer therapeutics by targeting tubulin polymn.  Currently, there are several tubulin inhibitors that are in the drug development pipeline for various cancers alone or in combination including antibody-conjugated drugs (ACDs).: Important patents focusing on the development of tubulin inhibitors published from 2013 to 2018 are covered.  This review mainly focuses on the tubulin inhibitors that are being synthesized and studied in cancer research along with their structures and their phases of development in preclin. and clin. research.: Regulation of microtubules is important for cell division, cell motility, intracellular transport, and cell shape maintenance.  Modulating its activity proved to be very effective in various diseases including different types of cancers.  Microtubules are composed of two units, namely, alpha and beta-tubulin, and modifications at these ends affect both its functions and dynamics.  A no. of compds. that have been designed and synthesized bearing various heterocyclic scaffolds have been proven to modulate its activity and have emerged as potent tubulin inhibitors.  This encourages more to study microtubules in order to find a variety of novel, potent compds. as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMeZtUEnfGPrVg90H21EOLACvtfcHk0li7IoBVJ6yEqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSrur7L&md5=813a1c993e5e8ddcd86ffdd7ead6ba24</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1648433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1648433%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DK.%26aulast%3DRahaman%26aufirst%3DS.%26aulast%3DYar%26aufirst%3DM.%2BS.%26aulast%3DKamal%26aufirst%3DA.%26atitle%3DTubulin%2520inhibitors%2520as%2520novel%2520anticancer%2520agents%253A%2520an%2520overview%2520on%2520patents%2520%25282013-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D623%26epage%3D641%26doi%3D10.1080%2F13543776.2019.1648433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4704</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4704-4719&author=M.+P.+Smolinskiauthor=Y.+Buauthor=J.+Clementsauthor=I.+H.+Gelmanauthor=T.+Hegabauthor=D.+L.+Cutlerauthor=J.+W.+Fangauthor=G.+Fetterlyauthor=R.+Kwanauthor=A.+Barnettauthor=J.+Y.+N.+Lauauthor=D.+G.+Hangauer&title=Discovery+of+novel+dual+mechanism+of+action+Src+signaling+and+tubulin+polymerization+inhibitors+%28KX2-391+and+KX2-361%29&doi=10.1021%2Facs.jmedchem.8b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)</span></div><div class="casAuthors">Smolinski, Michael P.; Bu, Yahao; Clements, James; Gelman, Irwin H.; Hegab, Taher; Cutler, David L.; Fang, Jane W. S.; Fetterly, Gerald; Kwan, Rudolf; Barnett, Allen; Lau, Johnson Y. N.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4704-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal.  Herein we describe the discovery of two such clin. candidates that inhibit the tyrosine kinase Src.  Compd. 1 is a phase 3 clin. trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing std. therapy.  Compd. 2 is a phase 1 clin. trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models.  The discovery strategy for these compds. iteratively utilized mol. modeling, along with the synthesis and testing of increasingly elaborated proof of concept compds., until the final clin. candidates were arrived at.  This was followed with mechanism of action (MOA) studies that revealed tubulin polymn. inhibition as the second MOA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6WD_5NG6-7Vg90H21EOLACvtfcHk0li7IoBVJ6yEqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D&md5=b35b9fb022675d3d4c37e3ac8225ab67</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00164%26sid%3Dliteratum%253Aachs%26aulast%3DSmolinski%26aufirst%3DM.%2BP.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DClements%26aufirst%3DJ.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DHegab%26aufirst%3DT.%26aulast%3DCutler%26aufirst%3DD.%2BL.%26aulast%3DFang%26aufirst%3DJ.%2BW.%26aulast%3DFetterly%26aufirst%3DG.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520mechanism%2520of%2520action%2520Src%2520signaling%2520and%2520tubulin%2520polymerization%2520inhibitors%2520%2528KX2-391%2520and%2520KX2-361%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4704%26epage%3D4719%26doi%3D10.1021%2Facs.jmedchem.8b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2079-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1007%2Fs00280-013-2079-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=23314737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=883-892&author=E.+S.+Antonarakisauthor=E.+I.+Heathauthor=E.+M.+Posadasauthor=Y.+Y.+Evanauthor=M.+R.+Harrisonauthor=J.+Y.+Bruceauthor=S.+Y.+Choauthor=G.+E.+Wildingauthor=G.+J.+Fetterlyauthor=D.+G.+Hangauer&title=A+phase+2+study+of+KX2-391%2C+an+oral+inhibitor+of+Src+kinase+and+tubulin+polymerization%2C+in+men+with+bone-metastatic+castration-resistant+prostate+cancer&doi=10.1007%2Fs00280-013-2079-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Antonarakis, Emmanuel S.; Heath, Elisabeth I.; Posadas, Edwin M.; Yu, Evan Y.; Harrison, Michael R.; Bruce, Justine Y.; Cho, Steve Y.; Wilding, Gregory E.; Fetterly, Gerald J.; Hangauer, David G.; Kwan, Min-Fun R.; Dyster, Lyn M.; Carducci, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymn.  In phase 1 trials, prostate-specific antigen (PSA) declines were seen in patients with advanced prostate cancer.  We conducted a single-arm phase 2 study evaluating KX2-391 in men with chemotherapy-naive bone-metastatic castration-resistant prostate cancer (CRPC).  We treated 31 patients with oral KX2-391 (40 mg twice-daily) until disease progression or unacceptable toxicity.  The primary endpoint was 24-wk progression-free survival (PFS); a 50 % success rate was pre-defined as clin. significant.  Secondary endpoints included PSA progression-free survival (PPFS) and PSA response rates.  Exploratory outcomes included pharmacokinetic studies, circulating tumor cell (CTC) enumeration, and anal. of markers of bone resorption [urinary N-telopeptide (uNTx); C-telopeptide (CTx)] and formation [bone alk. phosphatase (BAP); osteocalcin].  The trial closed early after accrual of 31 patients, due to a pre-specified futility rule.  PFS at 24 wk was 8 %, and median PFS was 18.6 wk.  The PSA response rate (≥30 % decline) was 10 %, and median PPFS was 5.0 wk.  Addnl., 18 % of men with unfavorable (≥5) CTCs at baseline converted to favorable (<5) CTCs with treatment.  The proportion of men with declines in bone turnover markers was 32 % for uNTx, 21 % for CTx, 10 % for BAP, and 25 % for osteocalcin.  In pharmacokinetic studies, median C max was 61 (range 16-129) ng/mL, and median AUC was 156 (35-348) ng h/mL.  Common toxicities included hepatic derangements, myelosuppression, fatigue, nausea, and constipation.  KX2-391 dosed at 40 mg twice-daily lacks antitumor activity in men with CRPC, but has modest effects on bone turnover markers.  Because a C max of ≥142 ng/mL is required for tubulin polymn. inhibition (defined from preclin. studies), higher once-daily dosing will be used in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok7d6u2qkQ_7Vg90H21EOLACvtfcHk0lgbH7-n2Vi5Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D&md5=117681a5f5cb6d09865c707673ec3e27</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2079-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2079-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DEvan%26aufirst%3DY.%2BY.%26aulast%3DHarrison%26aufirst%3DM.%2BR.%26aulast%3DBruce%26aufirst%3DJ.%2BY.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DWilding%26aufirst%3DG.%2BE.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DA%2520phase%25202%2520study%2520of%2520KX2-391%252C%2520an%2520oral%2520inhibitor%2520of%2520Src%2520kinase%2520and%2520tubulin%2520polymerization%252C%2520in%2520men%2520with%2520bone-metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26spage%3D883%26epage%3D892%26doi%3D10.1007%2Fs00280-013-2079-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1’s low clinical toxicity</span>. <i>J. Bio. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">18099</span>– <span class="NLM_lpage">18108</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.010732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1074%2Fjbc.RA119.010732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=31628188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=18099-18108&author=L.+Niuauthor=J.+Yangauthor=W.+Yanauthor=Y.+Yuauthor=Y.+Zhengauthor=H.+Yeauthor=Q.+Chenauthor=L.+Chen&title=Reversible+binding+of+the+anticancer+drug+KXO1+%28tirbanibulin%29+to+the+colchicine-binding+site+of+%CE%B2-tubulin+explains+KXO1%E2%80%99s+low+clinical+toxicity&doi=10.1074%2Fjbc.RA119.010732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity</span></div><div class="casAuthors">Niu Lu; Yang Jianhong; Yan Wei; Yu Yamei; Zheng Yunhua; Ye Haoyu; Chen Qiang; Chen Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">18099-18108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KXO1 (tirbanibulin or KX2-391) is as a non-ATP-competitive inhibitor of SRC proto-oncogene nonreceptor tyrosine kinase (SRC) and is being clinically investigated for the management of various cancers and actinic keratosis.  Recently, KXO1 has also been shown to strongly inhibit tubulin.  Interestingly, unlike conventional tubulin-targeting drugs, KXO1 has exhibited low toxicity in preclinical and clinical studies, but the reason for this remains elusive, as are the KXO1-binding site and other details of the interaction of KXO1 with tubulin.  Here, cell-based experiments revealed that KXO1 induces tubulin depolymerization and G2/M phase cell cycle arrest at low nanomolar concentrations, similar to colchicine, used as a positive control.  Results from biochemical experiments, including an N,N-ethylenebis(iodoacetamide) competition assay, disclosed that KXO1 binds to the colchicine-binding site on β-tubulin, further confirmed by the crystal structure of the tubulin-KXO1 complex at 2.5-ÅA resolution.  A high-quality electron density map of the crystallographic data enabled us to unambiguously determine the position and orientation of KXO1 in the colchicine-binding site, revealing the detailed interactions between KXO1 and tubulin.  We also found that KXO1 binds reversibly to purified tubulin, induces a totally reversible cellular effect (G2/M cell cycle arrest), and possesses no cellular toxicity 5 days after drug washout, explaining KXO1's low toxicity.  In summary, we show that KXO1 binds to the colchicine-binding site of tubulin and resolved the crystal structure of the tubulin-KXO1 complex.  Importantly, KXO1's reversible binding to tubulin explains its clinically low toxicity, an insight that could guide further clinical applications of KXO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhfWQ2BlTvKJZoeNcnHOQ9fW6udTcc2ebUJvxJ61qt8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D&md5=b3eac35ef261149a46a2531ff014ced1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010732%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DReversible%2520binding%2520of%2520the%2520anticancer%2520drug%2520KXO1%2520%2528tirbanibulin%2529%2520to%2520the%2520colchicine-binding%2520site%2520of%2520%25CE%25B2-tubulin%2520explains%2520KXO1%25E2%2580%2599s%2520low%2520clinical%2520toxicity%26jtitle%3DJ.%2520Bio.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D18099%26epage%3D18108%26doi%3D10.1074%2Fjbc.RA119.010732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span> <span> </span><span class="NLM_article-title">Targeting tubulin-colchicine site for cancer therapy: inhibitors, antibody-drug conjugates and degradation agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1304</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190618130008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568026619666190618130008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=31210108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1289-1304&author=Y.+Duanauthor=W.+Liuauthor=L.+Tianauthor=Y.+Maoauthor=C.+Song&title=Targeting+tubulin-colchicine+site+for+cancer+therapy%3A+inhibitors%2C+antibody-drug+conjugates+and+degradation+agents&doi=10.2174%2F1568026619666190618130008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents</span></div><div class="casAuthors">Duan, Yongtao; Liu, Wei; Tian, Liang; Mao, Yanna; Song, Chuanjun</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1289-1304</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubules are essential for the mitotic division of cells and have been an attractive target for antitumor drugs due to the increased incidence of cancer and significant mitosis rate of tumor cells.  In the past few years, tubulin-colchicine binding site, as one of the three binding pockets including taxol-, vinblastine- and colchicine-binding sites, has been focused on to design tubulin-destabilizing agents including inhibitors, antibody-drug conjugates and degrdn. agents.  The present review is the first to cover a systemic and recent synopsis of tubulin-colchicine binding site agents.  We believe that it would provide an increase in our understanding of receptor-ligand interaction pattern and consciousness of a series of challenges about tubulin target druggability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbFqJ3AOtMzLVg90H21EOLACvtfcHk0liiXQZJZS5CRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLvP&md5=22e8286a4e99012ae44d6024755b1c12</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190618130008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190618130008%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DC.%26atitle%3DTargeting%2520tubulin-colchicine%2520site%2520for%2520cancer%2520therapy%253A%2520inhibitors%252C%2520antibody-drug%2520conjugates%2520and%2520degradation%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1289%26epage%3D1304%26doi%3D10.2174%2F1568026619666190618130008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0lg-m0ZvNSl2Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer,  Jr, D. G.</span></span> <span> </span><span class="NLM_article-title">Biaryl compositions and methods for modulating a kinase cascade</span>. US Patents: <span class="NLM_patent">7,968,574</span>, Jun 28, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+G.+Hangauer&title=Biaryl+compositions+and+methods+for+modulating+a+kinase+cascade"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DBiaryl%2520compositions%2520and%2520methods%2520for%2520modulating%2520a%2520kinase%2520cascade%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+Automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lhGbsUQx0ngdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520Automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+G.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0lhGbsUQx0ngdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, A.</span></span> <span> </span><span class="NLM_article-title">Microtubule destabilising agents: far more than just antimitotic anticancer drugs</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1111/bcp.13126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1111%2Fbcp.13126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=27620987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=255-268&author=D.+Batesauthor=A.+Eastman&title=Microtubule+destabilising+agents%3A+far+more+than+just+antimitotic+anticancer+drugs&doi=10.1111%2Fbcp.13126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule destabilizing agents: far more than just antimitotic anticancer drugs</span></div><div class="casAuthors">Bates, Darcy; Eastman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-268</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Vinca alkaloids have been approved as anticancer drugs for more than 50 years.  They have been classified as cytotoxic chemotherapy drugs that act during cellular mitosis, enabling them to target fast growing cancer cells.  With the evolution of cancer drug development there has been a shift towards new "targeted" therapies to avoid the side effects and general toxicities of "cytotoxic chemotherapies" such as the vinca alkaloids.  Due to their original classification, many have overlooked the fact that vinca alkaloids, taxanes and related drugs do have a specific mol. target: tubulin.  They continue to be some of the most effective anticancer drugs, perhaps because their actions upon the microtubule network extend far beyond the ability to halt cells in mitosis, and include the induction of apoptosis at all phases of the cell cycle.  In this review, we highlight the numerous cellular consequences of disrupting microtubule dynamics, expanding the textbook knowledge of microtubule destabilizing agents and providing novel opportunities for their use in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4cJkJIQJPLVg90H21EOLACvtfcHk0lhGbsUQx0ngdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D&md5=e859fcd74dd984b711065f278abb5479</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13126%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DD.%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DMicrotubule%2520destabilising%2520agents%253A%2520far%2520more%2520than%2520just%2520antimitotic%2520anticancer%2520drugs%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D255%26epage%3D268%26doi%3D10.1111%2Fbcp.13126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, K. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setaluri, V.</span></span> <span> </span><span class="NLM_article-title">Microtubule-associated proteins as targets in cancer chemotherapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2854</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-3040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F1078-0432.CCR-06-3040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=17504982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Krsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2849-2854&author=K.+M.+R.+Bhatauthor=V.+Setaluri&title=Microtubule-associated+proteins+as+targets+in+cancer+chemotherapy&doi=10.1158%2F1078-0432.CCR-06-3040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-Associated Proteins as Targets in Cancer Chemotherapy</span></div><div class="casAuthors">Bhat, Kumar M. R.; Setaluri, Vijayasaradhi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2849-2854</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural and synthetic compds. that disrupt microtubule dynamics are among the most successful and widely used cancer chemotherapeutic agents.  However, lack of reliable markers that predict sensitivity of cancers to these agents and development of resistance remain vexing issues.  There is accumulating evidence that a family of cellular proteins that are assocd. with and alter the dynamics of microtubules can det. sensitivity of cancer cells to microtubule-targeting agents and play a role in tumor cell resistance to these agents.  This growing family of microtubule-assocd. proteins (MAP) includes products of oncogenes, tumor suppressors, and apoptosis regulators, suggesting that alteration of microtubule dynamics may be one of the crit. events in tumorigenesis and tumor progression.  The objective of this review is to integrate the knowledge on these seemingly unrelated proteins that share a common function and examine their relevance to microtubule-targeting therapies and highlight MAPs-tubulin-drug interactions as a novel avenue for new drug discovery.  Based on the available evidence, we propose that rational microtubule-targeting cancer therapeutic approaches should ideally include proteomic profiling of tumor MAPs before administration of microtubule-stabilizing/destabilizing agents preferentially in combination with agents that modulate the expression of relevant MAPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCwiEFkyEsrVg90H21EOLACvtfcHk0lhU9-y9SFLXHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Krsrw%253D&md5=719cc6f219556505b5562b1201171911</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3040%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DK.%2BM.%2BR.%26aulast%3DSetaluri%26aufirst%3DV.%26atitle%3DMicrotubule-associated%2520proteins%2520as%2520targets%2520in%2520cancer%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2849%26epage%3D2854%26doi%3D10.1158%2F1078-0432.CCR-06-3040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannakakou, P.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules for cancer chemotherapy</span>. <i>Curr. Med. Chem.-Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.2174/1568011053352569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568011053352569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15720262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-71&author=J.+Zhouauthor=P.+Giannakakou&title=Targeting+microtubules+for+cancer+chemotherapy&doi=10.2174%2F1568011053352569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting microtubules for cancer chemotherapy</span></div><div class="casAuthors">Zhou, Jun; Giannakakou, Paraskevi</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer.  As knowledge of microtubule-targeting drugs increases, the mechanism underlying the anticancer activity of these agents may mainly lie in their inhibitory effects on spindle microtubule dynamics, rather than in their effects on microtubule polymer mass.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell cycle progression at mitosis and eventually leading to apoptotic cell death.  The effectiveness of microtubule-targeting drugs for cancer therapy has been impaired by various side effects, notably neurol. and hematol. toxicities.  Drug resistance is another notorious factor that thwarts the effectiveness of these agents, as with many other cancer chemotherapeutics.  Several new microtubule-targeting agents have shown potent activity against the proliferation of various cancer cells, including cells that display resistance to the existing microtubule-targeting drugs.  Continued investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI0IucAUr4V7Vg90H21EOLACvtfcHk0lhU9-y9SFLXHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D&md5=e5d34ca2c4d4adf0e6975989da8aaee8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568011053352569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011053352569%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGiannakakou%26aufirst%3DP.%26atitle%3DTargeting%2520microtubules%2520for%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.-Anti-Cancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D71%26doi%3D10.2174%2F1568011053352569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vornov, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlefield, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesJardins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyderman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span> <span> </span><span class="NLM_article-title">Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: correlations with time course and neurotoxic severity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3332</span>– <span class="NLM_lpage">3339</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F0008-5472.CAN-15-2525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=27197173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3332-3339&author=K.+M.+Wozniakauthor=J.+J.+Vornovauthor=Y.+Wuauthor=K.+Nomotoauthor=B.+A.+Littlefieldauthor=C.+DesJardinsauthor=Y.+Yuauthor=G.+Laiauthor=L.+Reydermanauthor=N.+Wongauthor=B.+S.+Slusher&title=Sustained+accumulation+of+microtubule-binding+chemotherapy+drugs+in+the+peripheral+nervous+system%3A+correlations+with+time+course+and+neurotoxic+severity&doi=10.1158%2F0008-5472.CAN-15-2525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity</span></div><div class="casAuthors">Wozniak, Krystyna M.; Vornov, James J.; Wu, Ying; Nomoto, Kenichi; Littlefield, Bruce A.; Des Jardins, Christopher; Yu, Yanke; Lai, George; Reyderman, Larisa; Wong, Nancy; Slusher, Barbara S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3332-3339</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chemotherapy-induced peripheral neuropathy is a dose-limiting side effect of many antineoplastic agents, but the mechanisms underlying the toxicities are unclear.  At their MTDs, the microtubule-binding drugs paclitaxel and ixabepilone induce more severe neuropathy in mice relative to eribulin mesylate, paralleling their toxicity profiles in clinic.  We hypothesized that the severity of their neurotoxic effects might be explained by the levels at which they accumulate in the peripheral nervous system.  To test this hypothesis, we compared their pharmacokinetics and distribution in peripheral nerve tissue.  After administration of a single i.v. dose, each drug was rapidly cleared from plasma but all persisted in the dorsal root ganglia (DRG) and sciatic nerve (SN) for up to 72 h.  Focusing on paclitaxel and eribulin, we performed a 2-wk MTD-dosing regimen, followed by a detn. of drug pharmacokinetics, tissue distribution, and multiple functional measures of peripheral nerve toxicity for 4 wk.  Consistent with the acute dosing study, both drugs persisted in peripheral nervous tissues for weeks, in contrast to their rapid clearance from plasma.  Notably, although eribulin exhibited greater DRG and SN penetration than paclitaxel, the neurotoxicity obsd. functionally was consistently more severe with paclitaxel.  Overall, our results argue that sustained exposure of microtubule-binding chemotherapeutic agents in peripheral nerve tissues cannot by itself account for their assocd. neurotoxicity.  Cancer Res; 76(11); 3332-9. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq980Gmeq_gibVg90H21EOLACvtfcHk0lg45bZoSokOGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLg%253D&md5=137bb427a63ea717cdcba8afb3e08d0f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2525%26sid%3Dliteratum%253Aachs%26aulast%3DWozniak%26aufirst%3DK.%2BM.%26aulast%3DVornov%26aufirst%3DJ.%2BJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DNomoto%26aufirst%3DK.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26aulast%3DDesJardins%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DG.%26aulast%3DReyderman%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26atitle%3DSustained%2520accumulation%2520of%2520microtubule-binding%2520chemotherapy%2520drugs%2520in%2520the%2520peripheral%2520nervous%2520system%253A%2520correlations%2520with%2520time%2520course%2520and%2520neurotoxic%2520severity%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3332%26epage%3D3339%26doi%3D10.1158%2F0008-5472.CAN-15-2525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Towle, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvato, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wels, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aalfs, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seletsky, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melvin, J. Y.</span></span> <span> </span><span class="NLM_article-title">Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F0008-5472.CAN-10-1874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=21127197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=496-505&author=M.+J.+Towleauthor=K.+A.+Salvatoauthor=B.+F.+Welsauthor=K.+K.+Aalfsauthor=W.+Zhengauthor=B.+M.+Seletskyauthor=X.+Zhuauthor=B.+M.+Lewisauthor=Y.+Kishiauthor=J.+Y.+Melvin&title=Eribulin+induces+irreversible+mitotic+blockade%3A+implications+of+cell-based+pharmacodynamics+for+in+vivo+efficacy+under+intermittent+dosing+conditions&doi=10.1158%2F0008-5472.CAN-10-1874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions</span></div><div class="casAuthors">Towle, Murray J.; Salvato, Kathleen A.; Wels, Bruce F.; Aalfs, Kimberley K.; Zheng, Wanjun; Seletsky, Boris M.; Zhu, Xiaojie; Lewis, Bryan M.; Kishi, Yoshito; Yu, Melvin J.; Littlefield, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">496-505</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Eribulin (E7389), a mechanistically unique microtubule inhibitor in phase III clin. trials for cancer, exhibits superior efficacy in vivo relative to the more potent compd. ER-076349, a fact not explained by different pharmacokinetic properties.  A cell-based pharmacodynamic explanation was suggested by observations that mitotic blockade induced by eribulin, but not ER-076349, is irreversible as measured by a flow cytometric mitotic block reversibility assay employing full dose/response treatment.  Cell viability 5 days after drug washout established relationships between mitotic block reversibility and long-term cell survival.  Similar results occurred in U937, Jurkat, HL-60, and HeLa cells, ruling out cell type-specific effects.  Studies with other tubulin agents suggest that mitotic block reversibility is a quantifiable, compd.-specific characteristic of antimitotic agents in general.  Bcl-2 phosphorylation patterns parallel eribulin and ER-076349 mitotic block reversibility patterns, suggesting persistent Bcl-2 phosphorylation contributes to long-term cell-viability loss after eribulin's irreversible blockade.  Drug uptake and washout/retention studies show that [3H]eribulin accumulates to lower intracellular levels than [3H]ER-076349, yet is retained longer and at higher levels.  Similar findings occurred with irreversible vincristine and reversible vinblastine, pointing to persistent cellular retention as a component of irreversibility.  Our results suggest that eribulin's in vivo superiority derives from its ability to induce irreversible mitotic blockade, which appears related to persistent drug retention and sustained Bcl-2 phosphorylation.  More broadly, our results suggest that compd.-specific reversibility characteristics of antimitotic agents contribute to interactions between cell-based pharmacodynamics and in vivo pharmacokinetics that define antitumor efficacy under intermittent dosing conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi9gbxI_sn-7Vg90H21EOLACvtfcHk0lg45bZoSokOGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFKlsA%253D%253D&md5=f0a39e79ab77340170d7a10edb3077c9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1874%26sid%3Dliteratum%253Aachs%26aulast%3DTowle%26aufirst%3DM.%2BJ.%26aulast%3DSalvato%26aufirst%3DK.%2BA.%26aulast%3DWels%26aufirst%3DB.%2BF.%26aulast%3DAalfs%26aufirst%3DK.%2BK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSeletsky%26aufirst%3DB.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLewis%26aufirst%3DB.%2BM.%26aulast%3DKishi%26aufirst%3DY.%26aulast%3DMelvin%26aufirst%3DJ.%2BY.%26atitle%3DEribulin%2520induces%2520irreversible%2520mitotic%2520blockade%253A%2520implications%2520of%2520cell-based%2520pharmacodynamics%2520for%2520in%2520vivo%2520efficacy%2520under%2520intermittent%2520dosing%2520conditions%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D496%26epage%3D505%26doi%3D10.1158%2F0008-5472.CAN-10-1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorléans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span>. <i>P. Natl. A. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">13775</span>– <span class="NLM_lpage">13779</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorl%C3%A9ansauthor=B.+Gigantauthor=R.+B.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0ljwam8mxHUJug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorl%25C3%25A9ans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DP.%2520Natl.%2520A.%2520Sci.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez, R.</span></span> <span> </span><span class="NLM_article-title">New ligands of the tubulin colchicine site based on X-ray structures</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.2174/1568026614666141130092637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568026614666141130092637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=25434358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=2231-2252&author=R.+Alvarezauthor=M.+Medardeauthor=R.+Pelaez&title=New+ligands+of+the+tubulin+colchicine+site+based+on+X-ray+structures&doi=10.2174%2F1568026614666141130092637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">New Ligands of the Tubulin Colchicine Site Based on X-Ray Structures</span></div><div class="casAuthors">Alvarez, Raquel; Medarde, Manuel; Pelaez, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2231-2252</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Colchicine site ligands have proved to be potent inhibitors of tubulin polymn., which leads them not only to display cytotoxic effects but also vascular disrupting effects on tumor neovasculature.  In recent years, many compds. have been designed, synthesized and evaluated in order to improve the potency, stability and physicochem. properties of these agents with the aim of developing an agent that could reach the clin. assay level.  Here we analyze the eleven X-ray structures of tubulin in complex with ligands at the colchicine site by dividing it into four different zones of interaction, we review the new compds. that have appeared in the literature since 2008 and that were designed based on any of these X-ray structures and, finally, we describe our latest results in the design of new potent antimitotic indole derivs. that have confirmed the flexibility of one of the zones described for the colchicine site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6HvmgggtxbVg90H21EOLACvtfcHk0ljwam8mxHUJug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D&md5=a7a289b0e6b986e59c8e0f875d4ae51e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F1568026614666141130092637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666141130092637%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPelaez%26aufirst%3DR.%26atitle%3DNew%2520ligands%2520of%2520the%2520tubulin%2520colchicine%2520site%2520based%2520on%2520X-ray%2520structures%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D2231%26epage%3D2252%26doi%3D10.2174%2F1568026614666141130092637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Rapid discovery and structure–activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4697</span>– <span class="NLM_lpage">4710</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00065</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00065" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4697-4710&author=C.+Fraserauthor=J.+C.+Dawsonauthor=R.+Dowlingauthor=D.+R.+Houstonauthor=J.+T.+Weissauthor=A.+F.+Munroauthor=M.+Muirauthor=L.+Harringtonauthor=S.+P.+Websterauthor=M.+C.+Frameauthor=V.+G.+Bruntonauthor=E.+E.+Pattonauthor=N.+O.+Carragherauthor=A.+Unciti-Broceta&title=Rapid+discovery+and+structure%E2%80%93activity+relationships+of+pyrazolopyrimidines+that+potently+suppress+breast+cancer+cell+growth+via+SRC+kinase+inhibition+with+exceptional+selectivity+over+ABL+kinase&doi=10.1021%2Facs.jmedchem.6b00065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase</span></div><div class="casAuthors">Fraser, Craig; Dawson, John C.; Dowling, Reece; Houston, Douglas R.; Weiss, Jason T.; Munro, Alison F.; Muir, Morwenna; Harrington, Lea; Webster, Scott P.; Frame, Margaret C.; Brunton, Valerie G.; Patton, E. Elizabeth; Carragher, Neil O.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4697-4710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyrazolopyrimidines displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner.  Compds. were derived from the promiscuous kinase inhibitor PP1 to search for analogs that could potentially target a broad spectrum of kinases involved in cancer.  Phenotypic screening against MCF7 mammary adenocarcinoma cells generated target-agnostic structure-activity relationships that biased subsequent designs toward breast cancer treatment rather than to a particular target.  This strategy led to the discovery of two potent antiproliferative leads with phenotypically distinct anticancer mode of actions.  Kinase profiling and further optimization resulted in eCF506, the first small mol. with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concn. to inhibit ABL. eCF506 exhibits excellent water soly., an optimal DMPK profile and oral bioavailability, halts SRC-assocd. neuromast migration in zebrafish embryos without inducing life-threatening heart defects, and inhibits SRC phosphorylation in tumor xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq55yS4FWveyLVg90H21EOLACvtfcHk0ljwam8mxHUJug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D&md5=e56206009ccca680432d12db23aa29fd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00065%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%2BC.%26aulast%3DDowling%26aufirst%3DR.%26aulast%3DHouston%26aufirst%3DD.%2BR.%26aulast%3DWeiss%26aufirst%3DJ.%2BT.%26aulast%3DMunro%26aufirst%3DA.%2BF.%26aulast%3DMuir%26aufirst%3DM.%26aulast%3DHarrington%26aufirst%3DL.%26aulast%3DWebster%26aufirst%3DS.%2BP.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DPatton%26aufirst%3DE.%2BE.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DRapid%2520discovery%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520pyrazolopyrimidines%2520that%2520potently%2520suppress%2520breast%2520cancer%2520cell%2520growth%2520via%2520SRC%2520kinase%2520inhibition%2520with%2520exceptional%2520selectivity%2520over%2520ABL%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4697%26epage%3D4710%26doi%3D10.1021%2Facs.jmedchem.6b00065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Src in cancer: deregulation and consequences for cell behaviour</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1602</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/S0304-419X(02)00040-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2FS0304-419X%2802%2900040-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=12020799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=114-130&author=M.+C.+Frame&title=Src+in+cancer%3A+deregulation+and+consequences+for+cell+behaviour&doi=10.1016%2FS0304-419X%2802%2900040-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Src in cancer: deregulation and consequences for cell behavior</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-130</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Considerable evidence now implicates elevated expression and/or activity of Src in cancer development.  In cells, endogenous Src is switched from an inactive to an active state by a variety of mechanisms that simultaneously relieve constraints on the kinase and protein-interacting Src homol. (SH) domains.  As a result, Src is translocated to the cell periphery, often to sites of cell adhesion, where myristylation mediates attachment to the inner surface of the plasma membrane.  From these peripheral sites, Src's catalytic activity initiates intracellular signal transduction pathways that influence cell growth and adhesion strength, the latter contributing to control of cell migration.  De-regulation in cancer cells may therefore enhance tumor growth and/or stimulate migratory or invasive potential in cells that would normally be relatively non-motile.  Evidence now exists to suggest that Src may also influence the life or death decisions that cells make during many biol. processes.  Thus, Src modulation in cancer cells can alter cell responses that are often perturbed in cancer.  Consequently, there is optimism that drugs which inhibit Src's kinase activity, or the activity of its downstream effectors, might have profound effects on cancer cell behavior and be useful therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PUbbCfYCTrVg90H21EOLACvtfcHk0lgqnpOzJfUwLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D&md5=ac3f4d59c7979798349ea7f0db807d67</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900040-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900040-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DSrc%2520in%2520cancer%253A%2520deregulation%2520and%2520consequences%2520for%2520cell%2520behaviour%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2002%26volume%3D1602%26spage%3D114%26epage%3D130%26doi%3D10.1016%2FS0304-419X%2802%2900040-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhoff, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fincham, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1450</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(03)00544-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2FS0960-9822%2803%2900544-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=12932330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmslentbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=1442-1450&author=N.+O.+Carragherauthor=M.+A.+Westhoffauthor=V.+J.+Finchamauthor=M.+D.+Schallerauthor=M.+C.+Frame&title=A+novel+role+for+FAK+as+a+protease-targeting+adaptor+protein%3A+regulation+by+p42+ERK+and+Src&doi=10.1016%2FS0960-9822%2803%2900544-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Role for FAK as a Protease-Targeting Adaptor Protein Regulation by p42 ERK and Src</span></div><div class="casAuthors">Carragher, Neil O.; Westhoff, M. Andrew; Fincham, Valerie J.; Schaller, Michael D.; Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1442-1450</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cell migration on extracellular matrix requires the turnover of integrin-dependent adhesions.  The nonreceptor tyrosine kinases Src and FAK regulate focal-adhesion turnover by poorly understood mechanisms .  ERK/MAP kinase-mediated activation of the protease Calpain 2 also promotes focal-adhesion turnover ; however, it is not known if this is linked to the activities of Src and FAK.  Calpain 2 has previously been demonstrated to colocalize with focal-adhesion structures and can cleave several focal-adhesion complex components, including FAK .  Studies utilizing Calpain inhibitors or Calpain-deficient cells confirm that Calpain's role in regulating focal-adhesion turnover is necessary for cell migration .  We have identified a novel and kinase-independent function for FAK as an adaptor mol. that mediates the assembly of a complex consisting of at least Calpain 2 and p42ERK.  Mutation of proline residues (Pro2) in the amino-terminal region of FAK blocks direct binding with Calpain 2 and also prevents formation of the Calpain 2/p42ERK complex in cells.  We show that both complex formation and MEK/ERK activity are assocd. with Calpain-mediated proteolysis of FAK and focal adhesion turnover during transformation and migration.  Furthermore, FAK is necessary for recruiting both Calpain 2 and p42ERK/MAPK to peripheral adhesion sites facilitating maximal Calpain activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUPV_BzP9MD7Vg90H21EOLACvtfcHk0lgqnpOzJfUwLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmslentbY%253D&md5=4cc984f708f04e773c9164177e409d9a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2803%2900544-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252803%252900544-X%26sid%3Dliteratum%253Aachs%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DWesthoff%26aufirst%3DM.%2BA.%26aulast%3DFincham%26aufirst%3DV.%2BJ.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DA%2520novel%2520role%2520for%2520FAK%2520as%2520a%2520protease-targeting%2520adaptor%2520protein%253A%2520regulation%2520by%2520p42%2520ERK%2520and%2520Src%26jtitle%3DCurr.%2520Biol.%26date%3D2003%26volume%3D13%26spage%3D1442%26epage%3D1450%26doi%3D10.1016%2FS0960-9822%2803%2900544-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizawar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, S. J.</span></span> <span> </span><span class="NLM_article-title">c-Src and cooperating partners in human cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2Fj.ccr.2004.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15380511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Kis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=209-214&author=R.+Ishizawarauthor=S.+J.+Parsons&title=c-Src+and+cooperating+partners+in+human+cancer&doi=10.1016%2Fj.ccr.2004.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src and cooperating partners in human cancer</span></div><div class="casAuthors">Ishizawar, Rumey; Parsons, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-214</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The proto-oncogene c-src is rarely mutated in human cancers, and when overexpressed in normal cells is non- or weakly oncogenic.  These observations have raised doubts about the involvement of c-src in the etiol. of human tumors.  However, recent studies have shown that c-Src, a non-receptor tyrosine kinase, exhibits elevated protein levels and activity in numerous types of human cancers.  Furthermore, it has been found to be a crit. component of multiple signaling pathways that regulate proliferation, survival, metastasis, and angiogenesis.  Because of its important role in these oncogenic processes, it represents a therapeutic target ripe for exploitation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhanyde_CerVg90H21EOLACvtfcHk0lgP49uZ-hSAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Kis7w%253D&md5=7a9b3574284956171da59b093ab7c9d9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DIshizawar%26aufirst%3DR.%26aulast%3DParsons%26aufirst%3DS.%2BJ.%26atitle%3Dc-Src%2520and%2520cooperating%2520partners%2520in%2520human%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D209%26epage%3D214%26doi%3D10.1016%2Fj.ccr.2004.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2Fj.phrs.2015.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=25662515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=9-25&author=R.+Roskoski&title=Src+protein-tyrosine+kinase+structure%2C+mechanism%2C+and+small+molecule+inhibitors&doi=10.1016%2Fj.phrs.2015.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-25</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The physiol. Src proto-oncogene is a protein tyrosine kinase that plays key roles in cell growth, division, migration, and survival signaling pathways.  From the N- to C-terminus, Src contains a unique domain, an SH3 domain, an SH2 domain, a protein tyrosine kinase domain, and a regulatory tail.  The chief phosphorylation sites of human Src include an activating pTyr419 that results from phosphorylation in the kinase domain by an adjacent Src mol. and an inhibitory pTyr530 in the regulatory tail that results from phosphorylation by C-terminal Src kinase (Csk) or Chk (Csk homologous kinase).  The oncogenic Rous sarcoma viral protein lacks the equiv. of Tyr530 and is constitutively activated.  Inactive Src is stabilized by SH2 and SH3 domains on the rear of the kinase domain where they form an immobilizing and inhibitory clamp.  Protein kinases including Src contain hydrophobic regulatory and catalytic spines and collateral shell residues that are required to assemble the active enzyme.  In the inactive enzyme, the regulatory spine contains a kink or a discontinuity with a structure that is incompatible with catalysis.  The conversion of inactive to active Src is accompanied by electrostatic exchanges involving the breaking and making of distinct sets of kinase domain salt bridges and hydrogen bonds.  Src-catalyzed protein phosphorylation requires the participation of two Mg2+ ions.  Although nearly all protein kinases possess a common K/E/D/D signature, each enzyme exhibits its unique variations of the protein-kinase reaction template.  Bosutinib, dasatinib, and ponatinib are Src/multikinase inhibitors that are approved by the FDA for the treatment of chronic myelogenous leukemia and vandetanib is approved for the treatment of medullary thyroid cancer.  The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clin. trials for a variety of solid tumors including breast and lung cancers.  Both ATP and targeted therapeutic Src protein kinase inhibitors such as dasatinib and ponatinib make hydrophobic contacts with catalytic spine residues and form hydrogen bonds with hinge residues connecting the small and large kinase lobes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWw-wmm7q2cbVg90H21EOLACvtfcHk0lgP49uZ-hSAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D&md5=a40c394ab772b445fe0944c58e1f3deb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DSrc%2520protein-tyrosine%2520kinase%2520structure%252C%2520mechanism%252C%2520and%2520small%2520molecule%2520inhibitors%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D94%26spage%3D9%26epage%3D25%26doi%3D10.1016%2Fj.phrs.2015.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F1535-7163.MCT-12-0109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=23144237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntValtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=16-26&author=H.+J.+Namauthor=S.+A.+Imauthor=D.+Y.+Ohauthor=P.+Elvinauthor=H.+P.+Kimauthor=Y.+K.+Yoonauthor=Y.+J.+Bang&title=Antitumor+activity+of+saracatinib+%28AZD0530%29%2C+a+c-Src%2FAbl+kinase+inhibitor%2C+alone+or+in+combination+with+chemotherapeutic+agents+in+gastric+cancer&doi=10.1158%2F1535-7163.MCT-12-0109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer</span></div><div class="casAuthors">Nam, Hyun-Jin; Im, Seock-Ah; Oh, Do-Youn; Elvin, Paul; Kim, Hwang-Phill; Yoon, Young-Kwang; Min, Ahrum; Song, Sang-Hyun; Han, Sae-Won; Kim, Tae-You; Bang, Yung-Jue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-26</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, and tumorigenesis.  Increased Src activity has been reported in many types of human cancer, including gastric cancer.  Therefore, this factor has been identified as a promising therapeutic target for cancer treatments, and targeting Src in gastric cancer is predicted to have potent effects.  We evaluated the antitumor effect of a c-Src/Abl kinase inhibitor, saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model.  Among 10 gastric cancer cell lines, saracatinib specifically inhibited the growth and migration/invasion of SNU216 and NCI-N87 cells.  Saracatinib blocked the Src/FAK, HER family, and oncogenic signaling pathways, and it induced G1 arrest and apoptosis in SNU216 and NCI-N87 cells.  Apoptosis required induction of the proapoptotic BCL2 family member Bim.  Knockdown of Bim using siRNA decreased apoptosis induced by treatment with saracatinib, suggesting that Bim has an important role in saracatinib-induced apoptosis.  Saracatinib enhanced the effects of lapatinib, an EGFR/HER2 dual inhibitor, in SNU216 and NCI-N87 cells.  Furthermore, combined treatment with saracatinib and 5-fluorouracil (5-FU) or cisplatin exerted synergistic effects in both saracatinib-sensitive and saracatinib-resistant cells.  Consistent with our in vitro findings, cotreatment with saracatinib and 5-FU resulted in enhanced antitumor activity in the NCI-N87 xenografts.  These data indicate that the inhibition of Src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.  Mol Cancer Ther; 12(1); 16-26. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpFSWq6HNftrVg90H21EOLACvtfcHk0lgP49uZ-hSAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntValtw%253D%253D&md5=de92a9e602764f294ae9d231758ab283</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0109%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DH.%2BJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DElvin%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.%2BP.%26aulast%3DYoon%26aufirst%3DY.%2BK.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DAntitumor%2520activity%2520of%2520saracatinib%2520%2528AZD0530%2529%252C%2520a%2520c-Src%252FAbl%2520kinase%2520inhibitor%252C%2520alone%2520or%2520in%2520combination%2520with%2520chemotherapeutic%2520agents%2520in%2520gastric%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D16%26epage%3D26%26doi%3D10.1158%2F1535-7163.MCT-12-0109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Secord, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadwater, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havrilesky, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berchuck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenham, R. M.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5489</span>– <span class="NLM_lpage">5498</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F1078-0432.CCR-12-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=22837181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5489-5498&author=A.+A.+Secordauthor=D.+K.+Teohauthor=W.+T.+Barryauthor=M.+Yuauthor=G.+Broadwaterauthor=L.+J.+Havrileskyauthor=P.+S.+Leeauthor=A.+Berchuckauthor=J.+Lancasterauthor=R.+M.+Wenham&title=A+phase+I+trial+of+dasatinib%2C+an+SRC-family+kinase+inhibitor%2C+in+combination+with+paclitaxel+and+carboplatin+in+patients+with+advanced+or+recurrent+ovarian+cancer&doi=10.1158%2F1078-0432.CCR-12-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer</span></div><div class="casAuthors">Secord, Angeles Alvarez; Teoh, Deanna K.; Barry, William T.; Yu, Miao; Broadwater, Gloria; Havrilesky, Laura J.; Lee, Paula S.; Berchuck, Andrew; Lancaster, Johnathan; Wenham, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5489-5498</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in the treatment of advanced and recurrent epithelial ovarian cancer.  Exptl. Design: The primary objective was to det. the max. tolerated dose (MTD).  Secondary objectives included defining toxicity, response rate (RR), pharmacokinetics, and pharmacodynamics.  Using a "3+3" design, cohorts of three to six patients received paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 3 wk with escalating doses of dasatinib (100, 120, and 150 mg daily), followed by an eight-patient expansion cohort.  Results: Twenty patients were enrolled between June 2007 and Dec. 2009.  The median age was 61 years (range: 42-82) with a median of 2 prior regimens (range: 0-6), and 71% had platinum-sensitive disease.  There were three to six patients in each cohort, and eight in the expansion cohort.  Pharmacokinetics were obsd. over the first two cycles of therapy.  One DLT was obsd. in the 100 mg dasatinib cohort (grade 3 myalgia).  Other toxicities in all cycles included neutropenia (95% grade 3-4; 91% in the 150 mg dosing cohort), thrombocytopenia (35% grade 3-4), and fatigue (10% grade 3).  The RR was 40% [three complete responses, (15%); five partial responses, (25%)],10 patients (50%) had stable disease, and two were not evaluable.  The PFS6-month actuarial est. was 86%.  The median PFS and OS were 7.8 and 16.2 mo, resp.  Conclusions: Due to the high incidence of myelosuppression with subsequent cycles, the recommended phase II dose of dasatinib is 150 mg daily in combination with paclitaxel and carboplatin.  The combination was safe with evidence of clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWuV56MlqRILVg90H21EOLACvtfcHk0lgMkuSNccdE3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgurrM&md5=91ec89609ac00a56872ecfcb8a41be12</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0507%26sid%3Dliteratum%253Aachs%26aulast%3DSecord%26aufirst%3DA.%2BA.%26aulast%3DTeoh%26aufirst%3DD.%2BK.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DHavrilesky%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DBerchuck%26aufirst%3DA.%26aulast%3DLancaster%26aufirst%3DJ.%26aulast%3DWenham%26aufirst%3DR.%2BM.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520dasatinib%252C%2520an%2520SRC-family%2520kinase%2520inhibitor%252C%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520in%2520patients%2520with%2520advanced%2520or%2520recurrent%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5489%26epage%3D5498%26doi%3D10.1158%2F1078-0432.CCR-12-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southwood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1007/s10637-010-9611-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1007%2Fs10637-010-9611-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=21170669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=779-786&author=D.+J.+Renoufauthor=M.+J.+Mooreauthor=D.+Hedleyauthor=S.+Gillauthor=D.+Jonkerauthor=E.+Chenauthor=D.+Waldeauthor=R.+Goelauthor=B.+Southwoodauthor=I.+Gauthierauthor=W.+Walshauthor=L.+McIntoshauthor=L.+Seymour&title=A+phase+I%2FII+study+of+the+Src+inhibitor+saracatinib+%28AZD0530%29+in+combination+with+gemcitabine+in+advanced+pancreatic+cancer&doi=10.1007%2Fs10637-010-9611-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer</span></div><div class="casAuthors">Renouf, Daniel J.; Moore, Malcolm J.; Hedley, David; Gill, Sharlene; Jonker, Derek; Chen, Eric; Walde, David; Goel, Rakesh; Southwood, Bernadette; Gauthier, Isabelle; Walsh, Wendy; McIntosh, Lynn; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This phase I/II study of saracatinib in combination with gemcitabine in patients with advanced pancreatic cancer was conducted by the NCIC Clin. Trials Group.  The aims were to define the recommended phase II dose (RP2D) of saracatinib when combined with gemcitabine, and assess the efficacy of this combination in advanced pancreatic cancer.  Eligibility criteria included locally advanced or metastatic pancreatic adenocarcinoma and no prior chemotherapy.  In phase I saracatinib was escalated in combination with gemcitabine (1000 mg/m2) to det. the recommended phase II dose (RP2D).  The study was then expanded to a single arm phase II trial using a Simon 2-stage design.  The primary endpoint was objective tumor response (OR) plus stable disease ≥4 mo (SD4) rate; if ≥8 patients had OR+SD4, the study would proceed to stage 2.  Thirteen patients were enrolled into the phase I portion of this study.  Saracatinib 175 mg PO daily was chosen as the RP2D in combination with gemcitabine.  Twenty-one addnl. patients were then enrolled at the RP2D (phase II).  Of the 22 response evaluable patients treated at the RP2D, 9 patients (40.9%) had progressive disease, 6 patients (27.3%) had stable disease for less than 4 mo, 5 patients (22.7%) had SD4, and 2 patients (9.1%) had a partial response to treatment.  Objective criteria for continuing to stage 2 were thus not met and the trial was closed following the accrual of 34 patients.  Saracatinib 175 mg daily in combination with gemcitabine is well tolerated but the combination did not improve efficacy over what would be expected from gemcitabine alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RONoTvlAtrVg90H21EOLACvtfcHk0lgMkuSNccdE3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGmtLc%253D&md5=41aa8f7265dfb802472af5736b614173</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9611-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9611-3%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DJonker%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DWalde%26aufirst%3DD.%26aulast%3DGoel%26aufirst%3DR.%26aulast%3DSouthwood%26aufirst%3DB.%26aulast%3DGauthier%26aufirst%3DI.%26aulast%3DWalsh%26aufirst%3DW.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520the%2520Src%2520inhibitor%2520saracatinib%2520%2528AZD0530%2529%2520in%2520combination%2520with%2520gemcitabine%2520in%2520advanced%2520pancreatic%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D779%26epage%3D786%26doi%3D10.1007%2Fs10637-010-9611-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: the rise of multitarget drugs over combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.4155%2Ffmc.14.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=24649950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=485-487&author=M.+Rosini&title=Polypharmacology%3A+the+rise+of+multitarget+drugs+over+combination+therapies&doi=10.4155%2Ffmc.14.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: the rise of multitarget drugs over combination therapies</span></div><div class="casAuthors">Rosini, Michela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-487</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNBzYCAfAa7Vg90H21EOLACvtfcHk0liKcdUyakH9Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D&md5=0c32e1a1ae5a13cd25483ba18833fd54</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.25%26sid%3Dliteratum%253Aachs%26aulast%3DRosini%26aufirst%3DM.%26atitle%3DPolypharmacology%253A%2520the%2520rise%2520of%2520multitarget%2520drugs%2520over%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D485%26epage%3D487%26doi%3D10.4155%2Ffmc.14.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindyalov, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">The protein data bank</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1093/nar/28.1.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+protein+data+bank&doi=10.1093%2Fnar%2F28.1.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0liKcdUyakH9Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520protein%2520data%2520bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242%26doi%3D10.1093%2Fnar%2F28.1.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span> <span> </span><span class="NLM_article-title">Python: a programming language for software integration and development</span>. <i>J. Mol. Graphics Modell.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10660911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=57-61&author=M.+F.+Sanner&title=Python%3A+a+programming+language+for+software+integration+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Python: a programming language for software integration and development</span></div><div class="casAuthors">Sanner, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-61</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The use of interpreted languages in biocomputing has been investigated to create a programmable, dynamic environment in which components can be tied together at a high level.  This work has demonstrated the benefits of such an approach and the features of the interpreted language that are key to successful component integration.  This involved Python, an interpreted, interactive, object-oriented programming language.  It provides high-level data structures such as list and associative arrays, dynamic typing and dynamic binding, modules, classes, exceptions, automatic memory management and others.  Python has been found to be instrumental in the mol. modeling research environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaCFXA1JC8X7Vg90H21EOLACvtfcHk0liKcdUyakH9Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D&md5=3bf94934548080055dda54f68468c656</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanner%26aufirst%3DM.%2BF.%26atitle%3DPython%253A%2520a%2520programming%2520language%2520for%2520software%2520integration%2520and%2520development%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D1999%26volume%3D17%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasteiger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsili, M.</span></span> <span> </span><span class="NLM_article-title">Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3219</span>– <span class="NLM_lpage">3228</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(80)80168-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2F0040-4020%2880%2980168-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1980&pages=3219-3228&author=J.+Gasteigerauthor=M.+Marsili&title=Iterative+partial+equalization+of+orbital+electronegativity%E2%80%94a+rapid+access+to+atomic+charges&doi=10.1016%2F0040-4020%2880%2980168-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges</span></div><div class="casAuthors">Gasteiger, Johann; Marsili, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3219-22</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">A method is presented for the rapid calcn. of at. charges in σ-bonded and nonconjugated π-systems (alkyl halides and oxoalkanes, resp.), considering only the connectivities of the atoms.  Atoms are characterized by their orbital electronegativities.  Partial equalization of orbital electronegativity is obtained by an iterative procedure.  Excellent correlations of the at. charges with core-electron binding energies and with acidity consts. are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKA3wil1SiWrVg90H21EOLACvtfcHk0lipaLYDK_Xd-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D&md5=90c580857e6001482bee92450278fe9f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2880%2980168-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252880%252980168-2%26sid%3Dliteratum%253Aachs%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DMarsili%26aufirst%3DM.%26atitle%3DIterative%2520partial%2520equalization%2520of%2520orbital%2520electronegativity%25E2%2580%2594a%2520rapid%2520access%2520to%2520atomic%2520charges%26jtitle%3DTetrahedron%26date%3D1980%26volume%3D36%26spage%3D3219%26epage%3D3228%26doi%3D10.1016%2F0040-4020%2880%2980168-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open Babel: An open chemical toolbox</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=33&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+Babel%3A+An+open+chemical+toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520Babel%253A%2520An%2520open%2520chemical%2520toolbox%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D33%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods II. Applications</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1002%2Fjcc.540100209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=221-264&author=J.+J.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+II.+Applications&doi=10.1002%2Fjcc.540100209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  II.  Applications</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-64</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">MNDO/AM1-type parameters for 12 elements were optimized using a newly developed method for optimizing parameters for semiempirical methods.  With the new method, MNDO-PM3, the av. difference between the predicted heats of formation and exptl. values for 657 compds. is 7.8 kcal/mol, and for 106 hypervalent compds., 13.6 kcal/mol.  For MNDO the equiv. differences are 13.9 and 75.8 kcal/mol, while those for AM1, in which MNDO parameters are used for Al, P, and S, are 12.7 and 83.1 kcal/mol, resp.  Av. errors for ionization potentials, bond angles, and dipole moments are intermediate between those for MINDO and AM1, while errors on bond lengths are slightly reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofaR7BHv7vB7Vg90H21EOLACvtfcHk0lipaLYDK_Xd-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D&md5=b94fa02ec95f5b1b2d62c2014ac4c288</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100209%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520II.%2520Applications%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D221%26epage%3D264%26doi%3D10.1002%2Fjcc.540100209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rurainski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhof, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, D.</span></span> <span> </span><span class="NLM_article-title">A new Lamarckian genetic algorithm for flexible ligand-receptor docking</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1002/jcc.21478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1002%2Fjcc.21478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=20082382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=1911-1918&author=J.+Fuhrmannauthor=A.+Rurainskiauthor=H.+P.+Lenhofauthor=D.+Neumann&title=A+new+Lamarckian+genetic+algorithm+for+flexible+ligand-receptor+docking&doi=10.1002%2Fjcc.21478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A new Lamarckian genetic algorithm for flexible ligand-receptor docking</span></div><div class="casAuthors">Fuhrmann, Jan; Rurainski, Alexander; Lenhof, Hans-Peter; Neumann, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1911-1918</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors present a Lamarckian genetic algorithm (LGA) variant for flexible ligand-receptor docking which allows to handle a large no. of degrees of freedom.  The authors' hybrid method combines a multi-deme LGA with a recently published gradient-based method for local optimization of mol. complexes.  The authors compared the performance of their new hybrid method to two non-gradient-based search heuristics on the Astex diverse set for flexible ligand-receptor docking.  The authors' results show that the novel approach is clearly superior to other LGAs employing a stochastic optimization method.  The new algorithm features a shorter run time and gives substantially better results, esp. with increasing complexity of the ligands.  Thus, it may be used to dock ligands with many rotatable bonds with high efficiency. © 2010 Wiley Periodicals, Inc.  J Comput Chem, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoFNlhZnxim7Vg90H21EOLACvtfcHk0lgKSeC-MD1RTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D&md5=34a78af702d8ee9bace9b5db8221e2db</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21478%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann%26aufirst%3DJ.%26aulast%3DRurainski%26aufirst%3DA.%26aulast%3DLenhof%26aufirst%3DH.%2BP.%26aulast%3DNeumann%26aufirst%3DD.%26atitle%3DA%2520new%2520Lamarckian%2520genetic%2520algorithm%2520for%2520flexible%2520ligand-receptor%2520docking%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D1911%26epage%3D1918%26doi%3D10.1002%2Fjcc.21478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of KX01 derivatives with extended chains. (A) Chain length extended to <i>n</i> = 2 or 3. Predicted binding mode of (B) <b>6a</b> and (C) <b>6d</b> with tubulin (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>). Blue sticks show the structure of <b>6a</b> and <b>6d</b>; yellow dashed lines show the hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of KX01 Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, DMF, r.t., overnight, and 71.5%; (b) 4-hydroxybenzeneboronic acid pinacol ester, PdCl<sub>2</sub>(dppf)CH<sub>2</sub>Cl<sub>2</sub>, KF, 1,4-dioxane/H<sub>2</sub>O, 80 °C, 8 h, and 75.2%; (c) 1,2-dibromoethane or 1,3-dibromopropane or 1,4-dibromobutane, CsCO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, and 98%; (d) KI, Et<sub>3</sub>N, DMF, 50 °C, 8 h, and 25.4–80.2%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of KX01 Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TFA, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 2 h, and 84.5%; (b) HATU, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 4 h, and 52.5–97.3%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicting the binding mode of <b>6r</b> with tubulin (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>). Blue sticks show the structure of <b>6r</b>; yellow dashed lines show the hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antitumor effects of selected compounds on C26 and SKOV3 xenograft mouse models. C26 xenograft mice were administered <b>6r</b>, <b>8a</b>, or <b>8b</b> at a dose of 10 mg/kg (<i>p.o.)</i>, with KX01 (10 mg/kg, <i>p.o.</i>) as a control (<i>n</i> = 6, means ± SD). (A) Tumor volume (mm<sup>3</sup>) evaluated once every 2 days for 10 days. (B) Body weight (g) changes of each group. (C) Tumor weight (g) of each group on day 10. All the data are expressed as the mean ± SD (<i>n</i> = 6 per group). SKOV3 xenograft mice were administered <b>8a</b> at doses of 5 and 10 mg/kg (<i>p.o.)</i>, with KX01 (10 mg/kg, <i>p.o.</i>) as a control (<i>n</i> = 5, mean ± SD). (D) Tumor volume (mm<sup>3</sup>) evaluated once every 3 days for 1 month. (E) Body weight (g) of each group. (F) Tumor weight (g) of each group on day 30.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>8a</b> inhibited tubulin polymerization and induced G2/M-phase cell cycle arrest in SKOV3 cells. (A) SKOV3 cells were treated with 100 nM colchicine (Col), paclitaxel (PTX) or 10 or 100 nM <b>8a</b> for 16 h, and the microtubule morphology was monitored by immunofluorescence. (B) KX01, Col, and <b>8a</b> at 5.0 μM were coincubated with tubulin (3 mg/mL) at 37 °C, and the absorbance was collected every second for 30 min at 340 nm. (C) SKOV3 cells were treated with 0, 1, 5, or 10 nM <b>8a</b> or 10, 20, or 100 nM KX01 for 16 h, and the cell cycle was analyzed by PI staining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>8a</b> reversibly inhibited tubulin polymerization. (A) Time schedule of the mitotic block reversibility assay. (B) SKOV3 cell cycle histograms for colchicine (Col) and <b>8a</b> in the mitotic block reversibility assay. Blue rectangles show the minimum drug concentrations required to induce the SMB at 0 h or maintain the SMB at 10 h. Data represent the results of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structure of tubulin complexed with <b>8a</b>. (A) Chemical structure of <b>8a</b>. (B) Overall structure of the tubulin–<b>8a</b> complex (PDB code: 7CBZ). RB3-SLD is colored blue, TTL is yellow, α-tubulin is black, β-tubulin is gray, and <b>8a</b> is shown as cyan spheres. (C) Comparison of the binding modes between KX01 and <b>8a</b>. The crystal structures of tubulin–KX01 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>; green) and tubulin–<b>8a</b> (gray) were superimposed. (D) Interactions between tubulin and <b>8a</b>. <b>8a</b> is shown as sticks. Residues that formed interactions with <b>8a</b> are shown as sticks and labeled. Hydrogen bonds are shown as red dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/medium/jm0c01961_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>8a</b> inhibited the Src/FAK signaling pathway in the SKOV3 cell line. Data represent the results of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c01961/20210616/images/large/jm0c01961_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01961&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lhNCi5K1QFpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyams, J. S.</span>; <span class="NLM_string-name">Lloyd, C. W.</span></span> <i>Microtubules</i>; <span class="NLM_publisher-name">Wiley-Liss</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1993</span>, pp.  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">412</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=393-412&author=J.+S.+Hyams&author=C.+W.+Lloyd&title=Microtubules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHyams%26aufirst%3DJ.%2BS.%26btitle%3DMicrotubules%26pub%3DWiley-Liss%26date%3D1993%26spage%3D393%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurwerra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of action of microtubule-stabilizing anticancer agents</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1126/science.1230582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1126%2Fscience.1230582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=23287720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=587-590&author=A.+E.+Protaauthor=K.+Bargstenauthor=D.+Zurwerraauthor=J.+J.+Fieldauthor=J.+F.+D%C3%ADazauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=Molecular+mechanism+of+action+of+microtubule-stabilizing+anticancer+agents&doi=10.1126%2Fscience.1230582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Zurwerra, Didier; Field, Jessica J.; Diaz, Jose Fernando; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6119</span>),
    <span class="NLM_cas:pages">587-590</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Microtubule-stabilizing agents (MSAs) are efficacious chemotherapeutic drugs widely used for the treatment of cancer.  Despite the importance of MSAs for medical applications and basic research, their mol. mechanisms of action on tubulin and microtubules remain elusive.  We detd. high-resoln. crystal structures of αβ-tubulin in complex with two unrelated MSAs, zampanolide and epothilone A.  Both compds. were bound to the taxane pocket of β-tubulin and used their resp. side chains to induce structuring of the M-loop into a short helix.  Because the M-loop establishes lateral tubulin contacts in microtubules, these findings explain how taxane-site MSAs promote microtubule assembly and stability.  Further, our results offer fundamental structural insights into the control mechanisms of microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_p8NfCWTU-rVg90H21EOLACvtfcHk0lj6FMRRbFrbcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D&md5=b253c015f75f5eac4857d01e34d65f54</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1230582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1230582%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DZurwerra%26aufirst%3DD.%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DMolecular%2520mechanism%2520of%2520action%2520of%2520microtubule-stabilizing%2520anticancer%2520agents%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D587%26epage%3D590%26doi%3D10.1126%2Fscience.1230582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihydroindeno [1, 2-c] pyrazole analogues as potential anticancer agents targeting tubulin colchicine binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5341</span>– <span class="NLM_lpage">5355</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5341-5355&author=Y.-N.+Liuauthor=J.-J.+Wangauthor=Y.-T.+Jiauthor=G.-D.+Zhaoauthor=L.-Q.+Tangauthor=C.-M.+Zhangauthor=X.-L.+Guoauthor=Z.-P.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1-methyl-1%2C+4-dihydroindeno+%5B1%2C+2-c%5D+pyrazole+analogues+as+potential+anticancer+agents+targeting+tubulin+colchicine+binding+site&doi=10.1021%2Facs.jmedchem.6b00071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site</span></div><div class="casAuthors">Liu, Yan-Na; Wang, Jing-Jing; Ji, Ya-Ting; Zhao, Guo-Dong; Tang, Long-Qian; Zhang, Cheng-Mei; Guo, Xiu-Li; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5341-5355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By targeting a new binding region at the interface between αβ-tubulin heterodimers at the colchicine binding site, the authors designed a series of 7-substituted 1-methyl-1,4-dihydroindeno[1,2-c]pyrazoles as potential tubulin polymn. inhibitors.  Among the compds. synthesized, 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)acetamide (I), and 2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)-N-hydroxyacetamide, (II), showed noteworthy low nanomolar potency against HepG2, Hela, PC3, and MCF-7 cancer cell lines.  In mechanism studies, I inhibited tubulin polymn. and disorganized microtubule in A549 cells by binding to the tubulin colchicine binding site.  I arrested A549 cells in G2/M phase that was related to the alterations in the expression of cyclin B1 and p-cdc2.  I induced A549 cells apoptosis through the activation of caspase-3 and PARP.  In addn., I inhibited capillary tube formation in a concn.-dependent manner.  In a nonsmall cell lung cancer xenograft mouse model, I suppressed tumor growth by 59.1% at a dose of 50 mg/kg (i.p.) without obvious toxicity, indicating its in vivo potential as anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ-hoobIDuqrVg90H21EOLACvtfcHk0lj6FMRRbFrbcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslCqtrY%253D&md5=ba4652575e64aa805d859734ea5b3903</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00071%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-N.%26aulast%3DWang%26aufirst%3DJ.-J.%26aulast%3DJi%26aufirst%3DY.-T.%26aulast%3DZhao%26aufirst%3DG.-D.%26aulast%3DTang%26aufirst%3DL.-Q.%26aulast%3DZhang%26aufirst%3DC.-M.%26aulast%3DGuo%26aufirst%3DX.-L.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201-methyl-1%252C%25204-dihydroindeno%2520%255B1%252C%25202-c%255D%2520pyrazole%2520analogues%2520as%2520potential%2520anticancer%2520agents%2520targeting%2520tubulin%2520colchicine%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5341%26epage%3D5355%26doi%3D10.1021%2Facs.jmedchem.6b00071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botting, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naismith, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1038/ncomms12103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1038%2Fncomms12103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1-9&author=J.+Yangauthor=Y.+Wangauthor=T.+Wangauthor=J.+Jiangauthor=C.+H.+Bottingauthor=H.+Liuauthor=Q.+Chenauthor=J.+Yangauthor=J.+H.+Naismithauthor=X.+Zhuauthor=L.+Chen&title=Pironetin+reacts+covalently+with+cysteine-316+of+%CE%B1-tubulin+to+destabilize+microtubule&doi=10.1038%2Fncomms12103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fncomms12103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12103%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DBotting%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNaismith%26aufirst%3DJ.%2BH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DPironetin%2520reacts%2520covalently%2520with%2520cysteine-316%2520of%2520%25CE%25B1-tubulin%2520to%2520destabilize%2520microtubule%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D1%26epage%3D9%26doi%3D10.1038%2Fncomms12103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devi
Tangutur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamsi Krishna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantevari, S.</span></span> <span> </span><span class="NLM_article-title">Microtubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilizing and destabilizing agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2523</span>– <span class="NLM_lpage">2537</span>, <span class="refDoi"> DOI: 10.2174/1568026617666170104145640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568026617666170104145640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=28056738" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=2523-2537&author=A.+Devi%0ATanguturauthor=D.+Kumarauthor=K.+Vamsi+Krishnaauthor=S.+Kantevari&title=Microtubule+targeting+agents+as+cancer+chemotherapeutics%3A+an+overview+of+molecular+hybrids+as+stabilizing+and+destabilizing+agents&doi=10.2174%2F1568026617666170104145640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F1568026617666170104145640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026617666170104145640%26sid%3Dliteratum%253Aachs%26aulast%3DDevi%2BTangutur%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DVamsi%2BKrishna%26aufirst%3DK.%26aulast%3DKantevari%26aufirst%3DS.%26atitle%3DMicrotubule%2520targeting%2520agents%2520as%2520cancer%2520chemotherapeutics%253A%2520an%2520overview%2520of%2520molecular%2520hybrids%2520as%2520stabilizing%2520and%2520destabilizing%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D2523%26epage%3D2537%26doi%3D10.2174%2F1568026617666170104145640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bariwal, J.</span></span> <span> </span><span class="NLM_article-title">Recent developments in tubulin polymerization inhibitors: an overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2Fj.ejmech.2014.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=25240869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=89-124&author=R.+Kaurauthor=G.+Kaurauthor=R.+K.+Gillauthor=R.+Soniauthor=J.+Bariwal&title=Recent+developments+in+tubulin+polymerization+inhibitors%3A+an+overview&doi=10.1016%2Fj.ejmech.2014.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in tubulin polymerization inhibitors: An overview</span></div><div class="casAuthors">Kaur, Ramandeep; Kaur, Gurneet; Gill, Rupinder Kaur; Soni, Richard; Bariwal, Jitender</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-124</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Microtubules are protein biopolymers formed through polymn. of heterodimers of α- and β-tubulins.  Disruption of microtubules can induce cell cycle arrest in G2-M phase and formation of abnormal mitotic spindles.  Their importance in mitosis and cell division makes microtubules an attractive target for anticancer drug discovery.  A no. of naturally occurring compds. such as paclitaxel, epothilones, vinblastine, combretastatin, and colchicines exert their effect by changing dynamics of tubulin such as polymn. and depolymn.  During past few years, rapid development of the novel tubulin polymn. inhibitors has been witnessed.  Diverse classes of chem. compds. from the natural as well as from the synthetic origin have been extensively studied.  This review highlights the various classes of synthetically derived chem. compds. those have been reported in last few years as potential tubulin polymn. inhibitors.  A brief synthetic methodol. to access these compds. has been highlighted along with the brief SAR studies.  We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compds. to inhibit the tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV6nQysY8nvbVg90H21EOLACvtfcHk0lhPbuVon_jC-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE&md5=2ffd2f9bb073a7830f4aae7c29f070d9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DBariwal%26aufirst%3DJ.%26atitle%3DRecent%2520developments%2520in%2520tubulin%2520polymerization%2520inhibitors%253A%2520an%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D89%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2014.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haider, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yar, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span> <span> </span><span class="NLM_article-title">Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1648433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1080%2F13543776.2019.1648433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=31353978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSrur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=623-641&author=K.+Haiderauthor=S.+Rahamanauthor=M.+S.+Yarauthor=A.+Kamal&title=Tubulin+inhibitors+as+novel+anticancer+agents%3A+an+overview+on+patents+%282013-2018%29&doi=10.1080%2F13543776.2019.1648433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018)</span></div><div class="casAuthors">Haider, Kashif; Rahaman, Shaik; Yar, M. Shahar; Kamal, Ahmed</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">623-641</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  About 20 patents have been published from 2013 to 2018 for developing advanced cancer therapeutics by targeting tubulin polymn.  Currently, there are several tubulin inhibitors that are in the drug development pipeline for various cancers alone or in combination including antibody-conjugated drugs (ACDs).: Important patents focusing on the development of tubulin inhibitors published from 2013 to 2018 are covered.  This review mainly focuses on the tubulin inhibitors that are being synthesized and studied in cancer research along with their structures and their phases of development in preclin. and clin. research.: Regulation of microtubules is important for cell division, cell motility, intracellular transport, and cell shape maintenance.  Modulating its activity proved to be very effective in various diseases including different types of cancers.  Microtubules are composed of two units, namely, alpha and beta-tubulin, and modifications at these ends affect both its functions and dynamics.  A no. of compds. that have been designed and synthesized bearing various heterocyclic scaffolds have been proven to modulate its activity and have emerged as potent tubulin inhibitors.  This encourages more to study microtubules in order to find a variety of novel, potent compds. as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMeZtUEnfGPrVg90H21EOLACvtfcHk0lhPbuVon_jC-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSrur7L&md5=813a1c993e5e8ddcd86ffdd7ead6ba24</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1648433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1648433%26sid%3Dliteratum%253Aachs%26aulast%3DHaider%26aufirst%3DK.%26aulast%3DRahaman%26aufirst%3DS.%26aulast%3DYar%26aufirst%3DM.%2BS.%26aulast%3DKamal%26aufirst%3DA.%26atitle%3DTubulin%2520inhibitors%2520as%2520novel%2520anticancer%2520agents%253A%2520an%2520overview%2520on%2520patents%2520%25282013-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D623%26epage%3D641%26doi%3D10.1080%2F13543776.2019.1648433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4704</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4704-4719&author=M.+P.+Smolinskiauthor=Y.+Buauthor=J.+Clementsauthor=I.+H.+Gelmanauthor=T.+Hegabauthor=D.+L.+Cutlerauthor=J.+W.+Fangauthor=G.+Fetterlyauthor=R.+Kwanauthor=A.+Barnettauthor=J.+Y.+N.+Lauauthor=D.+G.+Hangauer&title=Discovery+of+novel+dual+mechanism+of+action+Src+signaling+and+tubulin+polymerization+inhibitors+%28KX2-391+and+KX2-361%29&doi=10.1021%2Facs.jmedchem.8b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)</span></div><div class="casAuthors">Smolinski, Michael P.; Bu, Yahao; Clements, James; Gelman, Irwin H.; Hegab, Taher; Cutler, David L.; Fang, Jane W. S.; Fetterly, Gerald; Kwan, Rudolf; Barnett, Allen; Lau, Johnson Y. N.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4704-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal.  Herein we describe the discovery of two such clin. candidates that inhibit the tyrosine kinase Src.  Compd. 1 is a phase 3 clin. trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing std. therapy.  Compd. 2 is a phase 1 clin. trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models.  The discovery strategy for these compds. iteratively utilized mol. modeling, along with the synthesis and testing of increasingly elaborated proof of concept compds., until the final clin. candidates were arrived at.  This was followed with mechanism of action (MOA) studies that revealed tubulin polymn. inhibition as the second MOA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6WD_5NG6-7Vg90H21EOLACvtfcHk0li9nauflrk5PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D&md5=b35b9fb022675d3d4c37e3ac8225ab67</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00164%26sid%3Dliteratum%253Aachs%26aulast%3DSmolinski%26aufirst%3DM.%2BP.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DClements%26aufirst%3DJ.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DHegab%26aufirst%3DT.%26aulast%3DCutler%26aufirst%3DD.%2BL.%26aulast%3DFang%26aufirst%3DJ.%2BW.%26aulast%3DFetterly%26aufirst%3DG.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520mechanism%2520of%2520action%2520Src%2520signaling%2520and%2520tubulin%2520polymerization%2520inhibitors%2520%2528KX2-391%2520and%2520KX2-361%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4704%26epage%3D4719%26doi%3D10.1021%2Facs.jmedchem.8b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2079-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1007%2Fs00280-013-2079-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=23314737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=883-892&author=E.+S.+Antonarakisauthor=E.+I.+Heathauthor=E.+M.+Posadasauthor=Y.+Y.+Evanauthor=M.+R.+Harrisonauthor=J.+Y.+Bruceauthor=S.+Y.+Choauthor=G.+E.+Wildingauthor=G.+J.+Fetterlyauthor=D.+G.+Hangauer&title=A+phase+2+study+of+KX2-391%2C+an+oral+inhibitor+of+Src+kinase+and+tubulin+polymerization%2C+in+men+with+bone-metastatic+castration-resistant+prostate+cancer&doi=10.1007%2Fs00280-013-2079-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Antonarakis, Emmanuel S.; Heath, Elisabeth I.; Posadas, Edwin M.; Yu, Evan Y.; Harrison, Michael R.; Bruce, Justine Y.; Cho, Steve Y.; Wilding, Gregory E.; Fetterly, Gerald J.; Hangauer, David G.; Kwan, Min-Fun R.; Dyster, Lyn M.; Carducci, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymn.  In phase 1 trials, prostate-specific antigen (PSA) declines were seen in patients with advanced prostate cancer.  We conducted a single-arm phase 2 study evaluating KX2-391 in men with chemotherapy-naive bone-metastatic castration-resistant prostate cancer (CRPC).  We treated 31 patients with oral KX2-391 (40 mg twice-daily) until disease progression or unacceptable toxicity.  The primary endpoint was 24-wk progression-free survival (PFS); a 50 % success rate was pre-defined as clin. significant.  Secondary endpoints included PSA progression-free survival (PPFS) and PSA response rates.  Exploratory outcomes included pharmacokinetic studies, circulating tumor cell (CTC) enumeration, and anal. of markers of bone resorption [urinary N-telopeptide (uNTx); C-telopeptide (CTx)] and formation [bone alk. phosphatase (BAP); osteocalcin].  The trial closed early after accrual of 31 patients, due to a pre-specified futility rule.  PFS at 24 wk was 8 %, and median PFS was 18.6 wk.  The PSA response rate (≥30 % decline) was 10 %, and median PPFS was 5.0 wk.  Addnl., 18 % of men with unfavorable (≥5) CTCs at baseline converted to favorable (<5) CTCs with treatment.  The proportion of men with declines in bone turnover markers was 32 % for uNTx, 21 % for CTx, 10 % for BAP, and 25 % for osteocalcin.  In pharmacokinetic studies, median C max was 61 (range 16-129) ng/mL, and median AUC was 156 (35-348) ng h/mL.  Common toxicities included hepatic derangements, myelosuppression, fatigue, nausea, and constipation.  KX2-391 dosed at 40 mg twice-daily lacks antitumor activity in men with CRPC, but has modest effects on bone turnover markers.  Because a C max of ≥142 ng/mL is required for tubulin polymn. inhibition (defined from preclin. studies), higher once-daily dosing will be used in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok7d6u2qkQ_7Vg90H21EOLACvtfcHk0li9nauflrk5PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D&md5=117681a5f5cb6d09865c707673ec3e27</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2079-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2079-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DEvan%26aufirst%3DY.%2BY.%26aulast%3DHarrison%26aufirst%3DM.%2BR.%26aulast%3DBruce%26aufirst%3DJ.%2BY.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DWilding%26aufirst%3DG.%2BE.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DA%2520phase%25202%2520study%2520of%2520KX2-391%252C%2520an%2520oral%2520inhibitor%2520of%2520Src%2520kinase%2520and%2520tubulin%2520polymerization%252C%2520in%2520men%2520with%2520bone-metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26spage%3D883%26epage%3D892%26doi%3D10.1007%2Fs00280-013-2079-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1’s low clinical toxicity</span>. <i>J. Bio. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">18099</span>– <span class="NLM_lpage">18108</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.010732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1074%2Fjbc.RA119.010732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=31628188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=18099-18108&author=L.+Niuauthor=J.+Yangauthor=W.+Yanauthor=Y.+Yuauthor=Y.+Zhengauthor=H.+Yeauthor=Q.+Chenauthor=L.+Chen&title=Reversible+binding+of+the+anticancer+drug+KXO1+%28tirbanibulin%29+to+the+colchicine-binding+site+of+%CE%B2-tubulin+explains+KXO1%E2%80%99s+low+clinical+toxicity&doi=10.1074%2Fjbc.RA119.010732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity</span></div><div class="casAuthors">Niu Lu; Yang Jianhong; Yan Wei; Yu Yamei; Zheng Yunhua; Ye Haoyu; Chen Qiang; Chen Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">18099-18108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KXO1 (tirbanibulin or KX2-391) is as a non-ATP-competitive inhibitor of SRC proto-oncogene nonreceptor tyrosine kinase (SRC) and is being clinically investigated for the management of various cancers and actinic keratosis.  Recently, KXO1 has also been shown to strongly inhibit tubulin.  Interestingly, unlike conventional tubulin-targeting drugs, KXO1 has exhibited low toxicity in preclinical and clinical studies, but the reason for this remains elusive, as are the KXO1-binding site and other details of the interaction of KXO1 with tubulin.  Here, cell-based experiments revealed that KXO1 induces tubulin depolymerization and G2/M phase cell cycle arrest at low nanomolar concentrations, similar to colchicine, used as a positive control.  Results from biochemical experiments, including an N,N-ethylenebis(iodoacetamide) competition assay, disclosed that KXO1 binds to the colchicine-binding site on β-tubulin, further confirmed by the crystal structure of the tubulin-KXO1 complex at 2.5-ÅA resolution.  A high-quality electron density map of the crystallographic data enabled us to unambiguously determine the position and orientation of KXO1 in the colchicine-binding site, revealing the detailed interactions between KXO1 and tubulin.  We also found that KXO1 binds reversibly to purified tubulin, induces a totally reversible cellular effect (G2/M cell cycle arrest), and possesses no cellular toxicity 5 days after drug washout, explaining KXO1's low toxicity.  In summary, we show that KXO1 binds to the colchicine-binding site of tubulin and resolved the crystal structure of the tubulin-KXO1 complex.  Importantly, KXO1's reversible binding to tubulin explains its clinically low toxicity, an insight that could guide further clinical applications of KXO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhfWQ2BlTvKJZoeNcnHOQ9fW6udTcc2eZqP_MY_frlebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D&md5=b3eac35ef261149a46a2531ff014ced1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010732%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DReversible%2520binding%2520of%2520the%2520anticancer%2520drug%2520KXO1%2520%2528tirbanibulin%2529%2520to%2520the%2520colchicine-binding%2520site%2520of%2520%25CE%25B2-tubulin%2520explains%2520KXO1%25E2%2580%2599s%2520low%2520clinical%2520toxicity%26jtitle%3DJ.%2520Bio.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D18099%26epage%3D18108%26doi%3D10.1074%2Fjbc.RA119.010732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span> <span> </span><span class="NLM_article-title">Targeting tubulin-colchicine site for cancer therapy: inhibitors, antibody-drug conjugates and degradation agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1304</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190618130008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568026619666190618130008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=31210108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1289-1304&author=Y.+Duanauthor=W.+Liuauthor=L.+Tianauthor=Y.+Maoauthor=C.+Song&title=Targeting+tubulin-colchicine+site+for+cancer+therapy%3A+inhibitors%2C+antibody-drug+conjugates+and+degradation+agents&doi=10.2174%2F1568026619666190618130008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents</span></div><div class="casAuthors">Duan, Yongtao; Liu, Wei; Tian, Liang; Mao, Yanna; Song, Chuanjun</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1289-1304</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubules are essential for the mitotic division of cells and have been an attractive target for antitumor drugs due to the increased incidence of cancer and significant mitosis rate of tumor cells.  In the past few years, tubulin-colchicine binding site, as one of the three binding pockets including taxol-, vinblastine- and colchicine-binding sites, has been focused on to design tubulin-destabilizing agents including inhibitors, antibody-drug conjugates and degrdn. agents.  The present review is the first to cover a systemic and recent synopsis of tubulin-colchicine binding site agents.  We believe that it would provide an increase in our understanding of receptor-ligand interaction pattern and consciousness of a series of challenges about tubulin target druggability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbFqJ3AOtMzLVg90H21EOLACvtfcHk0liafTIYJ9aT_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLvP&md5=22e8286a4e99012ae44d6024755b1c12</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190618130008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190618130008%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DC.%26atitle%3DTargeting%2520tubulin-colchicine%2520site%2520for%2520cancer%2520therapy%253A%2520inhibitors%252C%2520antibody-drug%2520conjugates%2520and%2520degradation%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1289%26epage%3D1304%26doi%3D10.2174%2F1568026619666190618130008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0ljRWkS6omfwpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer,  Jr, D. G.</span></span> <span> </span><span class="NLM_article-title">Biaryl compositions and methods for modulating a kinase cascade</span>. US Patents: <span class="NLM_patent">7,968,574</span>, Jun 28, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+G.+Hangauer&title=Biaryl+compositions+and+methods+for+modulating+a+kinase+cascade"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DBiaryl%2520compositions%2520and%2520methods%2520for%2520modulating%2520a%2520kinase%2520cascade%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+Automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lhxKM4XxRVISg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520Automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+G.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0lhxKM4XxRVISg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, A.</span></span> <span> </span><span class="NLM_article-title">Microtubule destabilising agents: far more than just antimitotic anticancer drugs</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1111/bcp.13126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1111%2Fbcp.13126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=27620987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=255-268&author=D.+Batesauthor=A.+Eastman&title=Microtubule+destabilising+agents%3A+far+more+than+just+antimitotic+anticancer+drugs&doi=10.1111%2Fbcp.13126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule destabilizing agents: far more than just antimitotic anticancer drugs</span></div><div class="casAuthors">Bates, Darcy; Eastman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-268</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Vinca alkaloids have been approved as anticancer drugs for more than 50 years.  They have been classified as cytotoxic chemotherapy drugs that act during cellular mitosis, enabling them to target fast growing cancer cells.  With the evolution of cancer drug development there has been a shift towards new "targeted" therapies to avoid the side effects and general toxicities of "cytotoxic chemotherapies" such as the vinca alkaloids.  Due to their original classification, many have overlooked the fact that vinca alkaloids, taxanes and related drugs do have a specific mol. target: tubulin.  They continue to be some of the most effective anticancer drugs, perhaps because their actions upon the microtubule network extend far beyond the ability to halt cells in mitosis, and include the induction of apoptosis at all phases of the cell cycle.  In this review, we highlight the numerous cellular consequences of disrupting microtubule dynamics, expanding the textbook knowledge of microtubule destabilizing agents and providing novel opportunities for their use in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4cJkJIQJPLVg90H21EOLACvtfcHk0lhxKM4XxRVISg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFajs74%253D&md5=e859fcd74dd984b711065f278abb5479</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13126%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DD.%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DMicrotubule%2520destabilising%2520agents%253A%2520far%2520more%2520than%2520just%2520antimitotic%2520anticancer%2520drugs%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D255%26epage%3D268%26doi%3D10.1111%2Fbcp.13126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, K. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setaluri, V.</span></span> <span> </span><span class="NLM_article-title">Microtubule-associated proteins as targets in cancer chemotherapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2854</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-3040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F1078-0432.CCR-06-3040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=17504982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Krsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2849-2854&author=K.+M.+R.+Bhatauthor=V.+Setaluri&title=Microtubule-associated+proteins+as+targets+in+cancer+chemotherapy&doi=10.1158%2F1078-0432.CCR-06-3040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-Associated Proteins as Targets in Cancer Chemotherapy</span></div><div class="casAuthors">Bhat, Kumar M. R.; Setaluri, Vijayasaradhi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2849-2854</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural and synthetic compds. that disrupt microtubule dynamics are among the most successful and widely used cancer chemotherapeutic agents.  However, lack of reliable markers that predict sensitivity of cancers to these agents and development of resistance remain vexing issues.  There is accumulating evidence that a family of cellular proteins that are assocd. with and alter the dynamics of microtubules can det. sensitivity of cancer cells to microtubule-targeting agents and play a role in tumor cell resistance to these agents.  This growing family of microtubule-assocd. proteins (MAP) includes products of oncogenes, tumor suppressors, and apoptosis regulators, suggesting that alteration of microtubule dynamics may be one of the crit. events in tumorigenesis and tumor progression.  The objective of this review is to integrate the knowledge on these seemingly unrelated proteins that share a common function and examine their relevance to microtubule-targeting therapies and highlight MAPs-tubulin-drug interactions as a novel avenue for new drug discovery.  Based on the available evidence, we propose that rational microtubule-targeting cancer therapeutic approaches should ideally include proteomic profiling of tumor MAPs before administration of microtubule-stabilizing/destabilizing agents preferentially in combination with agents that modulate the expression of relevant MAPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCwiEFkyEsrVg90H21EOLACvtfcHk0lieVxn5s-fEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Krsrw%253D&md5=719cc6f219556505b5562b1201171911</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3040%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DK.%2BM.%2BR.%26aulast%3DSetaluri%26aufirst%3DV.%26atitle%3DMicrotubule-associated%2520proteins%2520as%2520targets%2520in%2520cancer%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2849%26epage%3D2854%26doi%3D10.1158%2F1078-0432.CCR-06-3040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannakakou, P.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules for cancer chemotherapy</span>. <i>Curr. Med. Chem.-Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.2174/1568011053352569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568011053352569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15720262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-71&author=J.+Zhouauthor=P.+Giannakakou&title=Targeting+microtubules+for+cancer+chemotherapy&doi=10.2174%2F1568011053352569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting microtubules for cancer chemotherapy</span></div><div class="casAuthors">Zhou, Jun; Giannakakou, Paraskevi</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer.  As knowledge of microtubule-targeting drugs increases, the mechanism underlying the anticancer activity of these agents may mainly lie in their inhibitory effects on spindle microtubule dynamics, rather than in their effects on microtubule polymer mass.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell cycle progression at mitosis and eventually leading to apoptotic cell death.  The effectiveness of microtubule-targeting drugs for cancer therapy has been impaired by various side effects, notably neurol. and hematol. toxicities.  Drug resistance is another notorious factor that thwarts the effectiveness of these agents, as with many other cancer chemotherapeutics.  Several new microtubule-targeting agents have shown potent activity against the proliferation of various cancer cells, including cells that display resistance to the existing microtubule-targeting drugs.  Continued investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI0IucAUr4V7Vg90H21EOLACvtfcHk0lieVxn5s-fEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D&md5=e5d34ca2c4d4adf0e6975989da8aaee8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568011053352569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011053352569%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGiannakakou%26aufirst%3DP.%26atitle%3DTargeting%2520microtubules%2520for%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.-Anti-Cancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D71%26doi%3D10.2174%2F1568011053352569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vornov, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlefield, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesJardins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyderman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span> <span> </span><span class="NLM_article-title">Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: correlations with time course and neurotoxic severity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3332</span>– <span class="NLM_lpage">3339</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F0008-5472.CAN-15-2525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=27197173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3332-3339&author=K.+M.+Wozniakauthor=J.+J.+Vornovauthor=Y.+Wuauthor=K.+Nomotoauthor=B.+A.+Littlefieldauthor=C.+DesJardinsauthor=Y.+Yuauthor=G.+Laiauthor=L.+Reydermanauthor=N.+Wongauthor=B.+S.+Slusher&title=Sustained+accumulation+of+microtubule-binding+chemotherapy+drugs+in+the+peripheral+nervous+system%3A+correlations+with+time+course+and+neurotoxic+severity&doi=10.1158%2F0008-5472.CAN-15-2525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity</span></div><div class="casAuthors">Wozniak, Krystyna M.; Vornov, James J.; Wu, Ying; Nomoto, Kenichi; Littlefield, Bruce A.; Des Jardins, Christopher; Yu, Yanke; Lai, George; Reyderman, Larisa; Wong, Nancy; Slusher, Barbara S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3332-3339</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chemotherapy-induced peripheral neuropathy is a dose-limiting side effect of many antineoplastic agents, but the mechanisms underlying the toxicities are unclear.  At their MTDs, the microtubule-binding drugs paclitaxel and ixabepilone induce more severe neuropathy in mice relative to eribulin mesylate, paralleling their toxicity profiles in clinic.  We hypothesized that the severity of their neurotoxic effects might be explained by the levels at which they accumulate in the peripheral nervous system.  To test this hypothesis, we compared their pharmacokinetics and distribution in peripheral nerve tissue.  After administration of a single i.v. dose, each drug was rapidly cleared from plasma but all persisted in the dorsal root ganglia (DRG) and sciatic nerve (SN) for up to 72 h.  Focusing on paclitaxel and eribulin, we performed a 2-wk MTD-dosing regimen, followed by a detn. of drug pharmacokinetics, tissue distribution, and multiple functional measures of peripheral nerve toxicity for 4 wk.  Consistent with the acute dosing study, both drugs persisted in peripheral nervous tissues for weeks, in contrast to their rapid clearance from plasma.  Notably, although eribulin exhibited greater DRG and SN penetration than paclitaxel, the neurotoxicity obsd. functionally was consistently more severe with paclitaxel.  Overall, our results argue that sustained exposure of microtubule-binding chemotherapeutic agents in peripheral nerve tissues cannot by itself account for their assocd. neurotoxicity.  Cancer Res; 76(11); 3332-9. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq980Gmeq_gibVg90H21EOLACvtfcHk0lieVxn5s-fEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLg%253D&md5=137bb427a63ea717cdcba8afb3e08d0f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2525%26sid%3Dliteratum%253Aachs%26aulast%3DWozniak%26aufirst%3DK.%2BM.%26aulast%3DVornov%26aufirst%3DJ.%2BJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DNomoto%26aufirst%3DK.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26aulast%3DDesJardins%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DG.%26aulast%3DReyderman%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26atitle%3DSustained%2520accumulation%2520of%2520microtubule-binding%2520chemotherapy%2520drugs%2520in%2520the%2520peripheral%2520nervous%2520system%253A%2520correlations%2520with%2520time%2520course%2520and%2520neurotoxic%2520severity%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3332%26epage%3D3339%26doi%3D10.1158%2F0008-5472.CAN-15-2525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Towle, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvato, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wels, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aalfs, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seletsky, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melvin, J. Y.</span></span> <span> </span><span class="NLM_article-title">Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F0008-5472.CAN-10-1874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=21127197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=496-505&author=M.+J.+Towleauthor=K.+A.+Salvatoauthor=B.+F.+Welsauthor=K.+K.+Aalfsauthor=W.+Zhengauthor=B.+M.+Seletskyauthor=X.+Zhuauthor=B.+M.+Lewisauthor=Y.+Kishiauthor=J.+Y.+Melvin&title=Eribulin+induces+irreversible+mitotic+blockade%3A+implications+of+cell-based+pharmacodynamics+for+in+vivo+efficacy+under+intermittent+dosing+conditions&doi=10.1158%2F0008-5472.CAN-10-1874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions</span></div><div class="casAuthors">Towle, Murray J.; Salvato, Kathleen A.; Wels, Bruce F.; Aalfs, Kimberley K.; Zheng, Wanjun; Seletsky, Boris M.; Zhu, Xiaojie; Lewis, Bryan M.; Kishi, Yoshito; Yu, Melvin J.; Littlefield, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">496-505</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Eribulin (E7389), a mechanistically unique microtubule inhibitor in phase III clin. trials for cancer, exhibits superior efficacy in vivo relative to the more potent compd. ER-076349, a fact not explained by different pharmacokinetic properties.  A cell-based pharmacodynamic explanation was suggested by observations that mitotic blockade induced by eribulin, but not ER-076349, is irreversible as measured by a flow cytometric mitotic block reversibility assay employing full dose/response treatment.  Cell viability 5 days after drug washout established relationships between mitotic block reversibility and long-term cell survival.  Similar results occurred in U937, Jurkat, HL-60, and HeLa cells, ruling out cell type-specific effects.  Studies with other tubulin agents suggest that mitotic block reversibility is a quantifiable, compd.-specific characteristic of antimitotic agents in general.  Bcl-2 phosphorylation patterns parallel eribulin and ER-076349 mitotic block reversibility patterns, suggesting persistent Bcl-2 phosphorylation contributes to long-term cell-viability loss after eribulin's irreversible blockade.  Drug uptake and washout/retention studies show that [3H]eribulin accumulates to lower intracellular levels than [3H]ER-076349, yet is retained longer and at higher levels.  Similar findings occurred with irreversible vincristine and reversible vinblastine, pointing to persistent cellular retention as a component of irreversibility.  Our results suggest that eribulin's in vivo superiority derives from its ability to induce irreversible mitotic blockade, which appears related to persistent drug retention and sustained Bcl-2 phosphorylation.  More broadly, our results suggest that compd.-specific reversibility characteristics of antimitotic agents contribute to interactions between cell-based pharmacodynamics and in vivo pharmacokinetics that define antitumor efficacy under intermittent dosing conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi9gbxI_sn-7Vg90H21EOLACvtfcHk0lgnILMMJI2vwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFKlsA%253D%253D&md5=f0a39e79ab77340170d7a10edb3077c9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1874%26sid%3Dliteratum%253Aachs%26aulast%3DTowle%26aufirst%3DM.%2BJ.%26aulast%3DSalvato%26aufirst%3DK.%2BA.%26aulast%3DWels%26aufirst%3DB.%2BF.%26aulast%3DAalfs%26aufirst%3DK.%2BK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSeletsky%26aufirst%3DB.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLewis%26aufirst%3DB.%2BM.%26aulast%3DKishi%26aufirst%3DY.%26aulast%3DMelvin%26aufirst%3DJ.%2BY.%26atitle%3DEribulin%2520induces%2520irreversible%2520mitotic%2520blockade%253A%2520implications%2520of%2520cell-based%2520pharmacodynamics%2520for%2520in%2520vivo%2520efficacy%2520under%2520intermittent%2520dosing%2520conditions%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D496%26epage%3D505%26doi%3D10.1158%2F0008-5472.CAN-10-1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorléans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span>. <i>P. Natl. A. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">13775</span>– <span class="NLM_lpage">13779</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorl%C3%A9ansauthor=B.+Gigantauthor=R.+B.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0lgnILMMJI2vwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorl%25C3%25A9ans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DP.%2520Natl.%2520A.%2520Sci.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez, R.</span></span> <span> </span><span class="NLM_article-title">New ligands of the tubulin colchicine site based on X-ray structures</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.2174/1568026614666141130092637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.2174%2F1568026614666141130092637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=25434358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=2231-2252&author=R.+Alvarezauthor=M.+Medardeauthor=R.+Pelaez&title=New+ligands+of+the+tubulin+colchicine+site+based+on+X-ray+structures&doi=10.2174%2F1568026614666141130092637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">New Ligands of the Tubulin Colchicine Site Based on X-Ray Structures</span></div><div class="casAuthors">Alvarez, Raquel; Medarde, Manuel; Pelaez, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2231-2252</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Colchicine site ligands have proved to be potent inhibitors of tubulin polymn., which leads them not only to display cytotoxic effects but also vascular disrupting effects on tumor neovasculature.  In recent years, many compds. have been designed, synthesized and evaluated in order to improve the potency, stability and physicochem. properties of these agents with the aim of developing an agent that could reach the clin. assay level.  Here we analyze the eleven X-ray structures of tubulin in complex with ligands at the colchicine site by dividing it into four different zones of interaction, we review the new compds. that have appeared in the literature since 2008 and that were designed based on any of these X-ray structures and, finally, we describe our latest results in the design of new potent antimitotic indole derivs. that have confirmed the flexibility of one of the zones described for the colchicine site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6HvmgggtxbVg90H21EOLACvtfcHk0lgnILMMJI2vwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D&md5=a7a289b0e6b986e59c8e0f875d4ae51e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F1568026614666141130092637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666141130092637%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPelaez%26aufirst%3DR.%26atitle%3DNew%2520ligands%2520of%2520the%2520tubulin%2520colchicine%2520site%2520based%2520on%2520X-ray%2520structures%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D2231%26epage%3D2252%26doi%3D10.2174%2F1568026614666141130092637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Rapid discovery and structure–activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4697</span>– <span class="NLM_lpage">4710</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00065</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00065" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4697-4710&author=C.+Fraserauthor=J.+C.+Dawsonauthor=R.+Dowlingauthor=D.+R.+Houstonauthor=J.+T.+Weissauthor=A.+F.+Munroauthor=M.+Muirauthor=L.+Harringtonauthor=S.+P.+Websterauthor=M.+C.+Frameauthor=V.+G.+Bruntonauthor=E.+E.+Pattonauthor=N.+O.+Carragherauthor=A.+Unciti-Broceta&title=Rapid+discovery+and+structure%E2%80%93activity+relationships+of+pyrazolopyrimidines+that+potently+suppress+breast+cancer+cell+growth+via+SRC+kinase+inhibition+with+exceptional+selectivity+over+ABL+kinase&doi=10.1021%2Facs.jmedchem.6b00065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase</span></div><div class="casAuthors">Fraser, Craig; Dawson, John C.; Dowling, Reece; Houston, Douglas R.; Weiss, Jason T.; Munro, Alison F.; Muir, Morwenna; Harrington, Lea; Webster, Scott P.; Frame, Margaret C.; Brunton, Valerie G.; Patton, E. Elizabeth; Carragher, Neil O.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4697-4710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyrazolopyrimidines displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner.  Compds. were derived from the promiscuous kinase inhibitor PP1 to search for analogs that could potentially target a broad spectrum of kinases involved in cancer.  Phenotypic screening against MCF7 mammary adenocarcinoma cells generated target-agnostic structure-activity relationships that biased subsequent designs toward breast cancer treatment rather than to a particular target.  This strategy led to the discovery of two potent antiproliferative leads with phenotypically distinct anticancer mode of actions.  Kinase profiling and further optimization resulted in eCF506, the first small mol. with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concn. to inhibit ABL. eCF506 exhibits excellent water soly., an optimal DMPK profile and oral bioavailability, halts SRC-assocd. neuromast migration in zebrafish embryos without inducing life-threatening heart defects, and inhibits SRC phosphorylation in tumor xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq55yS4FWveyLVg90H21EOLACvtfcHk0lisiBoM8aQ35A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D&md5=e56206009ccca680432d12db23aa29fd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00065%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%2BC.%26aulast%3DDowling%26aufirst%3DR.%26aulast%3DHouston%26aufirst%3DD.%2BR.%26aulast%3DWeiss%26aufirst%3DJ.%2BT.%26aulast%3DMunro%26aufirst%3DA.%2BF.%26aulast%3DMuir%26aufirst%3DM.%26aulast%3DHarrington%26aufirst%3DL.%26aulast%3DWebster%26aufirst%3DS.%2BP.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DPatton%26aufirst%3DE.%2BE.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DRapid%2520discovery%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520pyrazolopyrimidines%2520that%2520potently%2520suppress%2520breast%2520cancer%2520cell%2520growth%2520via%2520SRC%2520kinase%2520inhibition%2520with%2520exceptional%2520selectivity%2520over%2520ABL%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4697%26epage%3D4710%26doi%3D10.1021%2Facs.jmedchem.6b00065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Src in cancer: deregulation and consequences for cell behaviour</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1602</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/S0304-419X(02)00040-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2FS0304-419X%2802%2900040-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=12020799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=114-130&author=M.+C.+Frame&title=Src+in+cancer%3A+deregulation+and+consequences+for+cell+behaviour&doi=10.1016%2FS0304-419X%2802%2900040-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Src in cancer: deregulation and consequences for cell behavior</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-130</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Considerable evidence now implicates elevated expression and/or activity of Src in cancer development.  In cells, endogenous Src is switched from an inactive to an active state by a variety of mechanisms that simultaneously relieve constraints on the kinase and protein-interacting Src homol. (SH) domains.  As a result, Src is translocated to the cell periphery, often to sites of cell adhesion, where myristylation mediates attachment to the inner surface of the plasma membrane.  From these peripheral sites, Src's catalytic activity initiates intracellular signal transduction pathways that influence cell growth and adhesion strength, the latter contributing to control of cell migration.  De-regulation in cancer cells may therefore enhance tumor growth and/or stimulate migratory or invasive potential in cells that would normally be relatively non-motile.  Evidence now exists to suggest that Src may also influence the life or death decisions that cells make during many biol. processes.  Thus, Src modulation in cancer cells can alter cell responses that are often perturbed in cancer.  Consequently, there is optimism that drugs which inhibit Src's kinase activity, or the activity of its downstream effectors, might have profound effects on cancer cell behavior and be useful therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PUbbCfYCTrVg90H21EOLACvtfcHk0lisiBoM8aQ35A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D&md5=ac3f4d59c7979798349ea7f0db807d67</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900040-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900040-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DSrc%2520in%2520cancer%253A%2520deregulation%2520and%2520consequences%2520for%2520cell%2520behaviour%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2002%26volume%3D1602%26spage%3D114%26epage%3D130%26doi%3D10.1016%2FS0304-419X%2802%2900040-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhoff, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fincham, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1450</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(03)00544-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2FS0960-9822%2803%2900544-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=12932330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmslentbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=1442-1450&author=N.+O.+Carragherauthor=M.+A.+Westhoffauthor=V.+J.+Finchamauthor=M.+D.+Schallerauthor=M.+C.+Frame&title=A+novel+role+for+FAK+as+a+protease-targeting+adaptor+protein%3A+regulation+by+p42+ERK+and+Src&doi=10.1016%2FS0960-9822%2803%2900544-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Role for FAK as a Protease-Targeting Adaptor Protein Regulation by p42 ERK and Src</span></div><div class="casAuthors">Carragher, Neil O.; Westhoff, M. Andrew; Fincham, Valerie J.; Schaller, Michael D.; Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1442-1450</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cell migration on extracellular matrix requires the turnover of integrin-dependent adhesions.  The nonreceptor tyrosine kinases Src and FAK regulate focal-adhesion turnover by poorly understood mechanisms .  ERK/MAP kinase-mediated activation of the protease Calpain 2 also promotes focal-adhesion turnover ; however, it is not known if this is linked to the activities of Src and FAK.  Calpain 2 has previously been demonstrated to colocalize with focal-adhesion structures and can cleave several focal-adhesion complex components, including FAK .  Studies utilizing Calpain inhibitors or Calpain-deficient cells confirm that Calpain's role in regulating focal-adhesion turnover is necessary for cell migration .  We have identified a novel and kinase-independent function for FAK as an adaptor mol. that mediates the assembly of a complex consisting of at least Calpain 2 and p42ERK.  Mutation of proline residues (Pro2) in the amino-terminal region of FAK blocks direct binding with Calpain 2 and also prevents formation of the Calpain 2/p42ERK complex in cells.  We show that both complex formation and MEK/ERK activity are assocd. with Calpain-mediated proteolysis of FAK and focal adhesion turnover during transformation and migration.  Furthermore, FAK is necessary for recruiting both Calpain 2 and p42ERK/MAPK to peripheral adhesion sites facilitating maximal Calpain activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUPV_BzP9MD7Vg90H21EOLACvtfcHk0lisiBoM8aQ35A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmslentbY%253D&md5=4cc984f708f04e773c9164177e409d9a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2803%2900544-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252803%252900544-X%26sid%3Dliteratum%253Aachs%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DWesthoff%26aufirst%3DM.%2BA.%26aulast%3DFincham%26aufirst%3DV.%2BJ.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DA%2520novel%2520role%2520for%2520FAK%2520as%2520a%2520protease-targeting%2520adaptor%2520protein%253A%2520regulation%2520by%2520p42%2520ERK%2520and%2520Src%26jtitle%3DCurr.%2520Biol.%26date%3D2003%26volume%3D13%26spage%3D1442%26epage%3D1450%26doi%3D10.1016%2FS0960-9822%2803%2900544-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizawar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, S. J.</span></span> <span> </span><span class="NLM_article-title">c-Src and cooperating partners in human cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2Fj.ccr.2004.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=15380511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Kis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=209-214&author=R.+Ishizawarauthor=S.+J.+Parsons&title=c-Src+and+cooperating+partners+in+human+cancer&doi=10.1016%2Fj.ccr.2004.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src and cooperating partners in human cancer</span></div><div class="casAuthors">Ishizawar, Rumey; Parsons, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-214</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The proto-oncogene c-src is rarely mutated in human cancers, and when overexpressed in normal cells is non- or weakly oncogenic.  These observations have raised doubts about the involvement of c-src in the etiol. of human tumors.  However, recent studies have shown that c-Src, a non-receptor tyrosine kinase, exhibits elevated protein levels and activity in numerous types of human cancers.  Furthermore, it has been found to be a crit. component of multiple signaling pathways that regulate proliferation, survival, metastasis, and angiogenesis.  Because of its important role in these oncogenic processes, it represents a therapeutic target ripe for exploitation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhanyde_CerVg90H21EOLACvtfcHk0lj6hz7bLMn8Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Kis7w%253D&md5=7a9b3574284956171da59b093ab7c9d9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DIshizawar%26aufirst%3DR.%26aulast%3DParsons%26aufirst%3DS.%2BJ.%26atitle%3Dc-Src%2520and%2520cooperating%2520partners%2520in%2520human%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D209%26epage%3D214%26doi%3D10.1016%2Fj.ccr.2004.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2Fj.phrs.2015.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=25662515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=9-25&author=R.+Roskoski&title=Src+protein-tyrosine+kinase+structure%2C+mechanism%2C+and+small+molecule+inhibitors&doi=10.1016%2Fj.phrs.2015.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-25</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The physiol. Src proto-oncogene is a protein tyrosine kinase that plays key roles in cell growth, division, migration, and survival signaling pathways.  From the N- to C-terminus, Src contains a unique domain, an SH3 domain, an SH2 domain, a protein tyrosine kinase domain, and a regulatory tail.  The chief phosphorylation sites of human Src include an activating pTyr419 that results from phosphorylation in the kinase domain by an adjacent Src mol. and an inhibitory pTyr530 in the regulatory tail that results from phosphorylation by C-terminal Src kinase (Csk) or Chk (Csk homologous kinase).  The oncogenic Rous sarcoma viral protein lacks the equiv. of Tyr530 and is constitutively activated.  Inactive Src is stabilized by SH2 and SH3 domains on the rear of the kinase domain where they form an immobilizing and inhibitory clamp.  Protein kinases including Src contain hydrophobic regulatory and catalytic spines and collateral shell residues that are required to assemble the active enzyme.  In the inactive enzyme, the regulatory spine contains a kink or a discontinuity with a structure that is incompatible with catalysis.  The conversion of inactive to active Src is accompanied by electrostatic exchanges involving the breaking and making of distinct sets of kinase domain salt bridges and hydrogen bonds.  Src-catalyzed protein phosphorylation requires the participation of two Mg2+ ions.  Although nearly all protein kinases possess a common K/E/D/D signature, each enzyme exhibits its unique variations of the protein-kinase reaction template.  Bosutinib, dasatinib, and ponatinib are Src/multikinase inhibitors that are approved by the FDA for the treatment of chronic myelogenous leukemia and vandetanib is approved for the treatment of medullary thyroid cancer.  The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clin. trials for a variety of solid tumors including breast and lung cancers.  Both ATP and targeted therapeutic Src protein kinase inhibitors such as dasatinib and ponatinib make hydrophobic contacts with catalytic spine residues and form hydrogen bonds with hinge residues connecting the small and large kinase lobes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWw-wmm7q2cbVg90H21EOLACvtfcHk0lj6hz7bLMn8Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D&md5=a40c394ab772b445fe0944c58e1f3deb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DSrc%2520protein-tyrosine%2520kinase%2520structure%252C%2520mechanism%252C%2520and%2520small%2520molecule%2520inhibitors%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D94%26spage%3D9%26epage%3D25%26doi%3D10.1016%2Fj.phrs.2015.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F1535-7163.MCT-12-0109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=23144237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntValtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=16-26&author=H.+J.+Namauthor=S.+A.+Imauthor=D.+Y.+Ohauthor=P.+Elvinauthor=H.+P.+Kimauthor=Y.+K.+Yoonauthor=Y.+J.+Bang&title=Antitumor+activity+of+saracatinib+%28AZD0530%29%2C+a+c-Src%2FAbl+kinase+inhibitor%2C+alone+or+in+combination+with+chemotherapeutic+agents+in+gastric+cancer&doi=10.1158%2F1535-7163.MCT-12-0109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer</span></div><div class="casAuthors">Nam, Hyun-Jin; Im, Seock-Ah; Oh, Do-Youn; Elvin, Paul; Kim, Hwang-Phill; Yoon, Young-Kwang; Min, Ahrum; Song, Sang-Hyun; Han, Sae-Won; Kim, Tae-You; Bang, Yung-Jue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-26</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, and tumorigenesis.  Increased Src activity has been reported in many types of human cancer, including gastric cancer.  Therefore, this factor has been identified as a promising therapeutic target for cancer treatments, and targeting Src in gastric cancer is predicted to have potent effects.  We evaluated the antitumor effect of a c-Src/Abl kinase inhibitor, saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model.  Among 10 gastric cancer cell lines, saracatinib specifically inhibited the growth and migration/invasion of SNU216 and NCI-N87 cells.  Saracatinib blocked the Src/FAK, HER family, and oncogenic signaling pathways, and it induced G1 arrest and apoptosis in SNU216 and NCI-N87 cells.  Apoptosis required induction of the proapoptotic BCL2 family member Bim.  Knockdown of Bim using siRNA decreased apoptosis induced by treatment with saracatinib, suggesting that Bim has an important role in saracatinib-induced apoptosis.  Saracatinib enhanced the effects of lapatinib, an EGFR/HER2 dual inhibitor, in SNU216 and NCI-N87 cells.  Furthermore, combined treatment with saracatinib and 5-fluorouracil (5-FU) or cisplatin exerted synergistic effects in both saracatinib-sensitive and saracatinib-resistant cells.  Consistent with our in vitro findings, cotreatment with saracatinib and 5-FU resulted in enhanced antitumor activity in the NCI-N87 xenografts.  These data indicate that the inhibition of Src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.  Mol Cancer Ther; 12(1); 16-26. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpFSWq6HNftrVg90H21EOLACvtfcHk0lj6hz7bLMn8Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntValtw%253D%253D&md5=de92a9e602764f294ae9d231758ab283</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0109%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DH.%2BJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DElvin%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.%2BP.%26aulast%3DYoon%26aufirst%3DY.%2BK.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DAntitumor%2520activity%2520of%2520saracatinib%2520%2528AZD0530%2529%252C%2520a%2520c-Src%252FAbl%2520kinase%2520inhibitor%252C%2520alone%2520or%2520in%2520combination%2520with%2520chemotherapeutic%2520agents%2520in%2520gastric%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D16%26epage%3D26%26doi%3D10.1158%2F1535-7163.MCT-12-0109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Secord, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadwater, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havrilesky, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berchuck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenham, R. M.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5489</span>– <span class="NLM_lpage">5498</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1158%2F1078-0432.CCR-12-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=22837181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5489-5498&author=A.+A.+Secordauthor=D.+K.+Teohauthor=W.+T.+Barryauthor=M.+Yuauthor=G.+Broadwaterauthor=L.+J.+Havrileskyauthor=P.+S.+Leeauthor=A.+Berchuckauthor=J.+Lancasterauthor=R.+M.+Wenham&title=A+phase+I+trial+of+dasatinib%2C+an+SRC-family+kinase+inhibitor%2C+in+combination+with+paclitaxel+and+carboplatin+in+patients+with+advanced+or+recurrent+ovarian+cancer&doi=10.1158%2F1078-0432.CCR-12-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer</span></div><div class="casAuthors">Secord, Angeles Alvarez; Teoh, Deanna K.; Barry, William T.; Yu, Miao; Broadwater, Gloria; Havrilesky, Laura J.; Lee, Paula S.; Berchuck, Andrew; Lancaster, Johnathan; Wenham, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5489-5498</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in the treatment of advanced and recurrent epithelial ovarian cancer.  Exptl. Design: The primary objective was to det. the max. tolerated dose (MTD).  Secondary objectives included defining toxicity, response rate (RR), pharmacokinetics, and pharmacodynamics.  Using a "3+3" design, cohorts of three to six patients received paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 3 wk with escalating doses of dasatinib (100, 120, and 150 mg daily), followed by an eight-patient expansion cohort.  Results: Twenty patients were enrolled between June 2007 and Dec. 2009.  The median age was 61 years (range: 42-82) with a median of 2 prior regimens (range: 0-6), and 71% had platinum-sensitive disease.  There were three to six patients in each cohort, and eight in the expansion cohort.  Pharmacokinetics were obsd. over the first two cycles of therapy.  One DLT was obsd. in the 100 mg dasatinib cohort (grade 3 myalgia).  Other toxicities in all cycles included neutropenia (95% grade 3-4; 91% in the 150 mg dosing cohort), thrombocytopenia (35% grade 3-4), and fatigue (10% grade 3).  The RR was 40% [three complete responses, (15%); five partial responses, (25%)],10 patients (50%) had stable disease, and two were not evaluable.  The PFS6-month actuarial est. was 86%.  The median PFS and OS were 7.8 and 16.2 mo, resp.  Conclusions: Due to the high incidence of myelosuppression with subsequent cycles, the recommended phase II dose of dasatinib is 150 mg daily in combination with paclitaxel and carboplatin.  The combination was safe with evidence of clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWuV56MlqRILVg90H21EOLACvtfcHk0lg10HpDtm3icw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgurrM&md5=91ec89609ac00a56872ecfcb8a41be12</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0507%26sid%3Dliteratum%253Aachs%26aulast%3DSecord%26aufirst%3DA.%2BA.%26aulast%3DTeoh%26aufirst%3DD.%2BK.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DHavrilesky%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DBerchuck%26aufirst%3DA.%26aulast%3DLancaster%26aufirst%3DJ.%26aulast%3DWenham%26aufirst%3DR.%2BM.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520dasatinib%252C%2520an%2520SRC-family%2520kinase%2520inhibitor%252C%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520in%2520patients%2520with%2520advanced%2520or%2520recurrent%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5489%26epage%3D5498%26doi%3D10.1158%2F1078-0432.CCR-12-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southwood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1007/s10637-010-9611-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1007%2Fs10637-010-9611-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=21170669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=779-786&author=D.+J.+Renoufauthor=M.+J.+Mooreauthor=D.+Hedleyauthor=S.+Gillauthor=D.+Jonkerauthor=E.+Chenauthor=D.+Waldeauthor=R.+Goelauthor=B.+Southwoodauthor=I.+Gauthierauthor=W.+Walshauthor=L.+McIntoshauthor=L.+Seymour&title=A+phase+I%2FII+study+of+the+Src+inhibitor+saracatinib+%28AZD0530%29+in+combination+with+gemcitabine+in+advanced+pancreatic+cancer&doi=10.1007%2Fs10637-010-9611-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer</span></div><div class="casAuthors">Renouf, Daniel J.; Moore, Malcolm J.; Hedley, David; Gill, Sharlene; Jonker, Derek; Chen, Eric; Walde, David; Goel, Rakesh; Southwood, Bernadette; Gauthier, Isabelle; Walsh, Wendy; McIntosh, Lynn; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This phase I/II study of saracatinib in combination with gemcitabine in patients with advanced pancreatic cancer was conducted by the NCIC Clin. Trials Group.  The aims were to define the recommended phase II dose (RP2D) of saracatinib when combined with gemcitabine, and assess the efficacy of this combination in advanced pancreatic cancer.  Eligibility criteria included locally advanced or metastatic pancreatic adenocarcinoma and no prior chemotherapy.  In phase I saracatinib was escalated in combination with gemcitabine (1000 mg/m2) to det. the recommended phase II dose (RP2D).  The study was then expanded to a single arm phase II trial using a Simon 2-stage design.  The primary endpoint was objective tumor response (OR) plus stable disease ≥4 mo (SD4) rate; if ≥8 patients had OR+SD4, the study would proceed to stage 2.  Thirteen patients were enrolled into the phase I portion of this study.  Saracatinib 175 mg PO daily was chosen as the RP2D in combination with gemcitabine.  Twenty-one addnl. patients were then enrolled at the RP2D (phase II).  Of the 22 response evaluable patients treated at the RP2D, 9 patients (40.9%) had progressive disease, 6 patients (27.3%) had stable disease for less than 4 mo, 5 patients (22.7%) had SD4, and 2 patients (9.1%) had a partial response to treatment.  Objective criteria for continuing to stage 2 were thus not met and the trial was closed following the accrual of 34 patients.  Saracatinib 175 mg daily in combination with gemcitabine is well tolerated but the combination did not improve efficacy over what would be expected from gemcitabine alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RONoTvlAtrVg90H21EOLACvtfcHk0lg10HpDtm3icw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGmtLc%253D&md5=41aa8f7265dfb802472af5736b614173</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9611-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9611-3%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DJonker%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DWalde%26aufirst%3DD.%26aulast%3DGoel%26aufirst%3DR.%26aulast%3DSouthwood%26aufirst%3DB.%26aulast%3DGauthier%26aufirst%3DI.%26aulast%3DWalsh%26aufirst%3DW.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520the%2520Src%2520inhibitor%2520saracatinib%2520%2528AZD0530%2529%2520in%2520combination%2520with%2520gemcitabine%2520in%2520advanced%2520pancreatic%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D779%26epage%3D786%26doi%3D10.1007%2Fs10637-010-9611-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: the rise of multitarget drugs over combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.4155%2Ffmc.14.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=24649950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=485-487&author=M.+Rosini&title=Polypharmacology%3A+the+rise+of+multitarget+drugs+over+combination+therapies&doi=10.4155%2Ffmc.14.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: the rise of multitarget drugs over combination therapies</span></div><div class="casAuthors">Rosini, Michela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-487</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNBzYCAfAa7Vg90H21EOLACvtfcHk0lg10HpDtm3icw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D&md5=0c32e1a1ae5a13cd25483ba18833fd54</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.25%26sid%3Dliteratum%253Aachs%26aulast%3DRosini%26aufirst%3DM.%26atitle%3DPolypharmacology%253A%2520the%2520rise%2520of%2520multitarget%2520drugs%2520over%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D485%26epage%3D487%26doi%3D10.4155%2Ffmc.14.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindyalov, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">The protein data bank</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1093/nar/28.1.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+protein+data+bank&doi=10.1093%2Fnar%2F28.1.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0lim84U-Qk3CjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520protein%2520data%2520bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242%26doi%3D10.1093%2Fnar%2F28.1.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span> <span> </span><span class="NLM_article-title">Python: a programming language for software integration and development</span>. <i>J. Mol. Graphics Modell.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10660911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=57-61&author=M.+F.+Sanner&title=Python%3A+a+programming+language+for+software+integration+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Python: a programming language for software integration and development</span></div><div class="casAuthors">Sanner, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-61</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The use of interpreted languages in biocomputing has been investigated to create a programmable, dynamic environment in which components can be tied together at a high level.  This work has demonstrated the benefits of such an approach and the features of the interpreted language that are key to successful component integration.  This involved Python, an interpreted, interactive, object-oriented programming language.  It provides high-level data structures such as list and associative arrays, dynamic typing and dynamic binding, modules, classes, exceptions, automatic memory management and others.  Python has been found to be instrumental in the mol. modeling research environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaCFXA1JC8X7Vg90H21EOLACvtfcHk0lim84U-Qk3CjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D&md5=3bf94934548080055dda54f68468c656</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanner%26aufirst%3DM.%2BF.%26atitle%3DPython%253A%2520a%2520programming%2520language%2520for%2520software%2520integration%2520and%2520development%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D1999%26volume%3D17%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasteiger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsili, M.</span></span> <span> </span><span class="NLM_article-title">Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3219</span>– <span class="NLM_lpage">3228</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(80)80168-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1016%2F0040-4020%2880%2980168-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1980&pages=3219-3228&author=J.+Gasteigerauthor=M.+Marsili&title=Iterative+partial+equalization+of+orbital+electronegativity%E2%80%94a+rapid+access+to+atomic+charges&doi=10.1016%2F0040-4020%2880%2980168-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges</span></div><div class="casAuthors">Gasteiger, Johann; Marsili, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3219-22</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">A method is presented for the rapid calcn. of at. charges in σ-bonded and nonconjugated π-systems (alkyl halides and oxoalkanes, resp.), considering only the connectivities of the atoms.  Atoms are characterized by their orbital electronegativities.  Partial equalization of orbital electronegativity is obtained by an iterative procedure.  Excellent correlations of the at. charges with core-electron binding energies and with acidity consts. are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKA3wil1SiWrVg90H21EOLACvtfcHk0lim84U-Qk3CjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhslCjtbs%253D&md5=90c580857e6001482bee92450278fe9f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2880%2980168-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252880%252980168-2%26sid%3Dliteratum%253Aachs%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DMarsili%26aufirst%3DM.%26atitle%3DIterative%2520partial%2520equalization%2520of%2520orbital%2520electronegativity%25E2%2580%2594a%2520rapid%2520access%2520to%2520atomic%2520charges%26jtitle%3DTetrahedron%26date%3D1980%26volume%3D36%26spage%3D3219%26epage%3D3228%26doi%3D10.1016%2F0040-4020%2880%2980168-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open Babel: An open chemical toolbox</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=33&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+Babel%3A+An+open+chemical+toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520Babel%253A%2520An%2520open%2520chemical%2520toolbox%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D33%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of parameters for semiempirical methods II. Applications</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/jcc.540100209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1002%2Fjcc.540100209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=221-264&author=J.+J.+Stewart&title=Optimization+of+parameters+for+semiempirical+methods+II.+Applications&doi=10.1002%2Fjcc.540100209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of parameters for semiempirical methods.  II.  Applications</span></div><div class="casAuthors">Stewart, James J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-64</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    </div><div class="casAbstract">MNDO/AM1-type parameters for 12 elements were optimized using a newly developed method for optimizing parameters for semiempirical methods.  With the new method, MNDO-PM3, the av. difference between the predicted heats of formation and exptl. values for 657 compds. is 7.8 kcal/mol, and for 106 hypervalent compds., 13.6 kcal/mol.  For MNDO the equiv. differences are 13.9 and 75.8 kcal/mol, while those for AM1, in which MNDO parameters are used for Al, P, and S, are 12.7 and 83.1 kcal/mol, resp.  Av. errors for ionization potentials, bond angles, and dipole moments are intermediate between those for MINDO and AM1, while errors on bond lengths are slightly reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofaR7BHv7vB7Vg90H21EOLACvtfcHk0lgAQAOEl6JNRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkt1ylu7o%253D&md5=b94fa02ec95f5b1b2d62c2014ac4c288</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjcc.540100209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.540100209%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DJ.%2BJ.%26atitle%3DOptimization%2520of%2520parameters%2520for%2520semiempirical%2520methods%2520II.%2520Applications%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1989%26volume%3D10%26spage%3D221%26epage%3D264%26doi%3D10.1002%2Fjcc.540100209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rurainski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhof, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, D.</span></span> <span> </span><span class="NLM_article-title">A new Lamarckian genetic algorithm for flexible ligand-receptor docking</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1002/jcc.21478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=10.1002%2Fjcc.21478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=20082382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=1911-1918&author=J.+Fuhrmannauthor=A.+Rurainskiauthor=H.+P.+Lenhofauthor=D.+Neumann&title=A+new+Lamarckian+genetic+algorithm+for+flexible+ligand-receptor+docking&doi=10.1002%2Fjcc.21478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A new Lamarckian genetic algorithm for flexible ligand-receptor docking</span></div><div class="casAuthors">Fuhrmann, Jan; Rurainski, Alexander; Lenhof, Hans-Peter; Neumann, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1911-1918</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors present a Lamarckian genetic algorithm (LGA) variant for flexible ligand-receptor docking which allows to handle a large no. of degrees of freedom.  The authors' hybrid method combines a multi-deme LGA with a recently published gradient-based method for local optimization of mol. complexes.  The authors compared the performance of their new hybrid method to two non-gradient-based search heuristics on the Astex diverse set for flexible ligand-receptor docking.  The authors' results show that the novel approach is clearly superior to other LGAs employing a stochastic optimization method.  The new algorithm features a shorter run time and gives substantially better results, esp. with increasing complexity of the ligands.  Thus, it may be used to dock ligands with many rotatable bonds with high efficiency. © 2010 Wiley Periodicals, Inc.  J Comput Chem, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoFNlhZnxim7Vg90H21EOLACvtfcHk0lgAQAOEl6JNRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFCksLg%253D&md5=34a78af702d8ee9bace9b5db8221e2db</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21478%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann%26aufirst%3DJ.%26aulast%3DRurainski%26aufirst%3DA.%26aulast%3DLenhof%26aufirst%3DH.%2BP.%26aulast%3DNeumann%26aufirst%3DD.%26atitle%3DA%2520new%2520Lamarckian%2520genetic%2520algorithm%2520for%2520flexible%2520ligand-receptor%2520docking%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D1911%26epage%3D1918%26doi%3D10.1002%2Fjcc.21478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ','PDB','6KNZ'); return false;">PDB: 6KNZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBZ','PDB','7CBZ'); return false;">PDB: 7CBZ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i69"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_84538"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01961?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Characterization of key compounds, antiproliferation activity data, MTD, table of protein crystal data collection and refinement statistics, and HPLC purity traces for key final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">CSV</a>)</p></li><li><p class="inline">Structural data for compounds <b>6a</b>, <b>6d</b>, and <b>6r</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">jm0c01961_si_001.pdf (3.72 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">jm0c01961_si_002.csv (28.0 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">jm0c01961_si_003.pdb (1.05 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">jm0c01961_si_004.pdb (1.05 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">jm0c01961_si_005.pdb (1.04 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The structural data of <b>8a</b> have been entered into the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>) and can be accessed with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBZ">7CBZ</a>. The authors will release the atomic coordinates upon publication of the study.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01961&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01961%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01961" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799ce128f4d22f0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
